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SUMMAI~Y 
Neuropathy, d common complication of buman diabetes is not prevented by 
current antidiabetic therapy. Several mechanisms, sone reversible, have 
been proposed. Clinical assessment of drug efficacy in this condition is 
dUficul t because of i t5 slow and unpredictable development & its 
possible irreversibility, once established. A reliable animal model of 
diabetic neuropathy would be very useful. Changes such as reduced nerve 
conduction velocity are used as models but their relationship to 
neuropathy is uncertain. The main }>urpose of this study was to examine 
autonomic changes in the experimentally diabetic rat with the aim of 
identifying more appropriate IIOdels. 'fhe effects of three treatments 
which correct specific biochemical abnormalities which may underlie 
diabetic complications, were also studied. 
Autonomic function was assesed by measuring responses to nervous 
stimulation and exogenous transmitters. In some tissues 
noradrenaline uptake and release and Ha+K+ ATPase activity was measured. 
Since diabetes induced changes are often time dependent, three periods 
of diabetes, six weeks, six months and one year were used. 
Diabetes induced changes in sensitivity and maximun responses to 
noradrenaline were observed in aorta <increased sensitivity and reduced 
maximal responses in 6 month animals and decreased sensitivity in 1 year 
animals), anococcygeus <increased sensitivity in 6 month animals) & vas 
deferens <increased maxiIlal response in 6 nonth animals). Reduced 
responses to both exogenous acetylcholine and nervous stimulation were 
observed in ileum, but not in oesophagus. Xost of these changes appeared 
to be due to post-synaptic rather than nervous changes. These results, 
therefore, do not provide evidence of significant neuropathy in the 
tissues examined after up to 1 year of diabetes. This questio;ns the link 
between changes which occur after only one or two weeks of diabetes such 
as reduced nerve conduction velocity and diabetic neuropathy and hence 
their validity as models of the latter. It may be that these changes, 
together with other unkno~n ones, contribute to neuropathy .in humans. 
Reduced Ia+K+ ATPase activity may contribute to neuropathy and other 
diabetic complications. Acti vi ty was reduced in skeletal muscle from 
diabetic rats. The latter- were hypothyroid & normalising plasma T3 
levels by s.c. T~ also prevented Ba*K+ ATPase activity depression. 
Hypothyroidisn, which also occurs in human diabetiCS, might, therefore, 
underlie this change. 
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CHAPTER ONE 
r---------------------------
INTRODUCTION 
1.1 HISTORICAL BACKGRQUND 
Diabetes, the Greek for syphon, as a hUJUan condition was first 
identified in the First Century by Arteus of CappadDCia. It was only in 
the Seventeenth Century that ThoDas Willis adjOined the term Jlellitus, 
Latin for honey, to describe the excess glucose present in urine in 
diabetic patients (Lewis, 1980). 
In the Eighteenth Century the condition was linked to a pancreatic 
disorder and this· was confirmed by lIinkowski & Heyer (1889) . In a 
classic experiment they induced diabetes in a healthy dog by removing 
its pancreas. 
Sharpley-Schafer and de Jleyer, both working independently in the 1910' s, 
postulated that the previously identified Islets of Langerhans were 
responsible for secreting a hormone which controlled carbohydrate 
metabolism. They termed the hormone" lliSULIIffi". 
Banting & Best (1922) extracted the hormone from a foetal calf pancreas, 
and su=eded in reducing the blood glucose level of a diabetic dog. 
Previously insulin extraction had been hampered by digestive juices in 
the pancreas which destroyed the hormone during the process. A foetal 
pancreas however has no digestive juices aod therefore the hormone was 
preserved. Soon after this, in 192'1, the hormone was extracted, 
purified, and crystallised by John Abel (Kurnagban & Talalay, 1961). 
It was nearly three decades later when the next pioneering steps were 
taken. Ryle aod his colleagues, working at Cambridge, carried out the 
liobel Prize-winning identification of the 51 amino acid residue 
sequences in bovine insulin <Ryle et aI, 1955). Following this Blundell 
and co-workers succesfuUy analysed the crystal structure of insulin 
(Blundell et aI, 1972), 
( 3 ) 
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Progress has carried on a pace to the present day. Nowadays synthetic 
hUDan insulin is commonly used in place of insulin iron animal sources . 
The effects of diabetes are just beginning to be fully under'stood; but 
all this would not have been possible without the innovative work of the 
early researchers. 
1. 2 THE BIOSYUHESIS. SECRETIOIl & ACTION OF US!!LIIl. 
1 ,2a The Pancreas, 
The DalIIIIIalian pancreas develops from two diverticula of the duodenum, 
one forming part of the head and the other forming the rest of the head, 
the body and the tail (Lacy & Greider, 1979) 
The islets of Langerhans are scattered throughout the mammalian 
pancreas, with the greatest number in the tail (Opie, 1900; Bellman, 
1959 & 1970). The total mass of the islets comprises apprOXimately 1-2~ 
of the wet weight of the adult human and rat pancreas (Lacy & Greider, 
1979) • 
The main part of islet population consists of medium-sized islets, 
approximately 200jUl in diameter; and these number approximately 876,00 
in the hUDan adult (Clarke, 1913), and 13,500 per rat pancreas (Haist & 
Pugh, 1948). 
The islets are arranged as cords along the capillary channels within the 
islets and individual cells are surrounded by distinct plasma membranes 
(Berlin et aI, 1975). , 
( 4 ) 
1.2b Pancreajic Cell Types. 
There are 6 types of cell occurring in the pancreas, of which only three 
are presently thought to be involved in blood glucose regulation. 
'(he alpha (a) cells ha .... e granules which are round with a close 
"" membranous sac, and the center is extremely electronically dense with a 
less dense area surrounding it. The distribution of a cells varies in 
different species: in the rat & mouse they form a riD in the islet; 
~ .. ---."" ,---- '--'--~"'-"---.'. -
whereas ~~man they are loc .. ted in the center (Lacy & Greider. 1979). 
Alpha cells comprise only 15-20:1; of the islet popul_~tion in malllllBls and 
are responsible for producing and storing glucagon. 
I 
Beta (/1) cell granules vary in species (Lacy, 1957): in the rat and 
lIIOUse they are round and relatively dense with a space between the 
granules and the membranous sacs; whereas in man they have a rectangular 
shape (Lacy & Greider, 1979). Beta cells comprise_~~oximately 75-80:1; 
-~ 
of the islet population in the adult human; and are responsible for 
---producing, storing, and releasing insulin. 
C cells were first described in 1911 (Bensley,1911) as a clear cell in , 
the islets o~ _ the guinea pig pancreas. The cell has no secretory 
granules, a few mitochondria, and a small amount of endoplaSDic 
reticulum (Lacy, 1957; Caramia et aI, 1965; Lacy & Greider, 1979). 
Delta (6) cells (Bloom, 1931) have large round secretory granules (250-
450nm) with a low electron opacity. Although the gastrin-secreting cells 
----------
in this group contain smll granules <150-250nm} that are electron 
opaque (Lacy & Greider, 1979). The 6 cells constitute LQughly 5~ of the 
-
---
po£.ul~tion and are responsible for gastrin and somatostatin production 
(Brazeau et aI, 1973; Koerker et aI, 1974). 
E cells have only been identified in the o~ossum pancreas (Thoms, 
( 5 ) 
1937) and are characterised by relatively large (350-400nm), irregular 
shaped granules of moderate electron density <Xunger et aI, 1965). 
F ~ls , ori~~nallY called X cells (Bencosme & Lei pa, 1955), were 
located in the, dog in the islets of the uncinate process of the 
pancr.!:!'s, an'!...!n the cat, where they,are".,dts;:!:!:!.!?~ted throughout, The F 
. ·_n __ ~,----....._. __ 
cells have moderately electron dense secretory granules which have a 
wide range of shapes g. si:z.es (Xunger et aI, 1965) . 
.... _.---
1. 2c Proi nsulin 
The discovery of proinsulin dispelled the generally held idea that 
insulin was fOrJIBd by the, combination of separately synthesized A & B 
chains (Steiner et aI, 1969; Steiner & Oyer, 1967), Proinsulin is 
-formed in_the rough endoplasmic reticulum and undergoes cleavage to 
yield insulin and C-peptide (See figure #1 & #2), 
\/heat,germ ribosomal systelll6 have been used to show the existance of a 
precursor to proinsulin, preproinsulin, which is a peptide with a 
molecular mass of 11,500 (Lernmark et aI, 1976; Chan et aI, 1964 & 1976; 
-:---.--
Permutt et al,.-l976; Lomedico & Saunders, 19'16), 
"---
----.•. -.-.--~- .--~ 
Preproinsulin consists of proinsulin with H-terminal peptide extensions 
that are 23 residues long (Chan et aI, 1976), This peptide has a very 
rapid turnover (Patzelt et aI, 1980) and is probably cleaved even before 
the peptide chain is completed (Steiner & Tager, 1979), 
Pro1.nsulJ.n is very similiar to insulin in many properties,_!.~ng 
~ 
sol_ubility, isoelectric point (Steiner ,et aI, 1972), self-associative 
properties (Steiner et aI, 197!2,) and reactiv~~y to insulin antisera 
(Steiner et aI, 1969; Rubenstein et aI, 1969 & 1970), It has been 
suggested that this similarity in properties is due to the conformation 
of the insulin moiety in proiusulin being very nearly identical to 
."., .. -"-... -.' ..... -~-~ 
·W"" ... "~._ • • ," '. . '"," __ ,.,...."_ • __ 
( 6 ) 
FIGURE #1 
STRUCTURE OF HUMAN FRO INSULIN 
(5 AA Re5,) (11 AA Re5,) (10 AA Res,) 
8 Chain --~ Phe-----------------Cys---------------------Cys---------------Thr" 
1 1 I 
I I I Y 
S S Arg 
I I I 
S S Arg Q 
I I I 
A Chain --~ 61y---------------Cy5,Cy5 Thr" Ser" lieu' CY5,A5p Glu 
I I I 8 9 10 I 
I I I 
I I I Arg I _______ S __________ S ______ I 
I 
P _l.ll Y<.o.5_ 
Glu 
I 
I (29 AA Re5,) 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
Human insulin consists of chains A & B, the connecting peptide being 
between I & Yi whilst the C-peptide is between P & Q. 
AA Res. - Amino Acid Residues, 
* 
Points of variation in insulin structure in species 
Human 
Porcine 
Rabbit 
Beef 
Ala ,.. Alanine 
Asp - Aspartic acid 
Glu - Glutamic acid 
lIe - Isoleucine 
Ket - Iethionine 
Ser - Serine 
Tyr - Tyrosi ne 
Residue Bumbers 
A Chain 
I 8 9 10 I 
Thr Ser Ileu 
Thr Ser Ileu 
Thr Ser Ileu 
Ala Ser Val 
CODE FOR !!IUO ACIDS 
Arg - Arginine 
Cys - Cysteine 
GIn - GlutaDine 
Leu - Leucine 
Phe - Phenylalanine 
Thr - Threonine 
Val - Valine 
(Figure from Lewis, 1989) 
( '1 ) 
B Chain 
30 
Thr 
Ala 
Ser 
Ala 
Asn - Asparagine 
Gly - Glycine 
His - Histidine 
Lys - Lysine 
Pro - Proline 
Trp - Tryptophan 
--------------------------- ----
FIGURE #2 
PROINSJJX.IN CX.EAVAGE 
B "C 'A 
IH2 - Phe-----Lys.Ala.Arg.Arg.Glu-------Gln.Lys.Arg.Gly------Asn 
I I I (S-S) 2 _________________________ _ 
Trypsin-like enz:pe 
B " A 
JH2 - Phe----Lys. Ala. Arg. Arg JH2. Gly-----Asn 
I I I (S-S) 2 ___________________________ ,1 
+ 
, , 
IH2-Glu------Gln. Lys. Arg 
Carbo~ptidase 
B-l1ke enzyae 
B A 
IHz - Phe-----Lys.Ala JH2.Gly-----Asn 
I I 
I (S-8> 2 ________________ 1 
Native Insulin 
+ 
IH2.Glu-------Gln 
C-Peptide 
+ 3 Arg + 1 Lys 
STRUCTURES OF GLUCAGON & pROGLUCAGON 
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 
NH.,His,Ser,6In.6Iy,Thr.Phe.Thr,Ser,Asp.Tyr.Ser,Lys,Tyr,Leu,Asp.Ser.Arg,Arg.Ala,6In.Asp 
22 23 24 25 26 27 28 29 
,Phe,Val,6In,Trp,Leu,Met,Asn,Thr,C~.H 
30 31 32 33 34 35 36 37 
(-Lys,Arg,Arg,Asn,Lys,Asn,lle,Ala,CO.H) 
The structure of glucagon is shown and consists of 29 amino acid 
residues whilst that of the proglucagon extension is shown in brackets. 
(Both figures fro» steiner & Tager. 1979) 
See figure #1 for amino acid codes. 
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insulin itself (Steiner et aI, 1972). 
).2d Biosynthesjs of lnsulin 
Following biosynthesis in the endoplasmic reticulum and cleav~e of the 
--'-~~ ~
and sulphydryl oxidation 
-
occur rapidly in the cisternal spaces. The folded pro,i_nsulin is then 
.-----
transported to the Golgi apparatus (;i.'( a process requiring about 20 
minutes'\J(Steiner et aI, 1972; Howell et aI, 1969; Orci et aI, 1971; 
Janieson III Palade, 196'la III 196'lb; see figure 83). Jewly synthesized 
'-'_.------0 
peptide material approaches the Golgi body as "progranules" or 
.------
condensing vacuales, and is taken in and formed into secretion granules 
which then pass out and migrate _t~..,~rds the membrane (Bowel! et aI, 
1969; Orci et aI, 1971) . 
The conversion of proinsulin to insulin, ~ __ f_ir:st-order reaction 
( Steiner, 196'l) , requires the joint action 
carboxypeptid~e B. If'e la~~:r-:':;'yne is 
of trypsin like protease and 
neccesary to remove the C-
terminal basic residues left after tryptic cleavage, giving rise to C-
peptide and insulin (steiner III Tager, 1979) (see figure 82\j As the 
secretory products IlIOve to the Golgi body and proteolysis begins, the 
cation arginine and lysine residues liberated during conversion Diiy 
diffuse out of the granules and be replaced by hydrogen ions, resulting 
in a decrease in the intracellular pH (Steiner III Tager, 1979). 
v[~s the insulin is liberated from proinsulin it crystallizes with zinc 
atoms (Greider et aI, 1969; Lange et aI, 19'12). The insulin is stored 
== 
as a crystal complex of 6 molecules of insulin to 2 atoms of zinc. 
Together with insulin and C-peptide there are also present small amounts 
of proinsulin and a variety of other proteins in the granule (Steiner et 
aI, 1972; Geller et aI, 1972; Judah et aI, 1973; Jacobson III Baltimore, 
{ 9 } 
FIGURE #3 
SCHEMATIC SUMMARY OF INSULIN 
BIOSYNTHESIS IN THE BETA CELL 
R.E.R. r 
{( OVly" "..". 
PROIlI"SUL Ill" 
(S-S Bond 
:CorDation) 
LY.... 
~ 
0 
0 
0 
PROIISULIlI"---O 
. c? 
XEIBRAIX 
BOUJID 
PROTEASES 
XAIILY IISULIlI", J 
(Cr~alOid) """(j) 
C-PEPTIDE-
(j) 
~ 
PLASK' !BIBRAJE - /n 
EIIIOCYTOSIS 
(EIOCYTOSIS) 
{
AXIIO ACIDS 
TRilSFER Rn 
--- ATP. GTP. JIg:>+ 
ElTZTIIES 
AlI"TIIIYCII BLOCKS 
- TRilSFER STEP 1 
(energy dependent) 
TRAlISFER STEP 2 
PROGRESSIVE 
C01lVE:RSIOI 
(t.,= =1 hour) 
TRAlISFER STEP 3 
(energy & Ca"+ 
dependent) 
SECRETED PRODUCTS 
Insulin & C-peptide = 94~ 
Proinsulin + others" 6~ 
(Figure:Crom steiner a Tager. 1979) 
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/ 1968; Kiehn "Holland, 19'70; Bornstein, 19'74). 
Due to the localization of the proinsulin conversion process within 
secretion granules, the C-peptide accumulates along with insulin in 
equimolar amounts (Steiner et aI, 1971) and is secreted along with the 
hormone by exocytosis of the granule contents 
19(6) • 
1.2e Release of rnsulin 
Beta cells secrete insulin in response to physiological levels of D-
glucose and ~>1~ the presence of substimulatory levels of gluco~ L-
amino acids, fatty acids, and ketone bodies O{atschinsky et aI, 1975; 
Pagliari et aI, 1974; see figure #4). 
once again in the presen~ of substimulatory levels of 
.-----. . 
glucose, also stimulates insulin release in amounts and duration very 
sinil1ar to glucose (Loubatieres-Kariani et aI, 1973). 
The cells release insulin in a biphasic manner in response to stimulus 
(see figure #5>. Initially there is a rapid burst of insulin release 
--' 
following stimulation which reaches a peak after 1 minute; this is 
followed by a resting phase lasting several minutes and then by a slowly 
rising second phase (Katschinsky et aI, 1979). 
The dose-response curve for insulin release compared to glucose 
concentration is sigmoidal in shape, reaching a plateau at approximately 
25nl{ glucose concentration, and corresponds to a decrease in glucagon 
secretion with the same levels of glucose. (see figure #5). 
SODe mechanisms have been proposed to account for the insulin release 
• 
occurring in ~ cells (Ashcroft & Randle, 1975; Katschinsky et aI, 1971; 
Xatschinsky 
'~ 1) The 
et aI, 1972; Lambert, 1976), 
Receptor or Regulator Site Xodel proposes that the islets 
( 11 ) 
FIGURE # 4 
HYPOTHETICAL MECHANISM FOR INSULIN 
REI.EASE 
substrate 
Sl1BSTRATBS ----
---- JlETABOLISJI 
carrier 
HEXOSE 
GLYCERALDEHYDE~ 
a-KETOlSOCAPROATE7 '/ 
j!-granules 
t 
YCLASE 
(Figure from Xatschinsky. Pagliari. Zawalich. & Trus. 1979) 
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FIGURE #5 
INSULIN RELEASE _~ct GLUCOSE EFFECT ON 
INSULIN & GLUCAGON RELEASE 
STIMULATED INSULIN RElEASE FROM PANCREATIC BETA CElLS EFFECT OF GLUCOSE ON INSULIN & GLUCAGON RELEASE 
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have receptors on their membrane surfaces capable of recognising 
the different agonists. 
2) The Substrate Site ](odel suggests that recognition of a "trigger" 
molecule may be mediated through events connected with the 
metaboli tes of this lOCllecules./ 
3) A combination of the above two working together simultaneously. 
It is most likely that the third option offers a working model. 
In insulin release the primary event is an alteration in ion 
conductivity caused by a lOCllecule attaching itself to the receptor 
(Katschinsky et aI, 1979; Xathews, 1975). This leads to opening of the 
calciuD ~tes, which together with cAMP (Xalaisse et aI, 1971), acts as 
the signal for insulin release. 
1.2f The Insu1 i n ReceptOT 
The insulin receptor is present in most human cells (Reddy & Kahn, 
1988). The receptor is a large transmembranous glycoprotein of 
approximately 300kD and is made up of 2 extracellular a-subunits (135kD) 
and 2 transmembrane jl-subunits (95kD each) united by disulphide bonds 
(see figure #6a). Both subunits contain carbohydrate chains capped by 
terminal sialic acid residues. The a-subunits contain the binding domain 
while the jl-subunits contain the tyrosine kinase domain (Reddy & Kahn, 
1988), 
It is currently proposed that insulin binding to the a-subunit 
stimulates autophosphorylation of tyrosine residues on the intracellular 
dODain of the jl-subunit which , in turn, triggers the activation of 
phosphotransferases and catalyses tyrosine phosphorylation of specific 
substrates (Carpentier, 1989; Rosen et aI, 1983; Yu & Czech, 1984; 
Herrera & Rosen, 1986). 
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FIGURE #6a. 
INSULIN RECEPTOR 
I1SUl.I1 RECEPTOR 
G 
OUT 
a a 
-S-8- -S-S f-S-S 
jI jI 
P-TYR- I-TYR-P 
111 
P-TYR- I-TYR-P 
Schemtatic view of the insulin receptor with it's two external 
binding domains (a-subunits) linked by two disulfide bonds to two 
tranSDembrane domains (jI-subunits) extending into the cytoplasm. On the 
outer portion of the jI-subunits tyrosine residues become phosphorylat~d 
(P-TIR) upon insulin binding to the a-subunits. 
(Figure from Carpentier, 1989) 
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Following binding of the receptor and insulin, the aggregate lIIOves in 
the plane of the plasma :membrane to reach membrane invaginations or 
pi ts. These pits are lined with a protein coat, clathrin, which Is 
associated with the cytoplaSllic leaflet of the membrane ( Carpentier, 
1989; Pearse & Bretscher, 1981; Carpentier et aI, 1986). The bound 
insulin is then internalized, through endocytosis, which results in the 
formation of a coated vesicle free in the subplasmalenmal cytoplasm; the 
life-time of the vesicle is. only 1-2 minutes or less and the process by 
which this coat is shed is unknown (Carpentier, 1989; see figure #Ub). 
Tbe endosomes, possesing proton pumps, quickly acidify the organelle; 
tbis acts to dissociate the insulin ligand from the receptor CTycko & 
](a,'sfield, 1982)' The liberated insulin tben travels to the late 
endosolles which contain lysosom~1 enzymes and Dannose-6-phosphate 
receptors. The insulin finally reaches a digestive vacuole where it is 
degraded, but the receptor itself is recycled to the cell surface (Brown 
& Farquhar, 1984; Gruenberg et aI, 1989; Carpentier et aI, 1979a & 
1979b; Carpentier. 1989). 
l,2g Action of Insylin 
Tbe principal action of insulin is at the cell surface where it 
regulates the redox-potential gradient across the me:mbrane. It thus 
controls the energy available to tbe cell for it's active glucose 
transport into the cell (Krahl, 1961). Insulin also inhibits the 
breakdown of glycogen, in the liver, to glucose. 
In the absence of insulin this process is responsible for Daintaining 
blood glucose levels. The tran6aDdnation of amino acids to pyruvic acid 
and thence to glucose via the Embden-Xayerhoi pathway is also inhibited 
( 16 ) 
FIGURE #6b 
INSULIN RECEPTOR 
ACTIOJ OF llSUI.I1 
.. 
XICROVILLUS 
.. I.SULI. :RECEPTOR 
PLASIlA IlEIBRAIli 11 
I 
~ 
~ rI' :RECYCLIIG 
/ /' I VESICLES? 
.//' © 
./ /' I 
/' /' / /' ./ I 
I 
/' I 
J---~~ 
,XYB DEJrSH BODY, 
LYSOSOJIES 
-----::> 
Schemetic representation of the intracellular pathway of insulin 
following binding to it's piaslti membrane receptor on microvillus. Also 
represented is the recycling route of the receptor from the endosomal-
lysosomal compartment and the possible insertion of the newly-
synthesized receptors. XVB= multi vesicular body. 
(Figures from Carpentier, 1989) 
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by insulin (Young et aI, 1960; see figure #7). 
It can be seen that insulin actively acts to reduce blood glucose levels 
and that it's absence would, and does, have severe consequences for 
blood glucose regulation. 
1,3 DIABETES AND IT'S DlAGNOSIS 
~.3a Classificatign. 
There are two main forms of diabetes, Diabetes Xellitus and Diabetes 
. Insipidus. Diabetes Insipidus is a rare condition which is caused either 
by an insufficient secretion of Antidiuretk· Hormone UDH or 
vasopressin) or a renal insensitivity to it. ADH is an essential hormone 
required for the reabsorption of water from the kidney tubules. An 
absence of this hormone leads to excessive water loss; and the disease 
is characterised by the production of large volumes of pale-colourless 
urine (De Wardener, 19'13). 
Diabetes Xell1 tus afflicts between 20-30 mIlion people in Europe and 
the U.S.A., nearly 1 in 50, although there are considerable regional 
variations (Xarks et al;1971). A recent report from the Office of Health 
Economics <l989} , the research arD of the pharmaceutical industry, 
estimated that, in the U. K. alone, there were more than 500,000 
undiagnosed diabetics. 
In diabetes mellitus there are two forms, Juvenile Diabetes and Maturity 
Onset Diabetes. 
Juvenile diabetes occurs either in childhood or adolescence, may be due 
to viral infection (Craighead, 1975; Rubenstein, 1979) , and is 
characterised by a total failure to secrete insulin (Parker et aI, 
( 18 ) 
FIGURE #7 
SCHEMATIC REPRESENTATION OF HORMONAl. 
PROTEIN 
CONTROL OF METABOLISM 
Ketone 
bo~es 
\ 
FFA 
DIET 
GLUCOSE 
FAT GLYCOGEN 
EXPLAII!ATIOlI OF SYMBOLS 
\Y 
OXIDATION 
I: Insulin. T3: Triioootbyronine, GH: Growtb Hormone, 
Gl: Glucocorticoids, & G: GlucBson. 
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1968>' The onset lIEIy he very quick or conversely very slow, and so it's 
occurence is very unpredictable (Baker & Stanley, 1979). Treatment for 
this disease consists of intravenous injections of soluble insulin to 
reduce blood glucose levels (Oakley et al; 1975). The incidences of this 
form of diabetes has increased in recent times . 
Katurity onset diabetes varies in its severity and may be characterised 
by a total failure of the pancreas or by an inappropriate aDllunt or 
pattern of insulin secretion; in either case treatment is required 
(Oal<ley et a1,1975; Kipnis, 1968». 
Diabetes mellitus is caused by certain dysfunctions (Marks et aI, 1971; 
Fajans, 1979) (see figure #8). 
In diabetes mellitus glucose, fat, and protein metabolism are all 
affected. Glucose blood levels are increased above the renal threshold 
so that glucose starts to appear in the urine (glucosuria). Deficiencies 
in fat netabolism results in a large production of ket.one bodies which 
leads to ketosis and ketonuria (see below). In mild form ketosis causes 
nausea, vomiting, and drowsiness; but in a severe form it can cause coma 
and poSSibly death (Oakley et al,1975; Liljenquist et aI, 1979». 
l,3b Fatty Acid Metabglism 
Normally in fatty tissue triglycerides are broken down to fatty acids, 
but are reincorporated into triglycerides by the action of 
glycerophosphate; which is synthesized from glucose (HcGarry & Foster, 
1979>' 
In diabetes the fatty tissue glucose content decreases so that 
glycerophosphate production also falls. This leads to a build-up of 
fatty acids which then enter the blood stream. The fatty acids in blood 
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FIGURE #8 
PROPOSED AETIOLOGICAL AND pATHOGENIC 
FACTORS IN DIABETES MELLITUS 
A.r~Det1ca]ly determined abnormality of beta cell fUnction Qr number. 
1. Delayed and decreased insulin secretory response to nutrients. 
(i) Decreased number of beta cell receptor sites to glucose or 
amno acids 
(i1) 
(i11) 
(iv) 
(v) 
Decreased affinity of receptor sites. 
Altered ~crotubular response. 
Altered nUcrofilaDentous activity. 
Altered cation sb1fts. 
(vi) Abnor:mal1ty in cAXP. 
2. Decreased insulin biosyntbesis. 
3. AbnorDBlity in conversion of proinsulin to insulin. 
4. Decrease in beta (P) cell replication - early senescence. 
5. ~thesis of an abnorD8l insulin witb i~ired biological activity. 
6. Increased susceptibility of p cells to envirODental factors linked to 
HLA syste •. 
B. Envirqqental factors altering beta cell integrit7 & function. 
1. Infective a~nts - viruses. 
2. AutoinmruDity - antipancreatic cell-mediated im.unitYi increased 
susceptibility to p cell daDBKe by viral a~nts due to defective 
inmrune response influenced by ~nes in the HLA cbro.:sO:lllJ1 region 
and lead:lng to an autoimmJDe process (in proportion of juveDile-
onset-type diabetes). 
3. Diet (calories) leading to obesity; pregnancy (.aturity-onset type). 
4. AutonOJDic nervous syste:a - increased adrenergic activity. 
c. AbnOrmalit7 of insulin action 
1. Insensitivity to endogenous insulin. 
(i) Release of insulin lfitb iBpaired biological activity. 
(ii) Decreased number of insulin receptor sites. 
(iii) Interference witb binding of insulin to its receptor sites -
antibodies to insulin receptors. 
(i v) Decreased acti vi ty of key e=yme (5) • 
D. AbnOrmalit7 in glucagon Secretion 
1. Secondary to insulin insufficiency. 
2. PriDBrY abnorDBlity. 
E. Abnormal fouaH on or degradation of ba""'''''nt ,...pbrane 
1. Pri.ary abnorDBlity on ~netic basis. 
2. Secondary to insulin insufficiency. 
(Figure fron Fajans, 1979) 
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are dealt with by the liver in several ways. They can either be forned 
into neutral fats or long chain fatty acids or ketone bodies such as 
acetoacetic acid, IS-hydroxybutyric acid and acetone (see figure 119). 
Indeed in severe uncontrolled diabetics one can discern the smell of 
acetone on the breath of patients (WillialllSOn & BeDS, 1970; Lewis, 
1980) • 
Ketone bodies are usually absorped by muscle tissue, but this process is 
slow and unable to cope with the excess production occuring in diabetes 
(AcGarry & Foster, 1979). This failure to absorb ketone bodies not only 
leads to ketosis, but their presence in the blood inhibits the 
production of long chain fatty acids; thus increasing the production of 
more ketone bodies (Liljenquist et aI, 1979). 
The increased circulating ketones bodies can be utilised by most 
extrahepatic tissues for energy. This displacement of glucose for 
energy increases plasma glucose levels and thus leads to an increase in 
hyperglycaemia (Liljenquist et aI, 1979; see figure #9). 
!,3c Maturity Onset 
In maturity onset diabetes insulin deficiency may be coupled with tissue 
insensitivity to insulin. "eight loss, which is common in untreated 
Juvenile onset, is less frequent in this form. 
The underlying causes may vary but the results are the same. In some 
diabetics obesity may contribute to tissue insensitivity to insulin. 
Since adipose tissue stores are increased in obesity, and adipose tissue 
is insensitive to insulin, the normal pattern of insulin secretion is 
insufficient to regulate blood glucose levels (Rubenstein, 19'{9). 
Thus there is an increase in insulin secretion to compensate for this; 
which over time may lead to exhaustion of the 11 cells (Best et al;1959). 
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TRIGLYCERIDES 
FIG[RE 19 
OCHEIAIIC REPRFSEI1AIIOI OF FAT 
IBTABO[.[SK If DIABETES J1E[.I.nus 
Glycerophosphate 
t----------------
-------.~ FATTY ACIDS 
1 
1 
1 
1 
1 
1 
1 
! 
Large increase in blood 
fatty acid levels. 
Increase in 
BODIES 
1 
1 
1 
1 
.j, 
~ 
KETOJE 
Poor uptake into 
DIlscles 
LIVER 
.--- I, 
.-- I ...... 
.-'- I ........ 
1 
1 
-Ye -------------~ 1 
1 
1 
1 
1 
.j, 
LOIG CIlAIJI 
FATTY ACIDS 
...... 
~ 
JEUTRAL 
FATS 
KETOBE BODIES: Acetoacetic Acid, ~-hydroxybutyric Acid, & Acetone. 
(Figure summarised from Lewis, 1980) 
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It has been shown that tissue sensitivity to insulin is inversely 
related to degree of obesity. 
SODe diabetics are however not obese and ther·e may be several reasons to 
explain hyperglycaemia ( see above), an absence of the first rapid phase 
of insulin secretion which occurs when glucose is presented to the II 
cells (Xatschinsky et aI, 1979); it has also been suggested that one of 
the basic abnormalities that characterize the diabetic state is 
a=elerated aging or senescence (Vracko & Benditt, 19'/4) and that this 
is responsible. 
1,3d Glucose Tglerance Test 
Certain people show glucose intolerance only in exceptional 
circumstances such as pregnancy or very severe stress. These people can 
be described as latent Diabetics and a glucose tolerance test (GTT) is a 
very effective means of aSBesing the degree and susceptibility to 
diabetes. However the age of the subject should be borne in Bind, 
especially those over 50, as tolerance to glucose decreases with 
advancing age (Fajans, 1965; Andres, 1971). 
The test involves a person fasting, 8-10 hours, to reduce the base level 
of glucose and then being given 50g of glucose, ideally in the morning. 
The blood glucose level is then DOni tared over a certain period and a 
graph versus time is drawn (Fajans, 1979). 
Bormal people have a low base level which rises sharply following 
glucose ingestion and then falls away rapidly. In latent diabetics there 
is a siBiliar ini tial phase but the decline phase is DOre gradual. In 
Bild diabetics the basal level is elevated, approaching the renal 
threshold of 180mg/100Dtl blood, the rise is much slower but is more 
elevated; whilst the decline gradient is eqUivalent to the incline. In 
( 24 ) 
severe diabetics glucose intolerance is profound. The base level is far 
in excess of the renal threshold, subsequantly the final plateau 
following ingestion is grossly elevated. The incline and decline phases 
are more gradual (see figure #10). 
Bearing in mind such factors as time of day, age, physical activity, 
coffee, smoking, acute or chronic illness all affect the GTT, it is not 
suprising that the GTT is one of the DOSt misused tests in performance 
and interpretation (Fajans, 1979). But these problems can be overcome if 
the correct procedure is adhered to and one of the IJany published 
criteria is used to interpret the results. Briefly the criteria for 
establishing diabetes is a test with a 1-hour value of 195 Bg/dl, and a 
2-hour value of 140Bg/dl or more (Fajans, 1979). 
l,3g Hypoglycaemia 
Vhilst diabete me1l1 tus is characterised by insufficient insulin , the 
converse condition is equally ser10us. 
If insulin secretion out paces carbohydrate intake there is a resultant 
low hlood glucose level. Though several mechanisms come into play, such 
as the conversion of glycogen and amino acids to glucose, to correct 
this aberration; a continued fall has serious implications (Best et aI, 
1959). The condition may also be caused by other factors, such as a 
failure of e1 ther glycogenolysi's or glucogensis, and also passi bly, by 
excess secretion of the thyroid hormones (Arky, 1979). 
If the blood glucose level faUs below 70Bg/100m! blood there appear 
characteristic signs of hunger, cold sweats, tremors and weakness. 
Should the blood glucose level fall far below the minimun limit then the 
brain suffers glucose depri~ation leading to convulsions, which may be 
fatal (Arky, 1979). 
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FIGURE ttlO 
TYPICAL GLUCOSE TOLERANCE CURVES FOR 
A RANGE OF SUBJECTS 
Blood glucose (1Jf!/rlD 
400 
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RmIAL TIlRESBOLD 
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o I~_---------.-----------.------------r-----------, 
1 2 3 
TilE l!fter taJdIl/f glucose (hours) 
A: Jormal Subject. Blood glucose returns to fasting level after 1.5hrs. 
B: Latent Diabetic. Slower return to fasting levels. 
C. II1ld Diabetic. 
D. Severe Diabetic. There is glycosuria at all times and blood glucose 
concentrations of 30o-400Dg per cent or more may be reached after 
glucose ingestion. 
(Figure from Lewis, 1980) 
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1,4 HORMONES AFFECTING B!.ooD GLUCOSE LEVELS 
1 ,48 Gl YcagQn 
It's existance was first postulated in 1923 by Kimball & Xurlin as a 
contarunant present in extracted insulin, since this "impure" insulin 
initially caused hyperglycaemia in subjects, 
It was another thirty years before its composition was established as 
consisting of a single chain polypeptide of 29 aruno acid residues 
(Staub et aI, 1955; see figure #2), 
It 1s secreted, as a precursor proglucagon (Steiner & Tager, 1979), by 
the a cells of the pancreas and by a-like cells present in the stoDach 
and the duodenum, Secretion is stimulated by a fall in the blood glucose 
level, decrease in free fatty acid blood content, an increase in 
sympathetic nervous activity, and also by physical excercise (Best, 
1959; Lefebvre & Unger, 1972), 
Glucagon acts at a variety of sites, the main outcome of which is an 
elevation in blood glucose levels (DevriD & Recant; 1966), Besides its 
main actions (see figure '11), it also acts to decrease gastrointestinal 
IDOvement and greatly increase the rate 11< force of cardiac contractions 
(Lewis, 1980), 
The secretion of glucagon and insulin are inter linked and function as a 
horueostatic mechanism: Glucagon invokes insulin secretion whilst insulin 
inhibits glucagon secretion (Devrim & Recant, 1956; see figure), 
It has been postulated (Unger & Orci, 1975) that glucagon is involved in 
diabetes mellitus, Injections of SODatostatin, a potent inhibitor 
of both glucagon & insulin, doesn't produce hyperglycaemia, It could be 
that low insulin secretion raises blood glucose levels by preventing the 
utilization of glucose, and thatconcurrent with this glucagon acts on 
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FIGURE #11 
EFFECTS OF GLUCAGON 
1. Greatly increases blood glucose levels. 
2. Increases circulating xree xatty acid levels. 
3. Increases GLYCOGENOLYSIS in the liver, the conversion ox 
glycogen to glucose. 
4. Increases GLUCONEOGENESIS , the transxormation of amino 
acids (xrom protein breakdown) to glucose. 
5. Stimulates the secretion ox adrenaline. 
6. Decreases gastrointestinal movement. 
7. Increases xeeling ox saition. 
8. Stimulates the secretion ox growth hormone. 
9. Greatly increases the rate ox cardiac contraction. 
10. Increases the xorce ox cardiac contraction. 
11. Causes hypocalcaemia. 
12. Induces insulin releases. 
13. Increases the release ox cAXP xrom the liver. 
( Figure from Lewis, 1980) 
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glycogen stores to produce elevated levels of circulating glucose. It is 
suggested that both these mechanisms come into play and produce the 
characteristic hyperglycaemia of diabetes. 
1. 4b The Adrenal Glucgcortico:ids 
The adrenal glands, situated just above the kidneys, are divided into 
two regions, the medulla and the cortex, of which the latter is the most 
iDportant secretor of a range of steroids which control salt and water 
balance and also metabolism of carbohydrates, fats, and proteins. The 
metabolisn of the carbohydrates plays a crucial role in maintaining 
blood glucose levels and so these steriods feature in diabetes. 
The steroids, hydrocortisone (cortisol>, corticosterone & aldosterone, 
all have a basic cyclopentanoperhydrophenanthrene ring structure with a 
two carbon side chain at position C17. In addition they all feature a 
ketol grouping at position C20, with an oxygen atom at C3 position (see 
figure 112). 
Although the action of these steroids overlap, aldosterone is 
principally a nineralocorticoid, concerned with sal t and water 
metabolisn, hydrocortisone is a glucocorticoid, controlling carbohydrate 
metabolisn, whilst corticosterone functions in both arenas (Currie et 
aI, 1962). Bydrocorti and corticosterone are biosynthesized in the 
fasciculata and reticularis zones of the adrenal cortex and their 
secretion is governed by the peptide adrenocorticotrophic hormone 
(ACTB) which is secreted by the anterior pituitary gland in response to 
circulating levels of the steroids (Brandon, 1962; Kyles & Daly, 1974; 
Ganong et aI, 1966). 
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FIGURE #12 
THE STRUCTURES OF ADRENOCORTICAL 
STEROIDS 
Co 11,0\\ 
I 
co 
- - -8fl 
Hydrocortisone Corticosterone 
(Cortisol, 17-hydroxycorticosterone) 
o~ 0.1,01-1 
I I 
........ 
Aldehyde fOrD Hemi -acetal 
Aldosterone 
(Figure from Lems, 1980) 
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FIGURE 613 
THE STRUCTURE OF MYO-INOSITOI. & ACTH 
OH 
lIIYO'" Inesi tol 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Ser-Tyr-Ser-Xet-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys 
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 
-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asp-Ala-Gly-Glu-Asp-Gln 
31 32 33 34 35 36 37 38 39 
-Ser-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe 
Acrn ( adrenocorticotrophic hOI"lllOne, or corticotrophin) 
The first 24 residues are identical in ACTH preparations from several 
species. A synthetic polypeptide containing the first 24 residues of ACTH 
has biological activity in vivo similar to that of the isolated hor.one. 
Thus, residues 25 to 33 are not essential for hOI"lllOnal action. However, 
these residues are significant for the species immunological specificity of 
the hormone. Re.aval of a few residues from the aDino-terndnal end of Acrn 
destroys biological activity. 
Ala - Alanine 
Asp - Aspartic acid 
Glu - GlutaDic acid 
!le .: Isoleucine 
Kat - Xethionine 
Ser - Serine 
Tyr - Tyrosine 
CODE FOR AKIIO ACIDS 
Arg - Arginine 
Cys - Cysteine 
GIn - GlutaDine 
Leu - Leucine 
Phe - Phenylalanine 
Thr - Threonine 
Val - Valine 
(Figure from Lems, 1980) 
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Asn - Asparagine 
Gly - Glycine 
His - Histidine 
Lys - Lysine 
Pro - Proline 
Trp - Tryptophan 
Though the steroids have a large spectrum 01 activity the following list 
only seeks to deal with their glucocorticoid behaviour (Leung 11 Kunck, 
1975; Slater, 1965). 
(i) Increase gluconeogenesis, the formation of glucose froD amino 
acids. 
(ii) Increase the breakdown of proteins to amino acids to promote the 
above-mentioned cycle. 
(iii) Directly inhibit the action of insulin and thus prevent glucose 
utilisation. 
(iv) Increase the IIIObilization of fats. 
(v) Increase the depOsition of glycogen in the liver. 
1.4c Adrenocorticotrophic HgTDQUe (ACTH) 
The adrenocorticotrophic horlIlOne ( ACTH or corticotrophin) is released 
by the anterior pitUitary gland in response to either the nervous system 
or circulating levels of corticosteroids in a negative feedback systeD. 
It is also released at times of extreme mental and physical stress such 
as haemorrhaging, burning, severe cold, and pain. It consists of thirty-
nine amino acid residues (see figure #13) and it is deactivated if a 
single amino acid is relOOved from the BIb-terminal end of the IOOlecule. 
It's primary action is to stimulate the secretion of the aforementioned 
glucocorticoids fron the adrenal cortex,' but it also acts to elevate 
blood glucose levels (Currie et aI, 1962; Kyles 11 Daly, 1974). 
1. 4e Regll! atory Peptides 
Kany regulatory peptides have a profound effect on either increasing or 
decreasing food intake and' blood glucose concentration in experimental 
animals (see figure #14, William 11 Bloom, 1989), but whether this is 
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FIGURE #J4 
EFFECTS OF CERTAIN PEPTIDES 
Bypergl yceamia 
10 Effect 
Hypoglyceamia 
Central Action 
Peripheral 
Action 
EFFECT ON m.m]) GLUCOSE aINCENIRATIOl 
Peptide Site of Action 
Bombesin ICV, VlIH, LBA 
Il-Endorphin ICV ( ?upper medulla) 
Thyrotrophin 
Releasing Bormone ICV 
Neurotensin ICV <large doses) 
Cholecystokinin ICV 
Somatostatin ICV 
Heurotensin VlIH, LHA 
Somatostatin VlIH, LBA 
OOIE EIPEBI!lEllTAL ACTIONS OF HEUROPEPIIDE Y 
Action 
Hyperphagia 
Polydipsia 
LH secretion stimulated & inhibited 
(depends on oestrogen status) 
ISH secretion inhibited 
GH secretion inhibited 
Prolactin secretion inhibited 
Vasopressin release stimulated 
Insulin release stimulated 
Hypotension 
Bradycardia 
Bradypnoea 
sedative 
libido inhibition 
Vasoconstriction 
Hypertension 
Site 
PVJ, VlIH, LHA 
PVJ, VlIH 
ICV 
? arcuate 
nucleus 
001 
ICV 
ICV 
ICV 
IV 
ICV, intracerebroventricular (3rd & 4th ventricle); VlIH, ventromedial 
hypothalmic nucleus; SOH supraoptic nucleus; IV, intravenous; LB!, 
lateral hypothalmic area; "PVH, paraventicular nucleus. 
(Figure from Villiam & Bloom, 1989). 
their true physiological role remains unclear. 
Somatostatin is a well established regulatory peptide, wh"ch occurs in 2 
forms, containing 14 and 28 amino acid residues (see figure #15; 
Pradayrol et aI, 1980). 
Somatostat1n-14 1s found in D-cells of the pancreatic islets and in the 
nerves supplying the stomach. SODatostatin-28 occurs in gut mucosa cells 
and in the retina; whilst both forms occur abundantly in the brain 
(Folak & Bloom, 1986; Ishikawa et aI, 198'1; Reichlin, 1983), 
Somatostatin release from pancreatic D-cells is stimulated by Dany 
factors including high glucose, glucagon, and ketone body concentrations 
,and also insulin deficiency (Ipp et aI, 1977; Vasada et aI, 1981). 
Somatostatin has a wide .spectrum of biological activity, including 
inhibition of growth hormone, insulin, and glucagon (Brazeau et aI, 
1979). It directly blocks nutrient transport across the gut mucosa, 
reduces exocrine gut secretions, inhibits the release of various gut 
peptides, and decreases gut DDtil1 ty and splanchic blood flow (Adrian 
et aI, 1981; Krejs et aI, 1980; Bloom et aI, 1974; Boden et aI, 1975; 
Price et aI, 1985; see figure #15). 
In experimental animals somatostatin levels, both circulating and D-cell 
content, are elevated. Both increased turnover and reduced clearance 
further contribute to elevate Circulating levels (Xakino et aI, 1977; 
Patel et aI, 1978; Pate I & Veir, 1976; Bellman & Petersson, 1963; Hara 
et aI, 1979; Trimble & Gerber, 1981; Ruggere & Patel, 1984; 
Schusdziarr'a et aI, 1981). In diabetic patients somatostatin levels are 
increased in both insulin-dependent and -independent diabetes melli tus 
(Williams III Bloom, 1989), 
Hat! ve somatostatin and i -£ s analogues have been used to reduce the 
elevated levels of growth hormone prevalent in diabetes mellitus 
( 34 ) 
FIGURE #15 
SOMATOSTAT IN; STRUCTURE & EFFECTS 
B-ALA-GLY-CYS-LYS-ASI-PBE-PBE-TRP-LYS-THR-PBE-THR-SER-CYS-OH 
I I 
Somtpstati n 
D-PBE-CYS-PBE-PHE-[D-TRPJ-LYS-THR-CYS-THR-DH 
I I 
OctepTide (SIS 201=995) 
(See figure #1 for Audno Acid code) 
(From Davies, Turner, Alberti, & Johnston, 1989) 
Endocrine actions 
(inhibition) 
Exocrine actions 
(inhi bi tion) 
Other gasterointestinal 
actions 
CJlS actions 
EFFECTS 
Pituitary: growth hOTDOne 
TSB 
ACTH 
Pancreas: insulin 
glucagon 
somatostatin 
Gut: gastrin 
gastric inhibitory peptide 
enteroglucagon 
cholecystokinin 
secretin 
DOtilin 
Salivary glands 
Stomach: acid, pepsin, intrinsic factor 
Pancreas: bicarbonate, enzymes 
Colonic fluid 
Reduces gut motility (stomach, intestine 
, gall bladder) 
Reduces splanchnic blood flow 
Reduces intestinal absorption 
Inhibits (or stimulates) feeding 
Inhibits centrally-mediated 
hyperglyceallda 
Analgesia 
(FroD YilliaDS & BlocD, 1989) 
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Ulansen, 1980; Press et aI, 1984; Gerich, 1984;Gerich et aI, 19'('1>. 
Octreotide is an analogue of somatostatin (Sandostatin/SKS 201-995, 
Sandoz Pharmaceutical) currently being evaluated for its potency. 
It has a duration time of 6-8hrs when administered subcutaneously. 
Compared to somatostatin this analogue has equipotency against insulin, 
but is xll lIlDre potent against glucagon and x45 lIlDre potent against 
growth hormone secretion (Davies et aI, ,1989; see figure #15). 
Beuropeptide Y is a 36 amino acid residue peptide which is structurally 
related to pancreatic polypeptide and is named for the tyrosine residue 
('Y') at either end of the molecule (liillialll & Bloom, 1989). It is 
widely distributed throughout the eBS, but is particularly high in the 
hypothalmus, cortex, basal ganglia, and limbic system (De Quidt & Emson, 
1986; AlIen et aI, 1982>. 
It's pri:nary action is to greatly stimulate appetite , and negate the-· 
effect of strong appetite suppressants such as cholecystokinin (liilliam 
& Bloom, 1989). It increases appetite for carbohydrate-rich foods, 
stimulates exploratory food-seeking behaviour, whilst suppressing other 
forms of activity, such as sex (Cl ark et aI, 1984; Stanley et aI, 1985 & 
1986; Karley et aI, 1987; Steinman et aI, 1987). 
Beuropeptide Y has powerful, and generally inhibitory, effects on 
anterior pituitary hormone secretion (Yilliam & Bloom, 1989). It s 
injection into the third ventricle 'of the hypothalamus blocks release of 
growth hormone, thyroid stinulating hormone (TSH) , prolactin, and under 
some circumstances, LH (XcDonald et aI, 1985; Harfstrand et aI, 1987 & 
1986; Kalra & Kalra, 1986>. In experimental diabetic animals elevated 
levels of the peptide have seen found, up to x5 greater than the control 
animals (Pierson et aI, 19~8; see figure #14). 
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It seems therefore that the neuropeptide Y has a homeostatic role, 
coming into play when insulin levels fall in the diabetic state, to 
maintain body weight and energy. 
It is obvious that DUch work remains to be carried out to elucidate the 
role and/or relevance of this and other peptides to diabetes. 
1.4£ Growth Hormgne 
Growth borllDne is released by the anterior pi tui tary gland in response 
to the Growth HorllDne Releasing Factor secreted by the hypothalanrus and 
it is species specific. 
The horllDne acts primarily on hones rapidly prollDting growth and 
consequantly there is a rise in plasma levels of alkaline phosphatase 
and inorganic phosphate. It is therefore not suprising that an excess or 
deficiency leads to gigantism and dwarfiSll respectively (Harris; 1955). 
In addition it utilises fat stores and there is a concurrent increase in 
blood glucose levels (Glick et aI, 1965). 
1. 4g Adrenaline 
Adrenaline, in addition to being a neurotranSDitter, is also present in 
the adrenal medulla and is released by extreme emotional or physical 
stress and hence fits its classical description of a 'fight or flight' 
hormone. 
It is biosynthesized from both tyrosine and phenylalanine via a very 
well understood pathway. Phenylalanine is converted to tyrosine and 
thence to 3- (3, 4-dihydroxyphenyU alanine or DOPA. DOPA then undergoes 
decarboxylation and forms 2-(3,4-dihydroxyphenyl)-ethylamine or 
dopamine, the precursor to 'noradrenaline; which is itself the precursor 
for adrenaline (Blascko, 1939). (see figure #16). 
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FIGURE #],6 
THE BIOSYNTHESIS OF NORADRENALINE 
AND ADRENALINE 
HD-CsR.-CRz-CH-BH2 
Tyrosine I 
L-DOPA 
Dopalline 
Noradrenaline 
Adrenaline 
COOH 
tyrosine bydroxylase 
~ 
{HO)2-GsHa-CB2-CH-BH2 
I 
COOH 
L-DOPA decarboxylase 
~ 
{HO)2-CsR.-CB2-CB2-~ 
dopamine-p-bydraxylase 
~ 
{HO)2-CsR.-CB2-CH-BH2 
I 
OH 
pbenyletbanolamine-N-
metbyltransferase 
, 
{HO)2-CsR.-CB2-CH-BH-GHa 
I 
OH 
. {-)Tyrosine is taken up by the chromaffin cells of the adrenal Dedulla. 
The conversion of noradrenaline to adrenaline only occurs in the 
chromaffin cells of the adrenal medulae which store adrenaline. 
(Figure frOD ~y, 1979) 
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Adrenaline has a wide range of effects within the body, this includes 
the cardiovascular systeD, the respiratory system, smooth DWscle tissue, 
the nervous system, exocrine glands, and also body metabolism. It's 
glucoactivity closely resembles glucagon and both it and noradrenaline 
prevent glucagon-stimulated insulin secretion (Currie et aI, 1962) 
Adrenaline acts directly to increase blood glucose levels by breaking 
down glycogen in the liver and it's secretion is also triggered off by 
falling blood glucose levels. It also has a strong stimulating effect on 
fat DDbilization leading to increased levels of circulating fatty acids 
and glycerol. Both of these actions are initiated by the activation of 
phosphorylase and lipase via the adenyl cyclase-cyclic AMP link. 
Adrenaline acts on two different types of receptors « and ~, which are 
further subdivided into «, & «2 and ~, ... ~2' Each of this quartet of 
receptors elicits a different cell response, but it is mainly the ~ 
receptors, together with some «2 activity, which control metabolic 
activity. ~, causes lipolysis whilst ~2 is responsible for the breakdown 
of liver glycogen (Lewis, 1980). 
1, 5 IREUXEIII 
1.5a InSulin Injection Therapy 
A normal person maintains a circulating plasma glucose level that 
fluctuates between 60 and 160 mg/dl during the fasting and fed states 
(Arky, 19'19), and the body easily restores glucose levels. In diabetes 
mellitus the pancreas is unable to cope with the high levels of glucose 
following a meal. Before insulin is used to control hyperglyco.em:la in 
either juvenile or maturity onset diabetes mellitus a controlled 
carbohydrate diet is essential. For patients suffering from juvenile 
onset diabetes a controlled carbohydrate diet is supplemented with 
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insulin injections. In obeoe patients suffering from maturity onset 
diabetes mellitus weight reduction is a first priority followed by a 
controlled carbohydrate diet, and if neccesary oral hypoglycaemics; if 
all these prove inadequate only then is insulin recommended (Oakley et 
aI, 1975). 
Since insulin is broken down in the gut it is adDinistered via a 
subcutaneous injection. The different preparations available on the 
market vary in their time of onset of action and in their duration of 
action; the onset time is directly related to the crystal size. 
The relatively quick onset preparations are: 
(i) Soluble Insulin - An aqueous solution of insulin crystals with an 
onset time of 1 hour or less and a duration of nearly 6 hours. 
(ii) Globin Zinc Insulin - A solution of insulin globin and zinc with 
an onset time of 2 hours and a duration of 24 hours or less. 
(Ui> lsophane Insulin - A DOdified protamine zinc insulin solution 
with an action spectruD siniliar to the previous one. 
(iv) Lente Insulin - Zinc insulin in an acetate buffer, pH 7.2-7.5, 
with an onset time of 2 hours and a duration of nearly 14 hours. 
(v) SeDilente Insulin - Amorphous zinc insulin in an acetate buffer, 
with an onset time of 2 hours and a duration of 10 hours. 
The slow onset and longer acting preparations are: 
(i) Protamine Zinc Insulin - Insulih/protaD1ne cODplex with a trace 
of zinc; onset time of 6-12 hours and duration of 48hrs. 
(ii) Insulin Ultralente - A suspension of the crystalline form of zinc 
insulin with a onset time of 5 hours and a duration of 36 hours. 
Any treatment involves tailoring the requirements of the patient to the 
preparations available. garely is only one preparation used, more 
usually a mixture of both the quick onset/short duration and slow 
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onset/longer acting preparations is used (Turner & Richens, 1978). 
There are however side effects associated with the use of insulin 
preparations. in some patients tumours develop at the injection site 
whilst in others atrophication 01 the subcutaneous fat occurs at these 
sites leading to unsightly hollows, though this side-effect has been 
known to be reversible in some. Some patients are allergic to all forms 
of insulin whilst some are only allergic to protamine zinc insulin 
preparations. )(ost of these problems are largely due to impurities 
present in insulin and since the introduction of purer animal and 
synthetic human insulins, they have become much less common. Continued 
use of insulin preparations can lead to tolerance, so diabetics require 
ever higher doses of insulin. 
1.5b Alternatives to Insulin Injections 
Efforts recently have been directed towards finding a replacement, 
for diabetics, for the daily injections of insulin. The alternatives are 
Islets of Langerhans transplant, whole pancreas transplant, artificial 
pancreases including full-mechanical models and hybrid models, and 
insulin pump implantation. Diet and oral hypoglycaemic drugs are also 
options in less severe maturity onset diabetes. 
Islets of LangerhaDShave recently been successfully implanted into 
diabetic patients by Norman Kneteman of the University of Alberta 
(Day ton, 1989). Pancreas implants have several disadvantages; patients 
reqUiring transplants are usually too weak to cope with the major 
surgery involved, they must also take immunosuppressants to overcome 
rejection and the implant must be carried out within hours of the organ 
becoming available (Day ton, 1989). 
Islet transplant in comparison 
le~ 
sufferA from rejection, and they 
is "'"<> re simple and safe, they 
can be . ~ "' 
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frozen and stored indefinitely (Rajotte, 1989). Initially the islets are I 
isolated and purified from a buman pancreas, about 2-3 g's, then they 
are inserted through a catheter into the portal vein troIll where they 
enter the liver and start to produce insulin (KneteIJlan et aI, 
1989; Day ton , 1989). Two patients who recieved transplants are, after si" 
months, producing enough insulin to significantly reduce their reliance 
on injected insulin (Day ton , 1989). 
Once the method has been fully developed it offers the possibility of 
transplants completely freeing diabetics from their daily chore of 
insulin injections. 
The development of artificial pancreases has been slow and probleIJlatic. 
There are currently two types undergoing development; a full-mechanical 
model comprising glucose sensor, insulin reservoir, and insulin pump, 
and a hybrid model consisting of living insulin-secreting tissue in a 
man-made chamber. 
In a bybrid artificial pancreas living insulin-secreting tissue is 
placed in a chamber composed of semi-permeable membrane shaped either as 
bollow fibres or simply as a bo". Xodern polymer chemistry offers the 
possibility of encapsulating individual islets in an inert polymer and 
inplanting them (Friedman, 1989). The sell1-perooable membrane allows the 
passive transfer of plasma and tissue solutes, both in and out, so that 
sufficient nutrition is provided i'or the cells (AI tman et aI, 1986; 
Aebischer et aI, 1986). 
Initial work shows that normalization of blood glucose levels, in 
experioontal diabetic animals, was achieved with a bybrid artificial 
pancreas containing eitber isolated islets or foetal pancreas, witb tbe 
inplant maintaining activity from a few days up to nearly a JIClntb 
(Friedman, 1989). 
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The search :for a full-JJechanical artificial pancreas has been going on 
for over two decades (Kadish, 1964), and the old external cumbersoJJe 
lIlOdels have given way to smaller implantable lIlOdels (Pfeiffer, 191;9). 
But the major problem of an imp1antable neutral glucose sensor has 
hampered progress. 
Currently a glucose sensor, 6cll. long and with a 2mm cross-sectional 
diaJJeter, is being evaluated by Pfeiffer and collegues (Pfeiffer, 191;9). 
The sensor, an amperoJJetric electrode, works on the electrical energy 
generated by the following chemical reaction: 
Glucose + O2 ------ Gluconic acid + H2~ 
The current flow, caused by the transfer of electrons, is proportional 
to the concentration of glucose (Pfeiffer, 1989). 
The sensor has been tested in experimental animals where it succesfully 
lIlOnitored blood glucose levels, its response to changes in blood sugar 
levels following an injection of either glucose or insulin was only 5-15 
minutes (Pfeiffer, 1989). 
There still remains a large alIlQunt of work to be carried out before 
either of these systems can be considered a serious alternative to 
insulin injections. 
Continuous subcutaneous insulin infusion (CSll) either by external or 
internal insulin pumps has been slowly developing over the years. 
There are three components to the pump, insulin, pump device, and 
catheter . The insulin used is buffered, neutral and human, such as U-
100 insulin (Hoechst). The main problem has been with the catheters 
which have suffered blockages, inner lUJJen fibrinous' and cellular 
material deposition, fibrous granuloma at the tip, and full or partial 
catheter encapsulation by' oJJentum. Other problems concern the pump 
device itself, which causes local irritation leading from pain to 
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infections and ulcers. Also the inherent task of refilling the 
reservoir, presents further probleDS. Considering these shortcomings it 
seems unlikely that implantable insulin pumps will gain wide currency 
(Selan, 1988). 
The obvious solution to pancreatic failure would appear to be whole 
pancreas transplants but these have had mixed results. Between Decenber 
17, 1966, and June 30, 1988, 1549 pancreas transplants were reported to 
the International Pancreas Transplant Registery. The overall one year 
acturial graft function was 42%, whilst reCipient survival rate was Duch 
higher at 80%. The longest surviving graft is over ten years, but the 
encouraging fact is that 441 transplants have survived for over a year 
and 597 grafts are still functioning to date. Failure of the transplants 
are due to rejection, prillilry thromboSis, local infections, and other 
iDlllOnological complications; whilst some patients (145) died with a 
functioning transplant (Sutherland & Xou dry , 1989). But no matter how 
succesful the survival rate donors will still remian the limiting 
factor; though recent advances in genetically engineering animals whose 
organs are conpatible with hUlIilns may offer an alternative. 
A nore 'physiological' administration of insulin prOViding continuous 
control of plasma glucose concentration might be particularly beneficial 
to diabetics who, because of inherent instability or loss of symptoms of 
hypoglycaemia or hyperglycaemia, have difficulty controlling their blood 
glucose concentrations. It might also reduce the incidence of diabetic 
complications. Unregulated acute hypoglycaemia or hyperglycaemia would· 
be particularly harmful, as susceptible tissues would be seriously 
damaged. Rather than insulin injections into the arm, delivery of it 
into the hepatic portal • vein, as in normal physiology, Day be IIIOre 
beneficial. 
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It is possible that one, or a combination, of the alternatives under 
development will offer a realistic choice to diabetics suffering daily 
-injections. 
l,5c Oral Hypoglycaemlcs 
There are two main classes of oral hypaglycaeDics, the sulphonylureas 
and the biguanides. 
The SULPBOIYLVREAS were first developed from carbutaDide which was found 
by Franks & Fuchs (1955) to produce hypoglycaemia. They can only work if 
there is SOD£! functioning islets 
compounds stimJlate the release of insulin. 
of Langerhans, since these 
In addition to this they 
sometiD£!s reduce the production of glucose from the liver. 
Chlorpropamide, a long acting hypoglycaeDic, occasionally has a fatal 
side-effect; it continues to stinulate insulin secretion at night when 
no food is being taken so that severe glucose depletion occurs leading 
to cena and finally death, though this is a problem which may also arise 
with the long acting insulin preparations. Apart from this some 
patients, =20~, suffer nausea and flushing if chlopropamide is taken in 
conjunction with alcohol. A very small nuDber of patients suffer skin 
rashes, gasterointestinal problems and fatigue 
1980; see figure #17). 
(Slater, 1961; Lewis, 
PhenforDin was the first BlGUAlIPE found and this was shortly followed 
by metfornin. These class of drugs have a different mechanisD of 
operation than the sulphonylureas; whereas the latter can cause death in 
healthy people the forD£!r have no effect. 
The biguanides act in three different ways: 
(i) Increase insulin-facilitated transport of glucose into cells. 
(ii) Greatly decrease glucose absorption from the gut. 
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FIGURE #1? 
Q.FAL HYPOGI.YCAEMICS FOR THE 
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(iii) Decrease glucose production in the liver from glycogen. 
Metformin has the unpleasent side-effects of gastrointestinal upset, by 
inhibiting Detabolism of lactic acid, leading to anorexia, nausea and 
vollli ting. Phenformin can cause lactic acidaemia in SODe patients 
suffering renal and cardiac probleJIIS. Phenfornin is also known to 
interact with ethanol and this problem has now Dade the drug obsolete. 
Both drugs, with prolonged use, can interfere with the proper absorption 
of B'2. Also metformin is not broken down by the body whereas phenformin 
is (see figure 117). 
L 6 mKP!.ICAIJOIS OF DIABETES 
In many diabetic patients conventional insulin treatment does not 
prevent the onset of a range of vascular and nervous complications. 
The onset and rate of progression of these diabetic complications which 
include neuropathy, cardiomyopathy, cataracts, corneal epitheliopathy, 
and vascular daDage leading to probleJIIS such as nephropathy and 
retinopathy, appear to be dependent upon both the duration and the 
severity of the disease. Surveys have shown that the prevalence of 
=mplicatfons is DUch greater in poorly controlled diabetes (lrada.r et 
al. 1985; Brownlee & Cerami, 1981» but severity of the disease has not 
been effectively linked to complications, although this _y, in part be 
due to difficulties in assessing control. However most studies suggest 
that duration of diabetes is an iDportant factor. 
l,6a IEUROPATIlY 
In the peripheral nerVe of· the diabetic axon dwindling and segmental 
demyelination are associated with a very high prevalence of DOtor, 
sensory and autonomic dysfunction (Brownlee & Cerami, 1981; Winegrad et 
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aI, 19'79; Thomas & Lascelles, 1965; Dyck et aI, 1971; Chopra et aI, 
1969} • 
These basic dysfunctions lead to a range of clinical symptoms. Commonest 
aDOng these is a loss of sensory function in the extremeties which 
contribute, with vascular problems, to a propensity among diabetics for 
'foot-related problems. Diabetics are particularly susceptible to 
gangrene and related infections, together with anesthesia to pin pricks 
below ankles and absent toe proprioception. Constant burning and aching 
of feet, intermittant sharp shooting pains in the legs and proximal leg 
weakness are all common symptoms in diabetes (Jaspan et aI, 1986). Motor 
deficit nanifestB itself by a weakness Of. hip flexors and knee 
extensors, together with an absence o:f knee and ankle jerk reflexes. 
Pain in the extrenaties in diabetics may be associated with hyperaemia 
which, in turn, nay reflect reduced sympathetically Dediated 
vasoconstriction. In diabetics noradrenaline Uptake 1 blockers, such as 
andtriptyline and desipramine, are effective in reducing both pain and 
hyperaemia (Max et aI, 1991). 
Loss of autonomic control of the heart is a common feature in diabetics 
leading to arrhythlnias. Also in diabetics peripheral sweating nay be 
absent, whilst there Day be an inappropriatly profuse upper body 
sweating. Neuropathic 'dysfunction in diabetics is indicated by reduced 
testicular sensation, impotence whose physiological rather than 
psychological cause may be confirmed by the absence of nocturnal penile 
tumescence, atony of the bladder, and urine retention (Jaspan et aI, 
1986) • 
The entire gastrolntestinai tract may also suffer severe autonomic 
disorder leading to reduced peristalsis and dilation of the oesophagus, 
delayed gastric eDptying, disordered snaIl bowel movenent, 
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and atony of the large bowel which occasionally results in gross 
dilation of the colon (Brownlee & Cerand, 1981; Goldstein et aI, 1973; 
Brody & DixOD, 1964; Chriestleib, 1973). 
Diabetic neuropathy is visibly manifested by structural alerations of 
neurones. Reduced conduction velocity is thought to result from 
diminished internodal resistance in nyelinated neurons leading to 
reduced current density at the nodes and delayed excitation (Brownlee & 
Cerami, 1981). Alterations in the internodal myelin membrane stucture 
are linked to decreases in the number of intramenbranous particles OD 
both the inner and outer nyelin surface. Together with thi~endoneurial 
oedema occurs, leading to shrinkage ofaxons and Schwann cells. The 
permeability of nodal gap substance is also increased (Brownlee & 
Cerami, 1981). In patients with diabetic neuropathy, loss of large and 
snall myelinated and unmyelinated fibers is evident early in the 
disease. All of these neuronal structural dysfunctions are present in 
both diabetic patients and experimental animals (Brownlee & Cerami, 
1981> • 
1 • 6b V4SCUl.OPATHY 
Peripheral vascular disease is commonly associated with diabetes 
mellitus in humans (Brody & Dixon, 1964). Vascular complications such as 
hypertension, atherosclerosis and thrombosis are prevalent in diabetic 
patients (Vaka~yashi et aI, 1987). 
Atherosclerosis, caused by a deposition of hard yellow plaques of lipOid 
material in the arteries and a thickening of the media, is believed to 
. 
be related to changes in the vascular endotheliun (Vakabayashi et aI, 
1987). The vascular endothelium, an iDportant regulator of vascular 
tonus (Xarks, 1971), is particularly susceptible to a range of agonists, 
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in addition it iorJIIS a barrier between the blood and the underlying 
vessel wall. Damage to the endothelium may be the primary event leading 
to the development of atherosclerosis. Diabetics also suffer increased 
atheromata in medium and large arteries which makes coronory arterial 
disease and stroke twice as common. Symptomatic peripheral arterial 
disease is three to four tiDeS JDDre cOllllllOn among diabetics (Paley et 
aI, 1961; Brownlee & Cerami, 1981; Brown et aI, 1976; Gregerson, 1968; 
Eliasson, 1964; Schmidt , 1985>-
Atherosclerotic vascular disease leads to myocardial infarcts, strokes 
and gangrene in diabetic patients (Chobanian et aI, 1982). In addition 
diabetics are prone to hyperlipoproteinemia, obesity and 
hypercoagulability of blood (Chobanian et aI, 1982). Vascular changes in 
nervous tissue may underlie or contribute to the problem of neuropathy 
(Brownlee & Cerami, 1981, see below). 
In the eye a large number of dysfunctions begin to appear in patients 
with diabetes. Retinal capillary damage leading to oedema 
together with new vessel formation and loss of intraDUral pericytes and 
microaneurysms cause severe problems for many diabetics (Caird et aI, 
1969; Davis et aI, 1969; Smith & Becker, 1976; Caird et al ,1964). In 
addition to this there appear areas of non-perfusion, haemorrhaging 
becomes CODIIIDn place, coupled with exudates into the vitreous hUllOur 
(Brownlee & Cerami, 1982; Cogan III Kuwabara, 1963; Ashton, 1963; Kohner 
et aI, 1973; ficho & Patz, 1973). A combination of these complications 
to make blindness twenty times DOre CODmOn among diabetics; and 
cataracts five tiDeS DOre comnon (Brownlee & Cerami, 1981). 
Diabetics suffer complications in the kidney leading to gross problems 
nearly as frequently as they suffer blindness. Patients very often 
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develop basement Dembrane thickening in the glomerulus. but the first 
sign of nephropathy is a SDall increase in urinary albumin excretion 
(llicroalbuminuria>. in addition there may be an initial increase in 
glomerular filtration rate (GFR> (0sterby. 1972; Watkins et al. 1972; 
Lundbaek 11< 0sterby. 1976; Westberg 11< ltichael. 1973). Jlephropathy 
progresses to proteinuria and a declining GFR which combine to make 
renal failure seventeen times more common in diabetic patients than in 
the general population (Clarke et al. 1979; Brownlee 11< Cerami. 1981; 
Beiswenger. 1975). 
Gangrene leading to amputation is at least five times more likely aDOng 
diabetics (Brownlee 11< Cerami. 1981; Bell, 1957). Concurrent with this a 
wide range of debilitating symptoms such as diarrhoea (or constipation), 
loss of sensation, pain. ulcers and postural hypotension may also begin 
to appear. Atherosclerotic heart disease. due to vasculopathy, is 
prevalent in diabetics, though there is some regional variation with 
Europe and ADerica having a higher rate than Japan (IIinegrad et al. 
1979; Blackard et al. 1965). 
1.6c eard1Pm1Qpathy 
Diabetes is believed to be associated with specific cardionyopathy 
(Ahmed et al. 1975; Hanby et aI, 1974; Regan et aI, 1974; Rubler et aI, 
1972; Seneviratne. 1977). Diabetes expresses itself in the heart with 
cardiac hypertrophy, congestive cardiac failure and paroxysmal nocturnal 
dyspnoea (Das et aI, 1987). 
Studies have shown inpaired myocardial peri'ormance in the hearts of 
streptozotocin-induced diabitic rats. Abnormalities include increased 
time-ta-peak isometric, decreased velOCity of isotonic shortening, 
delayed rates of relaxation, decreased left ventricular pressure 
. ~:,...:, 
:~f::"?'~'" . 
. ' 
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development and diminished rates of left ventricular pressure decline 
(Fein et al, 1980; Penpargkul et aI, 1980). Insulin treatment fails to 
correct these abnormalities (Kalhotra et aI, 1981). 
Reduced ATPase activity of actomyosin, myosin and actin-activated myosin 
have been found in streptozotocin-induced diabetic rats (Kalhotra et aI, 
1981). It has been proposed that ATPase activity is closely related to 
the contractile functions of skeletal muscle (Scheuer & Bhan, 1979) and 
is mediated by alterations in the isoenzyme of myosin (Flink et aI, 
1979; Hoh et aI, 1977; Lompre et aI, 1Y79). 
It has been proposed that the early changes in the nervous system and 
the vasculature (see above) contribute to cardiac problelllS. Reduced 
blood supply to the DYocardium due to vasculapothy is believed to result 
in angina. Sensory neuropathy Day allow diabetic patients to overstress 
the heart without the resulting pain, which would normally act as a 
warning. 
Recent studies have shown that the myocardiuD is itself directly damaged 
by diabetes. Contraction and relaxation times are slowed in the diabetic 
state, without any evidence of impaired nervous and vascular functions 
(Reddy ~ K~~, 1988). Prolongation of the total contractile phase would, 
presuDably, reduce the periods of relaxation during which most 
myocardial blood flow takes place. Reduced blood flow would contribute 
to the increased incidence of and sudden death due to arrhythmias in 
diabetic patients (Reddy g. Wlai\, 1988~. 
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POSSIBLE MECHANISMS OF DIABETIC COKPLICAIlOIS 
1.7a Prgposed Iechanism5 
(i) Ihe Sgrbltgl <Pglyo]) Pathway 
The sorbitol/polyol pathway has been suggested as one possible 
explanation for several complications which occur in diabetes. 
lany of the cell types which are most vulnerable to damage by diabetes 
e.g. neurones and vascular endothelial cell, are capable of insulin-
independent glucose transport, this leads to an increase in the 
intracellular glucose concentration during periods of hyperglycaenda. 
Intracellular glucose can suffer two fates, either glycolysis which 
requires phosphorylation by the enzyme hexokinase to glucose-6-phosphate 
or conversion to fructose and then glycolysis following phosphorylation 
by the enzyme fructokinase (Dvovnik, 1978). 
The conversion of glucose to fructose proceeds via the polyol pathway 
through the intermediate alcohol sorbitol under the action of two 
enzymes. Initially aldose reductase utilizes HA])PH to reduce the 
aldehyde form of glucose to its corresponding sugar alcohol, sorbitol. 
Higb Km Higb V.max 
GLUCOSE + HA])PR ---------------------~ SORBITOL + BADP· 
In the second step sorbitol dehydrogenase utilizes HA])· to oxidise the 
alcohol sorbitol to the sugar fructose. 
Low Km Law V_x 
SORBITOL + IADP· ---------------------~ FRUCTOSE + HADPH 
Under normal physiological conditions available glucose is rapidly 
phosphorylated by hexokinase rather than being converted to sorbitol, 
. 
since glucose has a greater affinity for hexokinase than aldose 
reductase. In diabetes hyperglycaemia raises intracellular glucose 
concentrations in susceptible cells and causes saturation of the 
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hexokinase, itself reduced in diabetes, so that the alternative pathway 
comes into play; resulting in the production of a significant amount 
of sorbitol. The polyol pathway functions unevenly however, sorbitol 
is produced more rapidly than it is converted to fructose, so that 
an a=ulDlllation of the alcohol occurs (Kador et aI, 1983). This 
accumulation of sorbitol inside affected cells is further increased by 
its polar nature, since its polarity prevents Denbrane penetration and 
subsequent reJllOval through diffusion. The intracellular sorbitol level 
increases to such an extent in some cells e.g. those of the lens in the 
eye, that an hyperosmotic effect occurs. This involves an infusion of 
fluid to counteract the resulting osnotic gradient. This influx of fluid 
may e.g. by damaging membrane permeability, contribute to cell 
pathology (Kinoshita, 19'14; Yard et aI, 19'12; Gabbay, 19'15; Palnano et 
aI, 19'1'1). It has been suggested that these permeability changes 
contribute significantly to diabetic cataract. Sorbitol accumulation in 
cells other than those of the lens may be insufficient to produce such 
gross oSDOtic effects but nay cause damage by other nechanisns e.g. via 
a depletion of myo-inositol (Kador et aI, 1985). 
Due to the sorbitol pathway dysfunction in the diabetic peripheral nerve 
the levels of myo-inositol, fructose and sorbitol are all altered 
(Gillon et aI, 1983). The sorbitol-producing enzyme aldose reductase can 
be inhibite~and this brings about restoration of the levels of these 
compounds whilst simultaneously preventing the fall in sodiun-potassium 
ATPase acti vi ty associated with diabetic neuropathy (Chandler & ltiller, 
1986). The effectiveness of these inhibitors has lead to their 
> 
development as a new class of drugs and Dany are undergoing clinical 
trials . 
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Aldose and aldehyde reductases are members of a group of enzymes known 
collectively as the aldo-keto reductases. The enzymes are monoueric. 
primarily JlADPH-dependent 
( 
oxireductases with a broad substrate 
specificity for aldehydes (Sarges & Peterson. 1986). 
There are three aIde-keto reductases present in animal tissue (Paulsen. 
1979): 
(i) ALR,. a high Km enzyme. called Aldose Reductase. 
(ii) ALRz. a low Km reductase. possibly involved in diabetic 
neuropathy. 
(iii) ALR3. the only ketone reductase & called carbonyl reductase. 
Aldose reductase contains sulphydryl groups and it is postulated to 
exist in a globular form. Three distinct enzyme regions have been 
identified; a substrate region. a nucleotide. and an inhibitor site. 
studies have revealed a nucleophile residue.. possibly tyrosine. is 
present at the inhibitor site (Sarges & Peterson. 1986). 
The aldose reductase inhibitors reversibly interact with ~ldose \) 
reductase at a common site independent of either the substrate or 
nucleotide cofactor fold. The inhi bi tion which results is. therefore. 
non-competitive inhibition of the enzyme and is in part related to the 
lipid solubility of these inhibitors; increased inhibition has been 
observed with the introduction of hydrophobic substituents (Flynn. 1986; 
Rador et al. 1986). This is not suprising since they must cross the cell 
membrane to reach their target. In addition studies reveal that 
inhibitory activi\".y is also increased in the presence of selective 
phenolic groups. The development of sterically constrained 
spirohydantoin aldose reductase inhibitors has also revealed that the 
enzyme can stereochemfc1llly differentiate between inhibitors; showing 
that inhibitory activity resided mainly with the S-enantiouer. Aldose 
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reductase inhibitors usually contain a group, such as carbonyl, 
thiocarbonyl etc. which is capable of undergoing reversible nucleophilic 
attack (Flynn, 1986; Srivastava et aI, 1986; Pitts et aI, 1986; Jaspan 
et aI, 1986). 
The iuplication of the polyol pathway in the onset of non-insulin 
treatable complications, which has been suspected for over a decade, has 
been supported by a vast range of experiDental and clinical data (see 
figure #18). Briefly aldose reductase inhibitors prevent sorbitol 
acculllllation in the<!~abetic periphe!al_~~erve, retina, lens, kidneys, 
microvasculature and red blood cells. In clinical trials aldose 
reductase inhi bi tors have been reported to alleviate a variety of 
autonomic and somatic neuropathic symptoms. 
Aldose reductase inhibitors prevent the build-up of sorbitol and 
fructose in the diabetic nerve and concurrently raise the level of myo-
inositol. Restoration of myo-inositol levels is believed by some to be 
the mechanism by which aldose reductase inhibitors restore sodium-
potassium ATPase activity. There are a range of inhibitors undergoing 
clinical evaluation ( see figure #19). 
<1i) X1o-Inositgl 8; the Phgsphgipositjdes jn Diabetes 
Inositol (hexahydroxycyclohexane) is an isomer of glucose which has 7 
optically inactive and one pair of optically active stereoisomers. The 
optically inactive form myo-inositol (see figure #13) is the one 
required by the body. Kyo-inositol is present in high concentrations in 
humiD Dilk, in vegatables and meat; cereals have the hexaphosphate 
. 
form, phytic acid, which is readily absorbed (Lewis, 1980). 
Deficiency of myo-inositol is difficult to demonstrate since the body 
readily manufactures it, but it has been demonstrated (Eagle et aI, 
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FIQ[LRR #18 
EFFECTS OF ALDOSE REDUCTASE 
INHIBITORS IN ANIMAL MODELS 
PERIPHERAl. JERYR 
Prevents changes in sorbitol, fructose, sodiuD-potassiuD ATPase, and 
myo-inositol levels in the sciatic nerve in diabetic rats. It also 
prevents or reverses changes in nerve conduction velocity and orthograde 
axonal transport. ( Greene, 1986; Yillars, Tomlinson & Robinson, 1986; 
Chandler & Killer; 1986) 
REIIU 
Prevents polyol accumulation in retinal capillaries and human retino-
blastoma cell line. 
In diabetic animals, prevents changes in retinal sorbitol, myo-inositol, 
sodiuD-potassiuD4 and associated retinal electrical activity. Prevents 
capillary basement menbrane-thickening in galactoseDic rats. 
(. Y1lliamson et al; 1986) 
Bormalizes sorbitol, fructose, sodium-potassium ATPase activity, 
glutathione, and myo-inositol.Prevents and reverses sugar cataracts. 
Diminishes cataract formation in aniDal senile cataract model. 
(Rador, Akagi & Kinoshita; 1986) 
IIDIEI 
Prevents changes in sorbitol and sodium-potassium ATPase activity in 
diabetic rats. 
Diminishes proteinuria in diabetic rats. 
( Beyer-)(ears, 1986;·' Cohen, 1986) 
llED BLOOD CELLS 
Bormalizes red blood cell sorbitol levels in diabetic rats. Prevents 
decrease in red blood cell. deformation in diabetic rats. 
(Peterson, Page, Just, Aldinger & Kalone; 1986) 
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FIGURE #19 
ALDOSE REDUCTASE INHIBITORS 
CURRENTLY BEING CLINICALLY TESTED. 
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1957) that eighteen human cell lines all required it for growth. 
Several observations have linked linked diabetic neuropathy to a 
reduction in the norJJiil ninety-fold nerve to plasma myo-inosi tol 
concentration gradient (Kayhew et aI, 1983; Winegrad & Greene, 1976; 
Gillon et aI, 1983). 
Tissue myo-inositol content is reduced by 20-30~ in the nerves of 
diabetic patients (Hale et aI, 1987). Acute experimental diabetes in the 
rat reduces nerve conduction velocity and nerve myo-inositol content by 
~25~ without changing plasma myo-inositol levels. In addition certain 
other abnorJJiilaties are present in the nerve, namely an increase in the 
levels of glucose, fructose, and sorbitol (Kayhew et aI, 1983; Dyck et 
aI, 1980; Tomlinson et aI, 1984). 
Insulin replacement that normalizes nerve conduction velocity in the 
diabetic rat also prevents the fall in Dyo-inositol nerve content. 
PharJJiicological elevation of plasma myo-inositol content by oral 
supplementation prevents or reverses both the reduced nerve myo-inositol 
content and motor nerve conduction velocity in the diabetic rat without 
affecting hyperglyc~mia or the raised nerve glucose, fructose or 
sorbitol levels (Greene et aI, 1975). 
These observations suggest that alterations in nerve myo-inositol 
content impairs nerve impulse conduction and other nerve functions. 
Recent work has demonstrated a link between reduced myo-inositol 
content, the activity of the nerve Kg2+-dependent sodium potassium 
stimulated adenosine triphosphat= ("sodium-potassiuD ATPase), and 
plasmalel!Illal 'sodiuD gradient (Greene, 1986.; Greene & Lattiner, 1982 & 
1983) . 
A reduction of sodium-potassium ATPase activity in the diabetic nerve 
was postulated since the composite resting nerve energy utilization, 
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based on sodiuD-potassium ATPase activity, was reduced in experimental 
diabetes. Tbe membrane-bound pb06pboinosltides have been implicated in 
membrane-bound sodium-potassium ATPase function in some nammalian tissue 
lIyo-in06i tol uptake froD plasma into tissue occurs by two transport 
systeDS but mainly by a sodiuD and energy-dependent saturable transport 
systeD, which is responsible for at least 95~ of the uptake, is the 
mechanism central in understanding diabetic neuropathy. The carrier 
present in tbis system has an affinity for myo-inosi tol 500X greater 
than glucose; but in hyperglycaemia the raised blood glucose level 
reduces Dyo-inositol uptake by 30~ due to competitive inhibition. 
The hyperglycaemia undoubtedly inhibits mye-inositol uptake since in 
vivo equivalent amounts of fructose and mannitol have no effect (Greene 
& Lattimer; 1983). This primary uptake system probably contributes to 
the establishment and/or maintenance of the normal tissue to plasma DyO-
inositol concentration gradient (Greene & Lattimer, 1982; Gillon et aI, 
1983a & 1983b; ). Thus competitive inhibition of the carrier by glucose 
would seem to provide an explanation for the low levels of mye-inositol 
in, for example peripheral nerve, wbich has been observed in 
experimental diabetes. Though tbis mechanism doesn't explain 
normalization of myo-inositol levels by aldose reductase inhibitors. It 
would appear that raised intracellular sorbitol concentrations 
contribute to impaired cellular accumulation of myo-inositol. 
Recent data has suggested that diabetes significantly decreases resting 
energy utilization by peripberal nerve in vitro (Greene & Lattimer, 
. 
1984). As nearly half of the steady-state energy utilization occurs via 
tbe sodium-potassium ATPase system, any reduction in utilization could 
reflect a corresponding reduction in sodium-potassium ATPase activity 
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(Ritchie,1967). Since peripheral nerve myo-inositol uptake is driven by 
the sodium gradient, estab .. lished by the sodium-potassium ATPase, any 
reduction in the ATPase activity would seriouslJ impair mye-inositol 
uptake (Greene .,. LattiDer, 1985; Jlayer & Tonlinson, 1983). These 
interactions, it is proposed, thus forD a self-reinforcing cyclic 
metabolic derangeDent involving Dye-inositol and sodium-potassiuD ATPase 
(see figure 120). 
lIyo-inositol is a substrate for the synthesis of phosphotidylinositol 
and the higher phosphoinositides, which are endogenous regulators of 
microsomal sodium-potassium ATPase. Any reduction in myo-inositol 
uptake, as outlined above, is likely to reduce the turnover of the 
phospholipids. Studies have shown a depletion in the myo-inositol pool 
utilized for the synthesis of phosphatidylinositol in sciatic nerve from 
streptozotocin-induced diabetic rats (Zhu & Eichberg, 1990). The 
phospholipids and sodium-potassium ATPase are both membrane bound, 
suggesting that since both are reduced in diabetes they may be linked 
in SODe way (Bell et al,1982; Berti-Jlattera et al,1985a). 
Xye-inositol is required for the synthesis of phosphotidylinositol, 
which is a parent compound to two important intracellular regulators, 
inositol 1,4,5-trisphosphate <IP3 ) and diacylglycerol (00), The normal 
cycle of phosphotidylinositol and the higher phosphoinositides synthesis 
and metabolisDis shown in figure 121 (Natarajan et aI, 1984). 
Any reduction in the level of myo-inositol would tend to reduce the 
turnover of the phospholipids. This has been confirmed by the 
measurement of phospholipids in the nerve of the diabetic rat. The 
. 
levels of phosphotidylinosi tide (PI>, phosphotidylinosi tol 4-phosphate 
(PIP), and phosphotidylinosi tol 4,5-bisphosphate (PIP2) have all been 
found to be reduced; as well as the activity of CDP-diacylglycerol and 
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FIGURE tt2Q 
PROPOSED CYCLE TO SHOW THE 
CAUSE OF DIABETIC NEUROPATHY 
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'This leads to decreased motor nerve conduction velocity and sodium-
dependent amino acid uptake. 
Proposed schene interrelating glucose-mediated competitive inhibition of 
sodium-dependent ayo-inositol (XI) uptake, phosphoinositide metabolisn, 
and sodiuDrpotassium ATPase activity in the diabetic nerve. 
(Figure summarised from Greene, 1986) 
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FIGURE it21 
THE SYNTHESIS AND METABOLISM 
OF THE PHOSPHOINOSITIpEs. 
ElJ.lW.TIQ! OF PRQSPR4TIDYLIJQSlIOL 
Glucose 
I 
I 
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ROI.R OF PROOPRA.IlDU.I100IIQI. 
, /c-_-"'P:..aI ...... K .... iJl,nAa.se= ______ _ PIP Kinase 
PI PIP PIP2 
PIP Phospho.moesteras? PIP2 PhosphoJllOnoestera~ 
PI Phospho-
diesterase 
I 
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PIP Phospho-
diesterase 
I 
I 
I 
I 
, 
PIP2 Phospho-
diesterase 
I 
I 
I 
I 
, 
DG + IP 1---------------------- DG + IP2 1------------------- DG + IP" 
1!XPLAIATIDI OF SJ!IlQI S. 
PI: Phosphatidylinositol, PIP: Phosphatidylinositol 4-Phosphate, 
PIP2: Phosphatidylinositol.4,5-Bisphosphate, DG: DiacyIglycerol, 
GDP-DG: Gytidine Diphosphodiacylglycerol, PAl Phosphatidate, 
PG: Phosphotidylglycerol, IP: Inositol i-Phosphate, 
IP2: Inositol l,4-Bisphosphate & IP:>: Inositol l,4,5-Trisphosphate. 
(Figure summarised from Greene & Lattimer, 1983) 
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PIP kinase (Natarajan et aI, 1982). The reduction of PI is important 
since it also reduces levels of sodium-potassium ATPase, which in turn 
reduces the level of sodium-dependent myo-inosi tol uptake (GiUon & 
Hawthorne, 1983; Berti-Xattera et aI, 1985b). 
Measurements have shown raised levels of fructose and sorbitol 
concurrent with reductions in myo-inositol and sodium-potassium ATPase 
activity in the nerve of diabetics and experimental diabetic ani_Is 
respectively, which would seeD to support this proposal <" (Tree-A<:-: g.. '" 
Latt/;"'e.r, '~8S=-)_ 
However the above mechanism has been questioned by a recent observation 
that restoring myo-inositol levels is not necessary to restore 
functional sodium-potassium ATPase activity (Calcutt et aI, 1990), The 
sorbitol pathway hypothesis, to explain the various dysfunctions 
occuring in the diabetic state, has also been contradicted by the 
finding of raised ouabain-sensitive sodium-potassium ATPase activities 
in the sciatic nerves of galactosaemic rats; which like diabetic rats 
have reduced levels of nerve myo-inositol (Lambourne, 1989). In addition 
to this ,the observation that ouabain-sensitive sodium-potassium ATPase 
activities are depressed in several skeletal and cardiac muscles, has 
also cast doubt on the sorbitol proposal (Kjeldsen, 198'). Since glucose 
transport into skeletal muscle cells is generally insulin dependent it 
seems unlikely that sufficiently high intracellular glucose 
concentrations occur to activate the polyol pathway. It is possible that 
intracellular glucose concentration is raised sufficiently if in 
conjunction hexokinase activity is sufficiently depressed. 
. . 
This theory has been put forward to explain the many dysfunctions 
occuring in diabetes. It has gained so much currency that a whole range 
of aldose reductase inhibitors have been developed and are undergoing 
( 64 ) 
clinical trials. These drugs inhibit the enzYD" which converts glucose 
to sorbitol, and thus seek to prevent the accumulation of sorbitol and 
the fall in myo-inositol concentrations (Chandler & Miller, 1986). The 
results of clinical trials to date have, however, been disappointing 
(Florkowski et aI, 1990). It has been suggested that the early changes 
occuring in diabetes are' reversible whilst the later ones are not, so 
that aldose reductase inhibitors Day only be of use prophylactically. 
However such a use poses severe practical and ethical difficulties, 
these will be discussed later. 
(iil) Hypothyrpidism 
In consideration of the above findings an alternative suggestion has 
been made that the depression in sodium-potassium ATPase activities may 
be caused by hypothyroidism. 
The thyroid gland releases two main hormones, thyroxine (T4) & 
triiodothyronine (T .. ) , which are important regulators of body 
metabolism; in addition it also secretes thyrocalcitonin which acts in 
concert with parathyroid hormone to control calcium metabolisn. 
Thyroxine and Too control body metabolism in a positive/negative feedback 
mechanism. They regulate energy metabolisD at both the cellular and 
subcellular levels, and so control body growth (Lewis, 1980). 
The thyroid hormones are synthesized froD dietary iodide and tyrosine in 
the thyroid gland. Iodide ions are actively taken up by the follicle 
cells of the thyroid glands and oxidated to form iodine. 
21- ----------~ 12 
Thyroglobulin, a complex glycoprotein, is synthesized in the follicle 
cells where it also iodinated and during this process tyrosine 
residues of thyroglobulin are iodinated to give two forms. 
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Tyrosine + 12 -----------~ 3-lodotyrosine + 3,5-Diiodotyrosine 
The resulting two forms undergo a further reaction to give the final 
hormones (ThoDas & Xawhinney, 1973). 
3-Iodotyrosine 3,5,3'-Triiodothyronine (T3) 
+ ---------------+ + 
3,5-Diiodotyrosine 3,5,3' ,5' -Tetraiodothyronlne '(T .. ) 
The iodothyroglobulin complex forms a colloid, containing the various 
iodinated forlllS, and is stored in the follicles of the thyroid gland. 
The hormones are stored here as a colloid until required; in which case 
the colloid is taken back up by the epithelial cells. Here thyroglobulin 
is hydrolysed liberating T3 and T .. which are secreted into the blood 
stream. 3-iodotyrosine, 3,5-iodotyrosine, and other amino acids which 
are also liberated by the hydrolysis of thyroglobulin are reused. 
Two tissues are involved in the control of the release of the thyroid 
hormones, the hypotbalamus and the anterior pituitary gland. Of these 
the latter is the simplest and marely requires the pi tui tary gland to 
monitor circulating hormone levels and if these should fall it secretes 
Thyroid stimulating Hormone (TSH or thyrotrophin) which stimulates 
thyroid hormone secretion (Xaloaf & Sadook, 1963; Lewis, 1980). 
The hypotbalamus controls the secretion of the anterior pituitary gland 
by secreting Thyrotrophin Releasing Factor into the portal system of 
blood vessels which supply the anterior pituitary gland. 
Though both thyroxine and T3 have the sa:me action, there is a tima 
difference in their action (see figure #22); T3 acts immediately whereas 
there is a delay before thyroxine produces a response. The tetraiodo-
. 
form undergoes conversion to the more active triiodo form in the liver. 
Both hor.mones act on the mitochondria, the power house of the cell, to 
increase uetabolic activity. In addition they also sensitise cells to 
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adrenaline and noradrenaline by either increasing adenyl cyclase 
syntbesis or by producing transitory catecholanine receptors (Means et 
aI, 196 ; Lewis, 1980). 
Experimental diabetic rats have been found to be hypothyroid (Ganguly et 
aI, 1987; Goyal et aI, 198'1>; a condition which is known to affect 
sodiun-potassium ATPase activity. This activity has been normalised by 
the administration of triiodothyronine <T3) (Norgaard et aI, 198.). It 
has been proposed that altered vasculature reactivity is _diated by 
diabetes-induced hypothyroidism, at least in the early period of 
diabetes (Saunders et aI, 1978; Pittman et aI, 1979; Dillman, 1982; 
&lDdaresan et aI, 1984; Jop'"'' 1987). 
Various studies have found a decrease in vascular responsiveness in 
experiJDental animals (Turlapaty et aI, 1980; Pfaffman et aI, 1982 81 
1983; , __ ; Oyalllil et aI, 1986) which has been 
normalized by insulin treatJDent (Pfaffman et aI, 1983; Alexander 81 Oake, 
19·77; xacleod, 1985). Decreased responsiveness to isoproternal in 8 
weeks diabetic rats was restored by thyroxine treatJDent <Takiguchi et 
aI, 1989). However thyroxine treatment failed to nornalize responses to 
norepinephrine, 5-hydro~tryptandne and acetylcholine in 12 weeks 
diabetic rats (Takiguchi et aI, 1989), suggesting that altered 
responsiveness in early period of diabetes may be the result of 
hypothyroidisn whilst in later periods of diabetes other factors may be 
dominated e. g. hypoinsuli.o,emia or hyper8IyoC\~a. It seelllS insulin 
treatment is 'lIJediated through thyroid horlllOne levels; decreased 
myocardial ~-adrenoreceptors in diabetes are mediated by hypothyroidism 
and insulin is effective in restoring jl-adrenoreceptor numbers in the 
myocardiun only if the thyroid is present (Sunderesan et aI, 1984 
( 68 ) 
It is evident that early altered reacti vi ty of the rat vasculature is 
linked partly to thyroid hormone deficiency but this does not lead to 
neuropathy. It may be that hypothyroidism is the trigger which initiates 
the changes in the vasculature observed in diabetics, however there is 
little evidence to support this contention. 
Diabetes me11i tus is associated with cardiomyopathy in humans (Kannel & 
KCGee, 1979) and in experimental animals (Garber & Keely, 1983; 
Penparglrul et aI, 1980), with hypertension exacerbating the condition 
(Factor et aI, 1981>. Studies suggest that pressure load-induced left 
ventricular hypertrophy increases the susceptibility of myocardium to 
diabetes-related derangements (Fein et aI, 1984; Rodgers, 1986; 
Rodrigues & JllcJileil, 1986). Hypothyroidism is closely associated with 
diabetes (Pittman et aI, 1979) and has an equivalent effect on cardiac 
metabolism and function. Both conditions impair myocardial 
contractility, depress myosin adenosine triphosphate (ATPase) activity 
and sarcoplasmic reticular Ca2 + uptake and reduce sensitivity to 
adrenergic agonists (Dhalla et aI, 1985; Xorkin et aI, 1983; Rodgers et 
aI, 1986; Bilezikian & Loeb, 1983), TreatDent with T3,et a higher dosage 
than normal, of the diabetic spontaneously hypertensive rat was 
effective in preventing the depreSSions in measureDents of heart 
function, including pressure generation, rates of contraction, and 
stroke work (Davidoff & Rodgers, 1990). It is argued that dosage 
adequate for therapy of hypothyroidism may not correct the hypothyroid 
state induced by diabetes since sensitivity to T3 maybe reduced in the 
latter (Davidoff 8< Hodgers, 1990). Further studies found myocardial 
. 
dysfunction in diabetic rat heart including depressed nyosin ATPase 
activity and reduced calcium uptake in the sarcoplaSmiC reticulum 
(Buccino et aI, 1967; Ciaraldi 8< Karrinetti, 1977; Garber et 
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aI, 1983). These defects are normalised in diabetic rats by the joint 
adminstration of T3 and palmoxinate (Tahilani & XcNeil, 1985). The 
latter is a fatty acid analog which has been reported to decrease 
circulating glucose levels in diabetic rats, by inhibiting the excess 
fatty acid metabolism present in diabetes (Tu rile.( g, Ric:i\el\~ 1978>' 
In diabetes, not only are serulll levels depressed, but· there is al60 
tissue resistance. Diabetes impairs peripheral T4 to T3 conversion, 
tissue T3 uptake and both affinity and density of nuclear T3 receptors 
(Bagchi, 1982; Cantanni et aI, 1988). 
Diabetic cardiac hypertrophy and hypothyroidism leads to a shift from 
the predcminant 11, to V,. myosin eDZ)'D€ in rat ventricular muscle (Garber 
et aI, 1983; l{orkin et aI, 1983; Dil lman , 1982; Xalhotra et aI, 1981; 
1!ercadier et aI, 1981; Schaffer et aI, 1989), Ts may be effective in 
shifting the ratio of Dyosin isoenzyme activity in favour of V, 
(Davidoff & Hodgers, 1990). Treatment with T3 also corrected the 
bradycardia of diabetic spontaneously hypertensive rats <Davidoff & 
Rodgers, 1990). Impaired thyroid function among diabetics may be as high 
as 301. (Ganguly et aI, 1983) and T3 supplementation, with sufficient 
doses, may offer an effective treatment. 
It is clear that T3 is strongly implicated in the depression of skeletal 
and cardiac lIP.Iscle ATPase, and the sorbitol pathway, in some way, in 
nerve dysfunction and vasculopathy, but their interrelationship, if any, 
remains to be elucidated. 
(iy) Protein Glycgsylatign 
The non-enzymatic glycosylation of proteins is another mechanism 
proposed to account for the occurrance of both nervous and vascular 
diabetic complications. 
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JlorlMlly the free ... udno !!T0ups of pr£ltein lysine residues form !l 
Schiff's base with the aldehyde !!T0ups of sugars, and the resulting 
compound rearranges to form a stable Amadori end-product. 
In uncontrolled diabetics the increased sugar levels, due to 
hyperglycaeuda, lead to an increase in the proportion of· audno groups 
being glycosylated. One protein readily undergoing this reaction is 
heamoglobinj indeed the degree of heamoglobin glycosylation is an 
effective indicator of the degree and severity of diabetes (see figure 
#23), 
Intra and extracellular proteins also readily undergo glycosylation 
(XcVarry et aI, 1979). Glycosylation of albuudn leads to an increase in 
the rate of leakage froD microvasculature, possibly contributing to the 
initiation of udcroangiopathy (Sampietro et aI, 1987). Glycosylation of 
fibrinogen also o=urs and may affect the rate at which fibrin is 
cleared by plasudn (Brownlee et al,1983). Intracellular proteins, 
present in tissues permeable to glucose, also suffer the S!llIe fate 
(Vlassara et aI, 1981: Vost et aI, 1982). As in the sorbitol hypothesis 
those cells likely to be most affected are those displaying insulin-
independent glucose transport and which, therefore, are likely to 
experience high intracellular glucose concentrations in the presence of 
hyperglycaeuda. 
This process in particular occurs in the diabetic rat nerve where 
myelin, myelin-associated proteins and nerve tubulin are all affected; 
and which in turn mitigate the axonal transport of proteins (Villiams et 
al,1982>. This effect appears to be marginal since tubules are involved 
. 
in fast axonal transport whereas it is the slow transport which is 
deficient in the diabetic. state (Villiams et aI, 1982). This is 
underlined by the observation that repeated injections of glycosylated 
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prot .. ins into nonlal rats produced no discernable change in the nerves 
(l!cVarry et aI, 1980). Excess fructose produced by aldose reductase, 
from raised levels of sorbitol in hyperglycaemia, is more efficient than 
glucose at glycosylating proteins. Aldose reductase inhibitors have been 
reported to reduce glycosylation of proteins and this may be by reducing 
synthesis of fructose rather than lowering sorbitol levels (Xonnier et 
aI, 1991>. 
It has been shown that Amadori products undergo a further irreversible 
slow reaction leading to crosslinks in long half-life proteins (Brownlee 
et al,1984), which in turn inhibit the proteolytic degradation and 
turnover of the protein. This has led to the suggestion that this effect 
is responsible for the known thickening of the basment membranes of 
capillaries which reduces oxygen tensions in the nerve (Reiser, 1990). 
The reduced oxygen tension consequently inhibits all energy-dependent 
processes perhaps resulting in the type of neuropathy prevalent in the 
diabetic state. It has been demonstrated that keeping diabetic rats in a 
hyperbaric oxygen restores nerve conduction velocities to normal in 
these animals (Low et aI, 1980). 
Nitric oxide has been recently identified as an endothelium derived 
relaxing factor (EDRF) , an important mediator of smooth lIIJscle 
responsiveness and resting vascular tone (Furchgott, 1984>' EDRF is 
produced by endothelial cells, in response to agonists such as 
acetylcholine, and is responsible for activating smooth muscle responses 
by increasing intracellular levels of cyclic guanosine monophosphate 
<Ignarro et aI, 1987; Palmer et aI, 1987). However to initiate a 
response nitric oxide mus: traverse subendothelial collagen, and this 
protein accumulates, due to glycosylating modifications, over time 
(Bucala et aI, 1991; Tanzer et aI, 1982; Noonier et aI, 1984). It has 
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been demonstrated that oxidising moieties of AGE products react with and 
quench nitric oxide activity in both vivo and vitro; and impairuent of 
endotheliumrdependent relaxation correlates directly to formation of AGE 
products <Bucala et aI, 1991). 
Treatuent with aminoguanidine, a potent inhibitor of advanced 
glycosylation, prevented nitric oxide quenching and restored 
vasodt latory function <Bucala et aI, 1991>. Vasodilatory dysfunction 
appears to plateau after 2 months of diabetes, and it may be that other 
heamodynamc factors, e. g. prostaglandins, catecholaDines, and 
electrolytes, intervene to prevent further impairment of the vasculature 
<Bucala et aI, 1991; Tesfariariam et aI, 1990; Weidmann et aI, 1985 & 
1979), Impaired nitric oxide function is not ameliorated by insulin 
administration in diabetic rats <Bucala et aI, 1991). 
This recent data provides a key link between protein glycosylation and 
endothelium dysfunction, however the role of other factors remains to be 
established and anti-glycosylation treatment has failed to be as 
effective as originally thought. 
Evidence against glycosylation as a Dechanism of neuropathy includes the 
fact that aspirin, a blocker in the formation of Schiff's bases, has not 
been shown to alleviate diabetic neuropathy <Yue et aI, 1984); although 
a long term effect by aspirin may be possible. Also the time 
difference, between the relatively quick on-set of slowed axonal 
transport and nerve conduction nerve velocity in diabetic animals and 
the slower production of advanced glycosylation end-products, suggests 
that glycosylation doesn't produce these changes. The decreases in nerve 
conduction velocity and axonal transport may not however be directly 
related to diabetic neuropathy. 
< 74 ) 
-\ffr(··~· 
....... 
(v> Excess Free Radicals 
Tbe production of super oxide radicals, wbicb are known to cause tissue 
damage, by tbe autoxidation of sugars (see figure 123) has been 
suggested to explain tbe neuropatby and vasculopatby occurring in tbe 
diabetic state. 
Xonosaccbarides, in tbe presence of oxygen to form a-oxaldebydes and 
superoxide ions; and tbeir production i~ increased in diabetes due to 
hyperglycaemia (Thornballey ,11; Stern, 1984) The appearance of these 
superoxide radicals triggers off the body's iDlDune response and are 
qUickly detoxified by the enzyme super oxide dismutase or KADPH 
(Schaunstein et al,1977). Tbe a--oxaldebydes, wbich can cause protein 
crosslinks, are similiarly detoxified by tbe glyoxalase pathway wbich 
utilizes glutatbione <Carrol et al;1986). 
Ascorbic acid is a prime natural scavenger of free radicals in tbe 
body (Levine, 1986) and tbis vitamin is known to be deficient in 
diabetes, botb in plasma and tissue (Som et aI, 1981). 
Free radical scavenger treatment fails to prevent the development of 
cbaracteristic diabetic dysfunction such as reduced nerve conduction 
velocity, however, free radicals may participate in a more insidious 
manner (Stribling, 198). Alpha-oxaldebydes, produced by autoxidation 
of sugars, cause protein crosslinks and the formation of AGE-type 
products in proteins (Scbaunstein et aI, 1977). As previously Outlined 
AGE products are believed to be responsible for quenching nitric oxide 
released from endothelium cells, and a-oxaldehydes may also contribute 
to the quencbing effect. In addition it is significant that·tbe time 
course of quenching product fonmtion is similar to that wbich has 
been observed for the formation of free radicals <Rami""" ,11; Hayasbi, 
1981) . 
( 'r5 ) 
It may be that excess free radicals interfere with the free release of 
nitric oxide by endothelium cells and induce inhibition of the 
vasodilatory effect in the diabetic state, since however there is a 
plateauing of this effect (Bucala et aI, 1991>, it is reasonable to 
suggest this is not the sole uechanism responsible for development of . 
diabetic vasculopathy. 
The significance of autoxidation Day: be Darginal since free radicals 
scavengers do not prevent the development of tissue dam3.ge in the 
diabetic state, except that is in the lens,where low levels of reduced 
glutathione and elevated levels of oxidised glutathione have been 
found. However they are normal in the sciatic nerve of the 
streptozotocin-diabetic rats (Carrol et al,1986). Some distortion 
would be expected in these levels, to account for the numerous 
dysfunctions occurring in the diabetic nerve. It would seem therefore 
that the body's defence mechaniSDS can easily cope with the production 
of any free radicals by autoxidation. 
(yi) Gangligside Depletion 
Gangliosides have attracted considerable attention since their 
neuritogenic and neuronotrophic properties were discovered. 
Extraneural tissues and cells contain very small alllJunts of 
gangliosides (Brunngraber, 1979; Wiegandt, 1982 Ledeen, 1983) whereas 
neuronal plasma membrane has an estimated 10% of its total lipid in 
the form of sialoglycolipid (Ledeen, 1978) and nearly 20% in the outer 
leaflet of the biolayer. Also the majority of sialic acid is lipid 
bound rather protein bound. 
Gangliosides play an important role in neuronal differentiation and 
this has been supported by studies which showed expression of GXl on 
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maturing postDdtotic cerebellar granule cell neurons and growing 
neurites and a preponderance of complex gangliosides in neurons 
undergoing neuritogenesis and synaptogenesis (Willinger, 1981). 
Exogenously applied gangliosides are found to have 
neuritogenic and possibly neuronotropbic properties, influencing 
neuronal differentiation in vitro nerve regeneration in vivo (Ledeen, 
1984) • 
It has been established that ganglioside structure is important, and 
that gangliosides differ in their ability to affect the various phases 
of neurite formation e.g. initiation, elongation and branching 
(Leskawa & Hogan, 1983; Ledeen, 1984); the asialo derivatives, neutral 
glycolipid, sulphatide and free sialic acid all proved ineffective. 
Also certain lines of cells, PC12 pheOChromocytoma cells, failed to 
respond sufficiently to either gangliosides or nerve growth factor 
singally, but neuritic growth was promoted when both were administered 
jointly in the presence of high serum levels (Ferrari et aI, 1983; 
Roisen et aI, 1984; Katoh-Semba et aI, 1984). 
In vivo studies have demonstrated the beneficial effects of exogenous 
gangliosides in accelerating nervous system repair. Enhanced recovery 
of denervated cat nici tating membrane due to exogenous gangliosides 
has been found, for both pre- and postganglionic denervation, 
suggesting the effectiveness of this treatment for both cholinergic 
and adrenergic neurons (Ceccarelli et aI, 1976). Serotonergic neurons 
are also reported to be regenerated by ganglioside treatment (Jonsson 
et aI, 1983), In the extensor digitorum longus muscle of the rat 
exogenous gangliosides significantly increased polyneuronal 
innervation in the early. stages of regeneration by stimulating 
sprouting of the dendrites (Gorio et aI" 1980). Dosage is an 
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iDpOrtant feature since high levels of ganglioside produce an 
inhibitory effect on the recovery tine for the startle reaction in the 
optic system of the goldfish (Grafstein et aI, 1982). Axonal transport 
also appears to be increased by ganglioside application (Sbasehnig-
Agler. 1984>' It would seem that these neuritogenic and neurotrophic 
are directly linked to gangliosides as antibodies to mixed 
gangliosides or GIU retarded regeneration ofaxons in vivo (Gorio et 
aI, 1980), 
Ganglioside in addition promotes microvilli formation on the surface 
of the axon and tubulin mRNA (Spero & Resien, 1984; Rybak et aI, 
1983); di butryl cAMP has the sane effect. This is not suprising as 
gangliosides increase intracellular levels of cAMP. It has been 
'proposed that gangliosides affect the sprouting site ofaxons by 
possibly changing membrane ion perneability to increase ca2 - influx, 
so that it influences the membrane cytoskeletal relationship which 
might initiate neurite formation (Gorio et aI, 1983). 
In the diabetic state multiple dysfunctions occur in the axons, among 
these is decreased slow axonal transport of the Gl and G2 molecular 
forms of acetylcholinesterase and depressed nerve conduction veloCity. 
Daily gangliOSide injections to mutant diabetic DOUse C57BL/ks (db/db) 
normalized these dysfunctions and also corrected defects in auditory 
perception, myelin particle ,density and axonal morphometry <Gorio et 
aI, 1980). However in the early stages insulin was capable of 
improving nerve conduction velocity whilst gangliosides were 
ineffective. Ganglioside 'treatment was also observed to normalize 
axonal atrophy, sciatic nerve conduction velocity and auditory 
response in alloxan-induced.diabetic rats (Gorio et aI, 1984). 
( '18 ) 
It has been proposed that gangliosides normalize these dysfunctions by 
stimulating regeneration, or alternatively, by stimulation of membrane 
enzymes to reconstitute a proper ionic distribution inside and outside 
the neuron (Gorio et aI, 198,). This proposal has been supported by 
the recent observation that ganglioside treatment in human diabetics 
increased activity of Ia+K+ ATPase which had been previously decreased 
by 53Z (Della-Crippa et aI, 1990). 
It may-pethat ion channel irregularities in neurones are responsible 
for the reduced Ba+K+ ATPase activity in the diabetic state rather 
than a failure of secondary-messenger phosphoinositides due to lIIyo-
inositol depletion. This is supported by evidence that restoration of 
~o-inositol levels is not necessary for normalization of Ba+K+ ATPase 
activity in streptozotocin-induced diabetic rats and galactose-fed 
mice (Yeh et aI, 1987; Calcutt et aI, 1990). 
<yi j) Anoxia 
It has been proposed that anoxia is the central defect in diabetic 
neuropathy. 
Reduced oxygen tension in the nerve has been observed in the diabetic 
state (Brownlee et aI, 1984). Also, the organic phosphate 2,3-DPG, 
believed to play an important regulatory role in oxygen exchange by 
heamoglobin, has been found to be reduced in diabetic patients and 
this may decrease oxygen delivery to critical tissue (Brownlee & 
Cerami, 1981). Furthermore, Low et al (1985) have reported that 
maintaining diabetic rats in hyperbaric oxygen restores nerve 
conduction velocity to normal in diabetic rats. The role of anoxia in 
the diabetic state is bei;ng currently evaluated and further work 
should reveal its significance in the onset of neuropathy in diabetes. 
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<yii1}-Eicosangid !etabo1i6m 
Patients with diabetes mellitus have an excess activation of 
platelets, it is believed this, together with synthesis 
irregularaties, may contribute to vasculopathy and cardiomyopathy in 
diabetes (Xustard & Packham, 1984; lomasi et aI, 1986). 
In diabetes certain vascular dysfunctions occur, platelet release of 
thromboxane A:. <TXA:.) is increased, endothelial prostaglandin (PGLz) 
synthesis is decreased, and platelet sensitivity to PGI2 is decreased 
(Halushka et aI, 1981a & 1981b; Butkus et aI, 1980; Gerard et aI, 
1980; Schernth' ner et aI, 1981). Previously the ratio between platelet 
derived lXA2 (pro-coagulant) and endothelial synthesized PGI2 (anti-
coagulant) was believed to deterDine the aggregation of platelets; but 
however it is now acknowledged that other factors play a crucial part 
(Porta et aI, 1987). Endothelial cells also synthesize and release 
lXA:., von Willebrand Factor (vWF) (Tschapp et aI, 1984), platelet 
activating factor (PAF) (Ingerman-Wajenski et aI, 1981; Camussi et aI, 
1983; Prescott et aI, 1984), antithrombin III (Busch & Owen, 1982; 
Chan & Chan, 1981), and thrombomodulin (Esman & Owen, 1981). 
Studies have shown elevated plasma levels of vWF, a platelet-
subendothelial adhesive factor, in diabetic patients with 
microangiopathy, closely related to the duration of the disease 
(Bensoussan et aI, 1975; Coller et aI, 1978; Porta et aI, 1981>. It 
appears that the endothelium increases synthesis and release of this 
factor in diabetes, but its effect, in vitro, on platelet aggregation 
is minimal (Porta et aI, 1987). 
Vi tamin E significantly decreases platelet sensi t1 vi ty to the 
aggregation effects of ADP ~nd collagen (Karpen et aI, 1981; Steiner, 
1983) and is responsible for decreasing stimulated thromboxane release 
( 80 ) 
(Gisinger et aI, 1990). Normally membrane phospholipids release 
arachidonic acid which is converted to prostaglandin enderoperoxides, 
which in turn transforms to thromboxane and prostacyclin (Xoore, 
1985), Certain studies suggest that vitamin E reduces stimulated 
thromboxane release by reducing phospholipase kz activity, the enzyme 
responsible for arachidonic acid release from membrane phospholipids 
(Karpen et aI, 1981; steiner, 1983; Hamelin & Chan, 1983; Pritchard et 
aI, 1982). Vitamin E supplementation was effective in normalizing 
platelet TXL. production and PGb in diabetic animals (Karpen et aI, 
1982; Gilbe .t et aI, 1983) and patients (Gisenger et aI, 1988). 
The beneficial effects of vitamin E supplementation suggests that TXA2 
and PGh synthesis plays an important role in platelet aggregation, 
however whether thrombus or clot formation is ultimately responsible 
for vasculopathy in the diabetic state remains to be clarified. 
Pr06taglandins are synthesized in cardiac tissue and have potent 
effects on contractility, heart rate and coronary vessel tone (Limas 
et aI, 1973; Xalik 11 J!cGiff, 1976), Studies have shown increased 
arachidonic acid promoted formation of PGE" and PGE, in perfused 
hearts from diabetic rats (Rosen & Schror, 1980). Increased conversion 
of microsomal arachidonic acid in diabetic rats (Durante et aI, 1989) 
induces elevated levels of synthesis of prostaglandins. Increased PG 
production does not however , lead to any increase in their catabolism 
(Durante et aI, 1989), PGh is the Dajor prostanoid formed in both 
control and diabetic rat cardiac homogenates. It is suggested that 
PGI" is predominantly formed by vascular arteries, an effect which is 
enhanced in diabetes (Durante et aI, 1989). Increased PG levels in 
diabetes would have a detri~ntal effect on the heart rate, increasing 
the cardiac work load and poSSibly causing further complications. 
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Further work should establish which element is the keystone of 
prostaglandin synthesis dysfunction and offer the possibility of 
useful therapies. 
(ix) VitHnln C Depletion 
HyperglycaeDia leads to ascorbic acid depletion and this has been 
pr,oposed as a cofactor in the accUllDJlation of sorbitol in insulin-
independent cells, such as the endothelium, which has been proposed as 
a possible cause of vasculopathy in diabetics. 
Ascorbic acid concentration and turnover is decreased in the plaSDa 
and tissue of diabetics ';": Yew, 1983; 
: Chen et aI, 1983) Ascorbic acid uptake is inhibited by glucose 
in vitro, this may be due to similarities in structure between L-
ascorbic acid and D-glucose so that the ascorbic acid carrier is 
inhibited by glucose. This effect is exaggerated in hyperglycaeDia, 
and ascorbic acids reduced forD, dehydroascorbic acid, is inhibited in 
endothelial cells and erythrocytes (Kapeghian & Verlangier, 1984; Hann 
& Newton, 1975). Insulin actively promotes the uptake of ascorbic 
acid, thus in uncontrolled diabetes ascorbic acid uptake is doubly 
reduced due to hypoinsulinaemia and hyperglycaemia (Verlangieri 11 
Sestito, 1981; Berhanu & Olefsky, 1981). 
Ascorbic acid is essent.ial in affecting collagen biosynthesis and 
posttranslational modification by maintaining the enzyme prolyl 
hydroxylase (PRLase) which catalyses the hydroxylation of proline to 
form hydroxyproline, an aBino acid required for the stability of the 
collagen molecule (Barnes, 1976; Xyllyla et aI, 1978; Berg 11 Prockop, 
1973) PRLase activity has ~en observed to be decreased in the tissue 
of diabetic aniuals (Ramamurthy et aI, 1985; Yue et aI, 1987) and 
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appears to be strongly linked to ascorbic acid depletion. 
Ascorbic acid supplementation and tolerastat (an aldose reductase 
iOOibi tor) treatment in diabetic rats both prevented the previously 
observed decrease in PRLase (IcLennan et aI, 1988). Tolerestat appears 
to be linked to ascorbic acid levels, since treatment with this ARI 
increases as=rbic acid plasma levels O(CLennan et aI, 1988), A 
,possible mode of action is that tolerestat increases tissue 
concentration of reduced glutathione, which is required for the 
recycling of dehydroascorbate to ascorbic acid, and it is ascorbic 
acid in conjunction with an ARI which reduce cell sorbitol 
accumulation. If so, it may be beneficial to combine ARI therapy with 
ascorbic acid supplementation. 
AbnorDal sorbitol accumul'ation in erythrocytes is normalized by 
ascorbic acid supplementation in both vivo and vitro (Vinso/l'\ et aI, 
1989). It has been proposed that ascorbic acid consumes HADPH 
indirectly through the glutathione redox couple (Varma et aI, 1979), 
thus depleting JiADPH for the conversion of glucose to sorbitol (see 
above). 
Ascorbic acid is undoubtedly involved with regulating cell serb! tol 
levels, and Day be an iDpOrtant cofactor in the treatment of diabetes, 
wider clinical trials should be initiated to evaluate the efficacy of 
this treatment; since large ascorbate doses taken chronically appear 
to be free from ill effects, ethical problems in such trials would be 
minimal. 
(x) Blopd Rbeologlca1 Cbanges 
Diabetics have rheological. abnormalities including an increase in 
whole blood viscosity, plasma viscosity and red cell aggregation and a 
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reduction in red cell deformability (Barnes, 1988), and it has been 
proposed that this is responsible for reduced flow and sludging of 
blood within capillaries in patients suffering vasculopathy (Simpson. 
1988; Xacrury et aI, 1991). 
Patients with microvascular complications have BOre rheological 
abnorDali ties than diabetics lacking vasculopathy (Lowe et aI, 1986; 
Hill et aI, 1982). Patients with and without diabetic neuropathy both 
had similar impairment of red blood cell deformability and increased 
blood viscosity, suggesting that abnorual rheology is not directly 
responsible for endoneurial hypoxia, jt may be a contributing factor 
(Hacrury et aI, 1991). Reduced microvessel radi coupled with abnormal 
rheology may seriously reduce vital blood flow and thus initiate 
vascular dysfunction (Xacrury et aI, 1991). 
Decreased red cell deformability in diabetic patients has been linked 
to increased platelet aggregation, due to increased synthesis of the 
coagulent ADP by red cells (Juhan et aI, 1982). Deformability of red 
cells is essential in the microvasculature, any reduction in 
deforDability hinders the cells passage across nutritive capillaries 
leading to narrowing of these capillaries and also reducing blood 
flow; these effects may combine to cause ischaemic organ da_ge 
(Xcrury et aI, 1991). 1f.hite blood cell deformabili ty is similarly 
reduced in diabetes (Ernst & Hatrai, 1986) leading to blocking of the 
microvasculature and thus reducing blood flow and increasing viscosity 
(Ernst et aI, 1987), In addition white and red blood cells show an 
increased tendency to adhere to the endothelial surface where they not 
only reduce blood flow but also da_ge the endothelium by releasing 
toxic oxygen compounds and. proteolytic enz)'lll"s O!crury et aI, 1991; 
Chien, 1985; Va~tier et aI, 1986). Lack of red cell deforDability 
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could also physically damage endothelial cells. 
It appears that changes in blood rheology may be a contributing factor 
to the development of vasculopathy, they are certainly important in 
causing hypoxia, and it is only in conjunction with metabolic 
abnorDalities that they cause dyst'unction in the vasculature. 
(xi) Blood Lipid Changes 
Essential fatty acid synthesis and metabolism is abnormal in vascular 
tissue in diabetic patients and animals <Horrobin, 1988; Rot et aI, 
1983) and it is believed that this alters the prost~cyclin and 
thromboxane Az levels leading to vasculopathy (Xoncada & Vane, 1979). 
Fatty acid composition is significantly affected in the phospholipids 
of experimentally-induced diabetic animals in a variety of tissue, 
such as erythrocytes, liver, heart and kidneys (Eck et aI, 1979; Faas 
& Carter, 1980 & 1983; HolDan et aI, 1983; Huang et aI, 1984; Dang et 
aI, 1988). 
Certain desaturase enzymes are essential for the formation of 
arachidonic acid, palmitoleic acid, eicosapentaenic acid (EPA) and 
docosapentaenic acid (DU). <l9 -desaturase converts saturated fatty 
acids to unsaturated ones, <l6 -desaturase converts linolenic acid to l-
linolenic acid, <ls-desaturase converts dihoDO-Y-linolenic acid to 
arachadonic acid and eicosatetraenoic acid to EPA, and <l4 -desaturase 
converts EPA to DHA. Dysfunction of fatty acid metabolism is probably 
linked to decreased acti vi ties of these desaturases, <I", <I'" and <Is 
(Eck et aI, 1979; Faas & Carter, 1980; Holman et aI, 1983; Dang et aI, 
1988) • 
Relative levels of arachidonic acid are decreased whilst c.r3 fatty 
acid content is increased in the tissue phospholipids of diabetic rats 
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(Holman et al, 1983). Reduced arachidonic acid levels would seriously 
compromise the formation of prostoglandins and subsequantly impair the 
normal rheological functions of the vasculature. 
Insulin therapy is effective in normalizing 69 and 66 -desaturase 
activities and fatty acid, composition, but fails to correct reduced 
arachidonic acid levels (Faas & Carter, 1983; Dang et al, 1988). 
Essential fatty acid suppleDentation has been su=esfully used to 
counteract the effects of diabetes. TreatlJEnt with evening primrose 
(Oenothera bienmis) oil, rich in ~-linolenic acid, was effective in 
inproving reduced nerve conduction velocity in diabetic rats and 
increasing endonurial capillary density (Tomlinson et al, 1989; Julu, 
1990; CaDeron et al, 1991). It may be that increased arachidonic acid 
levels lead to elevated phosphoinositide turnover and/or enhanced 
diacylglycerol stimulation of protein kinase C, thus restoring Ka+K+ 
ATPase activity and improving nerve conduction velocity. 
~-linolenic acid is reduced in diabetes because of a deficit in 
linolenic acid 6 desaturase (Poisson, 1985), evening primrose oil 
treatDent could correct this by allowing foruation of prostaglandin E, 
(PGE,) froD dihomo-~-linolenic acid and prostacyclin and PGE2 via 
arachidonic acid (Cameron et al, 1991>. PGE, , PGE:z and prostacyclin 
analogues have all been reported to be effective in improving blood 
flow and nerve conduction velocity in diabetic rats (Yasuda et aI, 
1989; Ito et al, 1990), 
Q-3 fatty acid suppleDentation, specifically eicosapentaenoic (EPA) 
and docosahexaeno±c acid <DHA) , has been reported to have dramatic 
effect on vascular function, they not only JOCKiify platelet function 
and eicosanoid synthesis but also affect many other mechanisms which 
may be involved in the pathogenesis of vasculopathy (Axelrod, 1989; 
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Leaf & 'Weber, 1988; Von Schacky, 1986). Q-3 fatty acids inhibit 
arachidonic acid synthesis, decrease platelet production of 
thromboxane A2 , increase platelet production of thrODboxane As, 
increase synthesis of prostaglandin 13 (PGI3), decrease platelet 
aggregation, decrease plasma lipoprotein levels, increase erythrocyte 
deforuabUity, decrease blood viscosity, decrease blood pressure and 
increase thrombolytic activity (Leaf & \/e:ber', 1988; Von Schacky, 
198$; Hero,ld & Kinsella, 1986). However in diabetics they have certain 
deleterious effects, namely increased plasma glucose levels, increased 
glycosylation of haemoglobin, and elevated plasma cholesterol levels 
(Axelrod, 1989); though there is some evidence to suggest that dosage 
may be the contributing factor (Axelrod, 1989). 
Abnorllal fatty acid DEitabolislR is an aknowledged defect in diabetes 
and its consequences may seriously impair normal vasculature function. 
Dietary fatty acid supplementation offers a useful method to correct 
the dysfunctions of the vasculature, but this must be balanced against 
its side effects, and studies to establish correct dosage should 
provide useful information for later therapeutic trials. 
(xii) Increased BlOOd Fibrinogen 
Blood clotting factors play an important role in blood viscosity, 
platelet aggregation and blood clotting, any al.teration in these 
factors would have serious implications for vasculature function. 
Fibrinogen, a priuary clotting factor, is increased in diabetes and 
which may result in hypercoagulability of the blood, so contributing 
to dysfunction of the vasculature (Kannel et aI, 1987>. 
Studies have shown that le~els of circulating fibrinogen are closely 
related to the development of strokes, cardiac disease, and 
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cardiovascular mortality (Aeade et aI, 1980; Yilhelmsen et aI, 1984). 
Raised fibrinogen levels increased the risk of strokes and myocardial 
infarction, even when other factors, such as blood pressure, serum 
cholesterol level and snoking, had been eliminated. 
hyperlipoproteJA'teM.~ a COmmon cau:plaint in diabetes, also increased 
levels of fibrinogen (Lowe et al. 1919). 
Atherosclerotic cardiovascular disease is linked to increased fibrinogen 
levels by its effect on hypercoagulability. blood viscosity. red cell 
defonaabili ty and heamorheology. espeCially in people with impaired 
circulation due to hyperlipidaemia. hypertension and glucose intolerance 
(Kannel et al. 1987). It is probable that fibrinogen is involved in 
fibrin accumulation and affects the binding of low-density lipoproteins 
(Lowe et aI, 1919; Smith et al. 1979). 
Fibrinogen levels can be reduced by weight reduction (a common feature 
of maturity-onset diabetes). Cigarette sDOking abatement, bloodletting, 
glucose control and reduction of hypertension (KaDDel et aI, 1981>. 
Treatnent with aspirin and pentoxyfylline has been suggested to 
counteract certain effects of fibrinogen. such as increased blood 
viscosity. platelet aggregation and red blood cell rigidity (Kannel et 
al. 1981>. 
Fibrinogen levels have important ranifications for the vasculature and 
are probably a cofactor for dysfunctions to normal blood flow. However, 
whether controlling fibrinogen levels or the underlying factors which 
give rise to elevated fibrinogen offers the best course of treatnent for 
diabetic vasculopathy remains to be elucidated. 
( 88 ) 
(xiii) HJPertensign 
Patients with diabetes mellitus often have hypertension and it is 
believed that this my play an important role in the development of 
vasculopathy (Karks, 1971; Chriestlieb, 1973). 
Angiotensin-converting enzyme (ACE) , responsible for converting 
angiotensin I to angiotensin II, is synthesized by vascular 
endothelium and has a potent effect on blood pressure (Caldwell et aI, 
1976; Dorer et aI, 1974). Levels of ACE have been reported to be 
increased in diabetic patients . (Schmitz et 
aI, 1985) and it may be that elevated ACE levels are responsible for 
producing hypertension. However, another study failed to confirm these 
observations (Porta et aI, 1987) and it appears that this effect is 
limi ted to a minor proportion of patients suffering microangiopathy. 
It is probably a manifestation of vascular dysfunction rather than a 
cause of it. 
It seems more probable that hypertension is a clinical SymptOD of 
various changes occurring in the vasculature, such as increased 
platelet aggregation, decreased red cell deformability, and increased 
blood viscosity (Porta et aI, 1987>' Treatment to reduce hypertension 
fails to tackle the basic dysfunctions inherant in diabetic 
vasculopathy; insulin succesfully reduces hypertension but endotheliuD 
irregularities still persist in diabetes (Alexander & Oake, 197'7>. 
Hypertension undoubtedly contributes to vasculopathy, but it is not 
the only factor. 
(xiy) Sympathetic leuropathy 
Diabetic patients and expeFiuental animals are abnormally sensitive to 
circulating vasoconstrictors, such as catecholamines, and this may be 
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caused by impairment in function of the sympathetic fibres which 
innervate the microvasculature, so that a process of denervation 
sensi tization occurs <Brody & Dixon, 1964), though this would only 
explain increased sensitivity to catecholamines and the profound 
neuropathy in diabetic patients. 
Alloxan-diabetic rats were found to be supersensitive to intra-
arterial injections of epinephrine, norepinephrine and synthetic 
angiotensin (Brody & Dixon, 1964) . Increased vascular reacti vi ty to 
K+, serotonin and prostaglandins has been reported in alloxan-diabetic 
rabbits and streptozotocin-diabetic rats (Agrawal et aI, 1985; Cseuz 
et aI, 1973; Scarborough & Carrier, 1984; Kacleod & KcNeil~ 1985). 
Sympathetic nervous function abnormalities have been observed in 
diabetic patients (Low et aI, 1975) and experimentally diabetic rats 
(Yoshida et aI, 1987; Ganguly et aI, 1987). Decreased nerve 
conduction, slowed axonal transport, axon dwindling and segmental 
demyelination are all common features of diabetic neuropathy (Brownlee 
& Cerami, 1981; Yinegrad et aI, 1979; Thoms & Lascelles, 196':; Dyck 
et aI, 1971). -- - It is believed these neuronal 
dysfunctions affect nor_l catecholamine turnover and lead to 
irregularities in the responses of the vasculature. Increase in 
peripheral blood flow, often accompanied by chronic pain, frequently 
DOCurs in diabetics. Turnover of catecholamines seems to be implicated 
in this since noradrenaline Uptake 1 blockers, such as desipramine, 
were effective in preventing these SymptODS (Kax et aI, 1991). 
Increased sensitivity to catecholamines appears to be linked to 
decreased sympathetic activity in the diabetic state, whether this is 
wholly responsible for vaooculopathy is doubtful, IJIOre likely it is a 
contributing factor. 
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(xv) Nerve Growth Factgr 
Alterations in nerve growth factor, an important peptide involved in 
the development, maintenance and regeneration of neurones (Levi-
JIontalcini It Calissano, 1979; Levi-Xontalcini, 1987; Jlobley et aI, 
1977; Calissano et aI, 1984), have been postulated as underlying 
diabetic neuropathy (J!obley et aI, 19'(7)-
Studies have shown that" alloxan and strept=otocin-induced diabetes 
mellitus is associated with neuropathy, and with impairment of nerve 
growth factor transport in nerve fibers (Longo, 1985; Sclmidt, 1985; 
Sch:llidt It Yip, 1985), In addition endogenous levels of nerve growth 
factor are altered in rodents during streptozotocin-induced diabetes 
both in nerve growth factor producing target organs (Hellweg It 
Hartung, 1990; Kasayama It Oka, 1989) and in neuronal stuctures known 
to transport nerve growth factor or to be nerve growth factor 
dependent (Hellweg It Hartung, 1990), 
Nerve growth factor producing tubulary cells of the submaxillary gland 
show vacuolization and rupture of granules from streptozotocin-induced 
diabetic rats (Camacho et aI, 1982), Studies in diabetic patients, 
suffering neuropathy, have found decreased nerve growth factor levels, 
and the severity of neuropathy, as assessed by reductions in motor 
nerve conduction velocity, is directly linked to low nerve growth 
factor levels (Faradji It Sotelo, 1990), 
Insulin has many functional and chemical similarities with nerve 
growth factor (Frazier et aI, 1972), such as physiological activity, 
and molecular structure (Frazier et aI, 1972; "Frazier et aI, 1973), It 
may be that in diabetes both peptides are similarly affected since, it 
is argued, diabetic complications are not common when diabetes 
mellitus is secondary to other diseases like chronic pancreatis 
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<Faradj i & Sotelo, 1990; Greenberger, 1950). 
In painful diabetic neuropathy increased numbers of small uwnyelinated 
axons have been found <Brown et aI, 1976), sugg-esting that abnormal 
regeneration could be due to low nerve growth factor levels. The primary 
target cells for nerve growth factor are sensory and sympathetic neurons 
<Levi-Aontalcini & Calissano, 1979; Levi-Xontalcini, 1987; Xobley et aI, 
1977), and since diabetic neuropathy is predominantly mixed or sensory 
(Brown & Asbury, 1984; Adams & Victor, 1985), there would appear to be a 
correlation. Insulin has trophic properties <Frazier et aI, 1972), it 
induces neuronal differentiation, and hypoinsulinaenia during 
unregulated diabetes could be a factor in the development of neuropathy 
(Sotello et aI, 1980). 
Reduced nerve growth factor levels have been normalized in the sciatic 
nerve, subnandibular gland and iris of streptozotocin-diabetic rats by 
allotransplantation of insulin-producing islets (Hellweg et aI, 1991). 
Daily injections of insulin were also succesful in normalizing nerve 
growth factor levels (Kasayana. a Oka, 1989), this suggests that nerve 
growth factor is not important in diabetes as properly regulated insulin 
therapy would presunably correct any defect in nerve growth factor 
levels. 
It is clear that nerve growth factor is involved, in some capacity, in 
diabetes; only further studies, such as nerve growth factor measurement 
in diabetics without neuropathy, in nerve biopsy, in insulin-dependent 
diabetiCS, and in other neuropathies of toxic and nutritional origin, 
can reveal its true. 
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1.7b SU'!Itnftry 
The difficulty of assigning any single clinical symptom in diabetes, 
to one of the three groups outlined above, is aptly demonstrated in 
the 'diabetic foot'. 
In diabetes ulceration of the foot is fifteen tiDeS IJIOre cOllllJlOn 
poSSibly leading to hospitalization and amputation <Boulton, 1990). 
The cause was originally believed to be vascular in genesis. Evidence 
of nicrovascular abnormalities and reduced blood flow all seemed to 
support this contention (Timperley et aI, 19B5). 
However evidence for a neuropathic factor, both somatic and 
sympathetic, in the aetiology of foot ulceration was found in studies 
which showed that canine hind paw ulceration only occurred if both 
sciatic and sympathetic nerves weretransected (Jrielubowicz et aI, 
1974). Various clinical studies showed 90~ <combined figure) of 
diabetic ulceration implicated neuropathy as the aetiological factor 
(Haul ton, 199q>. 
Inability to assign clinical symptOIllS to a single group makes the 
development of effective treatment even more difficult. 
The above mechanisms are not mutually exclusive, it is not a case of 
one or the other to explain diabetic complications. Several Dechanisms 
may contribute partially or wholly to cause the dysfunctions observed 
in diabetes. Some of these mechanisms may interact, in as yet unknown 
manner, to produce diabetic complications. The restoration of Jla+K+ 
ATPase activity in diabetes by the adJllinistration of gangliosides, '£3, 
myo-inositol and an aldose reductase inhibitor, suggests possibly that 
several different mechanisms are responSible. It is likely that only 
when investigators study a ·number of IDechanisns in conjunction that a 
true picture of diabetic complications will eDerge. 
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1.B HODELS OF DIABETIC mlPLICATIOIIS 
Various uechanisms have been proposed as being responsible for 
diabetic complications. Mechanisms such as sorbitol accunulation, myo-
inositol and phosphoinositide depletion, hypothyroidism, eicansoid 
metabolic dysfunction, non-enzymatic protein glycosylation, excess 
free radicals, ganglioside depletion, anoxia, vitamin C depletion, 
hypertension, reduced nerve growth factor, blood lipid, rheological 
and fibrinigen changes, and sympathetic neuropathy have all been 
investigated, to a lesser or greated degree, as the poSSible cause of 
diabetic conplications. The reversal of certain dysfunctions , e. g. 
sorbitol acculllllation by aldose reductase inhibitors, myo-inositol 
depletion by oral supplementation, hypothyroidism by triiodothyronine 
treatuent, and prostacyclin and thromboxane normalization by ~-3 fatty 
acids or thromboxane antagonists, requires them to be fully tested for 
efficacy. If they have therapeutic value these treatuents may then be 
introduced to patients suffering diabetic complications. 
studies to investigate the effects of diabetes and possible therapies 
can only occur on a suitable lOOdel, susceptible to all the symptoms 
prevelent in humans, which will reveal the full interplay of different 
factors. The interrelationship between vasculopathy, cardiomyopathy 
and neuropathy creates problems, as no single model suffers the full 
range Of defects detected in diabetic patients; though even diabetics 
vary in their susceptibility toconplications. Various animal models 
have been used for the complications occurring in the diabetic state. 
The ·spontaneously diabetic Chinese hamster develops autonomic 
neuropathy with bladder and bowel dysfunction but appears to be 
relatively resistant to the development of arterial disease and is of 
such small size that studies of various cardiovascular risk factors, 
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such as plasma lipoproteiDB, coagulation factors, and blood pressure, 
are impractical (J(cCombs et aI, 1974; Dail et aI, 19'17; Bryan et aI, 
1977; Diani et aI, 1978), Similar problems affect obese KK, ob/ob and 
db/db mice, they also fail to develop cardiovascular complications 
(Chobanian et aI, 1974; ColeDan, 1978; . 
Davalos et aI, 1970). 
Camerini-
The Wistar BB r~t develops hyperglycaemia, hypoinsulinaemia, platelet 
prostaglandin synthesis dysfunction, and endothelium arachidonic acid 
depression, butit is resistant to the development of atherosclerosis 
Cllakhooda et aI, 1976; Subbiah & Dietemeyer, 1980), Increases in 
plasma levels of cholesterol, triglycerides and free fatty acids have 
been found in the obese Zucker rat, but it fails to develop 
vasculopathy (Haudenschild et aI, 1981; Schonfeld et aI, 197~; Subbiah 
& Connelly, 1976). Arterial disease is present in obese hypertensive 
rats, together with hyperglycaemia, Darked hyperinsulinaemia, and 
hyperplastic pancreatic islets (Okamoto, 1972; Koletsky, 1973). 
Rats can be _de chemically diabetic by injection with alloxan or 
streptozotocin. Autonomic nervous dysfunctions have not been found in 
these animals (Still et aI, 1964). Diabetic rats do exhibit 
hyperlipoproteinaemia, hypercholesterolaemia, and hypertriglyceridae-
mia , though evidence for macrovascular disease is limited and they 
appear to be resistant to atherosclerotic vascular disease (Urrutia et 
aI, 1962; Wolinsky et aI, 1978; Schein et aI, 1971; Bar-On, et aI, 
1976; Christlieb, 1973). Rats offer an opportunity to study the 
effects of diabetes on lipid metabolism, though its metabolism in rat 
differs from that in man. Biochemical differences, rats lack 
cholesterol ester transfer -protein, mean that data from rat model 
studies should be 
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treated carefully (Chobanian et aI, 1982). 
Alloxan treatment can be used to make rabbits diabetic and they 
tolerate its effects remarkably well, provided severe ketosis and 
dehydration is avoided (Kushner et aI, 1969). Xacrovascular disease 
can be induced in rabbits with cholesterol feeding following which 
atherosclerosis succesfully develops <Duff & lIcllillan, 1949; Duff et 
aI, 1954; Duff & Payne, 1950). Rabbits suffer hyperlipidaeDia, 
increased phospholipid serum levels, reduced hexokinase activity, and 
hypertriglyceridaemia (Pierce, 1952; Xulcahy & Winegrad, 1962; . 
Morrison et aI, 1972). However they fail to develop 
hypertension, a drawback to investigating DIll tiple risk factors in 
diabetes (Clements et aI, 1969; Morrison et aI, 1972). 
Yucatan miniture swine with reduced glucose tolerance develop 
atherosclerosis spontaneously with invovlvement of both the coronary 
and cerebral circulations. In addition, the serum lipoproteins of 
swine appear to resemble those in mm, and the animals are of 
sufficient size to permit extensive metabolic investigations (Philips 
et aI, 1979>' 
Several species of DOnkeys develop a range of dysfunctions which 
mirror human diabetic complications. 
induced diabetes in black celebes 
Spontaneously and chemically-
macaques, squirrel DOnkeys, 
cynoDOlgus macaques, and obese rhesus DOnkeys leads to increased 
plasna triglycerides, elevated pre-beta lipoproteins, increased 
nonesterified fatty acids, development of atherosclerosis and Barked 
ketonuria and glucosuria (Howard, 1979; Howard & Palotay, 1979; 
Davidson et aI, 1967; Ausnan & Gallina, 197~; Gallina & Ausman, 1979; 
Lehner et aI, 1972; Hellinger & Bullock, 1980; Hamilton et aI, 1972; 
Lockwood et aI, 1979). 
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The neonatal lamb, with alloxan-induced diabetes, has been used to 
study cardiac dysfunction. Though nyocardial uptake of glucose and 
fatty acids was reduced, left ventricular perfoTnance was not affected 
(Lee III Downing, 1979). Since ventricular performance impairment is a 
primary cardiac defect in diabetes, this model offers lilllited scope 
for the assessment of cardiomyopathy. 
Alloxan-induced diabetes in dog leads to glucose intolerance and 
reduced cardiac stroke volume associated with reduced end-diastolic 
volume and high end-diastolic pressure (Regan et aI, 1974; Hiader et 
aI, 1977). 
The partial susceptibility of various species to diabetic 
complications requires workers to be particularly thoughtful when 
selecting the model of diabetes. Comparison of data among different 
species leads to difficulties, and fragmentation of the literature, 
. about a specific diabetic defect, among species hinders understanding. 
Konkeys, swine and dogs offer useful DOdels for studying vasculopathy 
~d cardionyopathy, but financial =nstraints limit their extensive 
use. Whilst rodents nay be financially more viahle, their relevance to 
human diabetes makes interpretation difficult. Rabbits offer a mediun 
=urse, they are susceptible to lIIOSt of the defects of human diabetes 
and readily available. 
There is a need for a suitable model of diabetes, one that is 
=nsistent and financially viable. 
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].9 ArKS OF THE PROJECT 
There is a need for a reliable animal BOdeI for diabetic 
complications to evaluate mechanisms and possible therapies. The large 
number of diabetics in population and the frequency at which they 
develop complications make the market for any effective therapy a very 
large one, particularly if prophylactic therapy proved necessary. 
Using human subjects as test subjects for understanding the disease 
has several disadvantages. Diabetic complications develop very slowly 
and inconsistantly, therefore large trials over several years would be 
required to evaluate the various changes occurring. There would also 
be ethical problems as subjects would be given treatment for probleDS 
they wouldn't develop. Xany experiments involving nerve tissue 
wouldn't be feasible with human subjects; experimental anillBl DOdels 
would appear to overCOme these disadvantages. 
Various abnormalities have been reversed by a wide range of therapies 
e.g. aldose reductase inhibitors, myo-inositol supplementation, T3 
treatment, ganglioside supplementation, aspirin, w-3 fatty acids, and 
of course insulin (see above for DOre detail). Aldose reductase 
inhibitors have been the only class of drugs to have undergone wide 
clinical assessment, though with mixed results. ReverSibility of some 
possible mechanisms, implicated in diabetic complications, by various 
treat:ments of:fers potentially use:ful therapies. However their 
assessment can initially only occur in an ef:fective diabetic model, 
the development o:f which DUSt be a priority. 
Current models of diabetes assess neuropathy by evaluating changes in 
nerve conduction velocity and axonal transport. Whether these observed 
changes are indeed central to diabetic neuropathy or merely side-
e:f:fects of other, as yet, unrecognised changes is the main fault with 
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the current models. This failure to appreciate alternatives and 
explore other possibilities in the current models means that perhaps 
the true cause of diabetic complications still eludes workers in this 
field. A good model should allow other possibilities to be tested. 
A wide range of aldose reductase inhibitors are being tested , but 
their effectiveness has been patchy. It may be that early changes 
leading to diabetic neuropathy do involve the polyol pathway but in 
which case trials should involve patients before neuropathic SymptoDS 
occur, perhaps from the time of diagnosis of diabetes and following up 
the patients for _ny years. Aldose reductase inhibitors, or other 
potential treatment, in this way would pose very severe ethical and 
practical (including cost) probleDS. 
The aims of the project are: 
(1) To examine autonomic and vascular function in the streptozotocin-
induced diabetic rat with the primary purpose of identifying nDre 
appropriate animal models of diabetic complications. 
(2) To investigate the effects of an aldose reductase inhibitor, 
dietary myo-inositol supplementation and triiodothyronine (Ts) on 
diabetes induced changes. 
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CHAPTER TWO 
METHODS AND MATERIALS 
• 
2.1 EXPERllffilITAI. A!lIMLS. 
Rats for the study were obtained from Nottingham University, from its 
site at Sutton Bonnington. 
Diabetes was induced in male Yistar rats, weighing between 200 - 250g, 
by a si ngle injection of Im!/Kg of a freshly prepared solution of 
streptozotocin (40 mg/m! pH 4.5 citrate buffer) via a tail vein. 
Control animals received an injection of just the citrate buffer, once 
again via the tail vein. 
Three days after the injection a small drop of blood was obtained by 
puncturing the tail vein with a sterile needle. The blood glucose 
concentration was assessed using test strips ( BX-test-BG; Boehringer 
Jlannheim>. All rats that had a blood glucose concentration of 22 
mXol/l or above were assigned to the diabetic groups. 
Aldose reductase inhibitor treated diabetic animals recieved a dose 
of 25 mg/Kg of 'ponalrestat', leI 128436; 3-G4-bromo-2-fluorobenzyl-4-
oxo-34 phthalazin-l-yl acetic acid; 2.5mg/Kg of a lOng/m! solution in 
1~ Tween 80 orally once a day. 
Kyo-inositol treated diabetic animals recieved an oral dose of myo-
inositol which was present in the drinking water (1 gll solution). 
Observations showed that the diabetic rats (weight between 200-250 g) 
drank approximately 250 m!/day of water; so that the animals received 
a dose of 1 g/Kg/day. This dose has been reported to prevent diabetes 
induced falls in sciatic nerve myo-inositol content. The untreated 
diabetic and the control groups both received oral l~ Tween 80 only. 
Triiodothyronine (T3) diabetic animals received triiodothyronine, 
25pg/Kg/day s.c. When the animals were to be sacrificed they were all 
first weighed. Then they were anaesthetised with sodium pentobarhitone 
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(6,0 mg/Xg ip). 
Once the animals were fully unconscious a O.lml sample of blood was 
taken for glucose measurement. 
Tissues required for study were then removed, described below. 
Finally, the animals were killed while still anaesthetised either by 
removal of the heart (where this was required) or by anaesthetic 
overdose. 
2.2 AROCQCCYGEVS METHODS 
2,2a SEJSITIVITI TO 10RAOREUI.lBE, PHEIITLEPHRII1l & CLOIfIDIIE 
The anococcygeus Dllscles were identified and removed as described by 
Gillespie (1972). 
They were placed in ice-cold physiological saline solution aerated 
with a 95" <k - 5% C<k gaseous mixture. The composition of the 
saline was BaCl 143.3m11, KCI 15.9m11, JlgSO,. 1.2mX, eaCh 2.6m11, KlkPO,.. 
2.2m11, NaHCQ3 24.9m11, glucose 10mll, ascorbic acid 0.07mX, and E.D.T.A. 
O.067Dll. The solution was then adjusted to pH 7.4; and this was the 
composition of the saline used throughout the study. 
A single anococcygeus muscle was suspended in a 50ml organ bath under 
a resting tension of O.5g. The bathing fluid was physiological saline, 
lIEIintai ned at 37°C, and aerated with the SaDe gaseous mixture as 
before. 
The muscle was suspended for 1 hour and allowed to reach a 
equilibrium state. Noradrenaline was then added cumulatively over a 
wide concentration range (0.1~ to O.3DI). The tissue was then washed 
several times, reequilibrated and the above procedure repeated 
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with phenylephrine. 
Finally the tissue was rewashed, reequilibrated, and in the presence 
of pra~osln (0.3~K) clonidine was added. The responses to the drugs 
were recorded on a Yashington Chart recorder. 
Following this procedure the tissue was removed from the organ bath, 
blotted dry and weighed. 
2.2b HEUROIAL 3[ Hl-!illRADREIALllE OVERFLDi' . BASAl. &. STIM1!!.ATED RELEASE 
AND THE EFFECTS OF UPTAKE 1 AND Al.PHA-2 BLOCKADE 
A single anoco=ygeus muscle was placed in 1nl physiological saline 
solution containing l~Ci 3B-noradrenaline/ml (total noradrenaline 
concentration was O. 614~). After 1 hour incubation, at 37°C, the 
tissue was mounted between two platinum wire electrodes under 0.5g 
tension and superfused with physiological saline at 37°C at a rate of 
approximately Iml/minute. 
After 1 hour superfusion the tissue was stimulated with a train of 300 
2DS pulses, supramaximal voltage, delivered at 5Hz. This stimulation 
was repeated at 1Y.. hrs., 2 hrs., and 2~ hrs., with two 4 minute 
samples of superfusate being collected each time. The first collection 
was immediately before stimulation and the second during the 1 minute 
period of stinulation plus a further 3 minutes. 
Following the second of the two superfusate collections at llOhrs., a 
10~ solution of desipraDine was infused by means of a syringe pump at 
• a rate of 20~1/min. into the superfusate to give a final concentration 
of 0.2~1I. This was continued until the 2hrs. superiusates were 
collected. 
Following this yohimbine, 50~A, was also superfused in, as well as the 
deSipramine already present, to give a final yohiDbine concentration 
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of 1~X. This infusion was continued until after 2 superfusate 
collections at 2~s. 
Once these had been collected the tissue was removed from the 
superfusion apparatus, blotted dry and weighed. The tissue were then 
solubilized by incubation at 500 C in Optisolve (LKB, Loughborough UK). 
Tissue and perfusate sample radioactivity was subsequently 
measured,after the addition of 10m! scintillation fluid (Ecoscint), in 
a LKB liquid scintillation counter. PrestiDUlation samples were taken 
to indicate basal 3H-JA release whilst stimulated release was 
estimated by subtracting these values from those obtained for the 
samples collected during and after stimulation. Stimulated 3H release 
was assumed to be "'H-NA and expressed as pg !lA (Doggerell 11< 'ioodruff, 
19'78). 
2.3 AORTIC RING METHOD 
The thoracic aorta was excised, and excess connective tissue and fat 
removed. 
The aorta was cut into rings approximately 5mm's in length and placed 
in ice-cold physiological saline solution aerated with a 95Z D2 11< 5~ 
CO2 Ddxture. The composition of the physiological saline was same as 
in the previous anocDCcygeus DUscle preparation. 
During the removal of the aorta care was taken to avoid contact with 
the luminal surface 60 as to preserve the endothelial cells. 
In one ring the endothelium was Dechanically reDDved (Furchgott, 
1983), whilst in the second the endothelium was undisturbed. The rings 
were suspended in 50m! organ baths containing physiological saline 
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solution maintained at 37°C and continously aerated with the same 
gaseous mixture as before. 
A tension of 2g per ring was applied and the preparation was left in 
the bath for 1 hour to allow for equilibrium. 
The fluid in the organ baths was changed after 30minutes during this 
period. 
Noradrenaline was then added cumulatively over a wide range, the final 
organ bath concentrations varied from 10nX to 0.3DK. 
Following this the tissue were flushed out twice with physiological 
saline and the basal tension allowed to return to 2g. 
After approximately 45 minutes 5-hydroxytryptamine (5-HT) was added 
to the organ baths over a wide range, 10nI to 0.3mK; following which 
the organ baths were once again flushed out and the tissue allowed to 
return to their equilibrium state. 
Following this a dose of desipramine (0.3}JJD was added to the organ 
baths and after a period of 20 minutes, 5-HT was once again added over 
a wide range as before. 
The responses to the drugs were recorded on a Vashington Chart 
recorder. 
Finally the tissue was blotted dry and weighed. 
The method was however DOdified in later experinents with only rubbed 
aorta being used. 
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2.4 THE RAT OFRClPHAGEAL IUSCULAR1S XQCQSA PREPARATIOll 
The oesophagus was removed according to established procedure (Bieger 
& Triggle, 1985), and placed in an ice-cold physiological saline 
solution which was aerated with a 95~ CbI 5~ CO2 gaseous Dixture. 
The excised oesophagus was pulled over a small plastic tube to 
facilitate the removal of the external layer. The outer layer was 
split length-wise and carefully removed whilst ensuring that the inner 
layer remained intact. 
The muscularis mucosa was suspended in a 50ml organ bath, between 2 
platinum electrodes, containing physiological saline maintained at 
370 C and aerated with the sama gaseous Dixture as before. The 
composi tion of the saline was BaCl 143.3m1l, KCl 15.9m1l, )(gSO.. 1. 2m1l, 
CaC12 2.6m1l, KH2 PO .. 2.2DI, lIaB~ 24.9m1l, glucose 10DK, ascorbic acid 
0.07m1l, and E.D.LA. 0.067m1l; and this was the composition of the 
physiological saline throughout the study. 
The tissue was allowed to equilibrate for 1 hour until a steady 
baseline had been achieved. After this period the tissue was 
stimulated for 10s by pulses of 0.5ms width, at a frequency of 30Hz., 
over a large voltage range until a supermaxillBl vol tage was 
deterDined. At this superllBximal voltage and pulse width the frequency 
was varied from l-l,OOOHz, again using train durations for 10s. 
FollOWing this atropine ,10~K, was added and the tissue restimulated 
as before. 
After washing' 'out the tissue was allowed to rest and recover for 
40Dins and a dose response curve to acetylcholine was obtained over a 
wide range, from 10nK to Im1l. Finally the tissue's length and weight 
were ueasured. 
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2.5 IERIUn!. I!.EUI LOBGIIUD1HA1. 
!IlJOC!.E PREPARATION 
Animals were weighed, anaesthetised with sodium pentobarbitone 
(60mg/Kg i.p.) and a small section (8-I0cm) of ileum just proximal to 
the ileocaecal valve and the oesophagus was removed and placed in ice-
cold modified Krebs-Henslei t solution. The composition of the 
physiological saline was HaCI I43.3m!, KCl I5.9mM, IgS04 1.2mK, CaCl2 
2. 6111, ~PO... 2.2m!, ][aHCQ. 24. gm!, glucose 10Dl{, ascorbic acid 
0.07mM, and R.D.I.A. 0.067m!; and this was the composition of the 
physiological saline throughout the study. 
Innervated longitudinal muscle of the terminal ileum was isolated by 
first carefully pulling the excised section of ileum over a snaIl 
glass rod (Paton & Aboo-Zar, 1967). Then the longitudinal muscle was 
gently separated from the underlying circular muscle using cotton wool 
swabs moistened with physiological saline. The tissue was frequently 
irrigated with physiological saline during this process. 
The tissue was mounted in a 50ml organ bath, which was filled with the 
physiological saline naintained at 370 C and continously aerated with 
951. ~ & 51. Co2. 
A tension of Ig was applied and the tissue left for 1 hour to allow it 
to equilibrate. 
A dose response curve to acetylcholine was obtained over a wide range, 
from 30nK to 3mM. Following this the length of the tissue was measured 
whilst it was still suspended and then it was gently blotted dry and 
weighed, and the mean cross sectional area was calculated (assuming a 
tissue density of 1.05g/cm3). 
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2.6 RAT BLADDER KElHOD 
The bladder, together with the urethra, was removed and placed in ice-
cold lIIOdified Krebs solution aerated with a 95% Ck/ II CO:. gaseous 
mixture. The composition of the physiological saline was HaCI 143.3mX, 
KCl 5.9mX, I!gS04 1.2mX, CaCl:z 2.6m!(, KH:zPO ... 2.2mX, BaHco" 24.9mX, and 
glucose lOm!(. Excess tissue was removed and the lower bladder portion 
containing the urethra was cut off and opened out by cutting along 
oneside, as described by Lincoln et al (1984). 
The preparation was suspended in a 50ml organ bath containing the 
modified Krebs solution ... intained at 37°C and aerated with the saJDe 
gaseous mixture as before. Two platinuD electrodes were placed on 
either side of the tissue, a tension of 19 was applied and the 
preparation was left for 1 hour until the tissue had reached a steady 
state had been achieved. 
Following the resting period the preparation was field stimulated for 
lOsecs duration, at a pulse width of 0.3ms, frequency 10Hz, over a 
large range of voltages (40-150 volts). After this the organ bath was 
washed out, the tissue allowed to recover for 30mins, and atropine 
,3pX, was added to the organ bath. Twenty minutes after the addition 
of atropine the field stiDulation was repeated. 
After allowing the tissue to recover for 40mins carbachol was added 
non-cumulatively to the organ bath in concentrations vairying from 1~ 
to O.lmX. 
Once the responses to carbachol had been elicited the organ bath was 
washed out twice and the tissue allowed to recover for 40 mins., and 
finally the tissue was gently blotted dry and weighed. 
.-,:".: M"*:; 
_;r: ~ 
.,'. 
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2.7 CHOLUlE ACETY!.TRAliSFERASE ASSAY 
Radiochemical assays of choline acetyl transferase depend upon 
efficient isolation of acetylcholine from the incubation mixture 
without contaudnation from acetyl-CoA (Fonnum , 1975). This simple and 
efficient method uses the scintillation mixture as an extraction 
solvent and carries out the extraction in the scintillation vial. 
Acetylcholine is isolated by liquid cation exchange using acetonitrile 
in a toluene scintillation mixture. Labelled acetylcholine moves into 
the organic phase to be counted at high efficiency; whilst acetyl-CoA 
remains in the aqueous phase and is not counted, since water does not 
function as a scintillation solvent. 
The IJII!thod was as described by Dietz & Sal vaterra (1980). Initially 
the tissue was homogenised in X10 volulJII! of 0.0251l sodium phosphate 
buffer and centrifuged for 0.5 hours using super-head at ~6000 RPX. 
The buffer was prepared froll 11l solutions of Ra2HPO .. and llaH2PO .. , 
mixed together and adjusted to pH 7.4. 
Following centrifugation 5~1 of the homogenate was added to 5~1 of a 
specially prepared mixture. The mixture contained ['''Cl Acetyl CoA 
0.4m1l (~ 5000 cpmlnll) , NaCI 0.61l, sodium phosphate buffer O.lX, 
choline bromide 16m1l, E.D.T.A 34m1l, eserine sulphate 0.2m1l, and 
bovine serum albumin 10,.. The resultant mixture was incubated in a 
vial at 37°C over a wide range of time periods. 
Following incubation the contents of the vial were flushed out, using 
a syringe, with 5ml of 10d sodium phosphate buffer. Rext 10ml of 
toluene-based scintillation fluid was added followed by 2Dl of sodium 
tetraphenyl boron in acetoni trUe (5mg/Dl). The contents were gently 
shaken for approximately a minute and then counted for 10mins in a LKB 
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Liquid Scintillation counter. 
The procedure was modified as results obtained were very variable. 
Fresh tissue rather than frozen tissue was used. The length of 
incubation tiDe was progressively increased from 15mins (as 
recommended by Dietz & Salvaterra ,1980) to 21 hours. The amount of 
'hot' ligand ( [l~Cl Acetyl CoA) was also progressively increased. All 
of the modifications were combined in different sequences to make the 
procedure work. The original experiment , with rat brain tissue, was 
succesfully performed. 
2.8 CHOLINE UPTAKE ASSAY 
The procedure used was as described by Beach & Jenden (1980). 
Previously weighed rings of rat ileum were placed in separate vials 
containing Krebs solution , 11'K choline chloride and 21'Ci/ml [N-
methyl-14Hlcholine chloride (Set #1). In parallel with this rings of 
rat ileum were placed in vials containing Krebs solution, 21'Ci/ml [6-
methyl-'~Hlcholine chloride. and O.lmK choline chloride and treated in 
the same manner as the other samples (Set 12). The composition of the 
Krebs solution was RaCl I43.3mX, KCl I5.9mK, KgSO~ 1.2mX, CaCl2 2.6mX, 
KlhPO~ 2.2mX, RaHCU. 24.9mK, and glucose 10mX. Each sample was 
triplicated. 
The mixture, containing the rings, was placed in a water bath and 
incubated at 3'l<-C ior var-ying lengths of ti_. Following this the 
rings were removed from the incubating mixture and placed in ice-cold 
Krebs for 20mins. They were then gently blotted dry and placed in 
counting vials, each containing 0.5ml of Optisolve, and incubated at 
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50°C. Following solubilization 5ml of scintillation fluid was added, 
and the vials were left to stand for 5mins and then counted in a LKB 
scintillation counter. 
Since the expected difference in counts between samples (Set 11 high & 
Set 112 low), without & with excess choline, did not appear the 
procedure was modified. The length of incubation time was increased 
from 3Dins to 3hrs. KCI was substituted in Set 112 for the high 
choline chloride concentration UmID. 1!odified Krebs solution was 
used, LiCI instead of IaCI. The choline chloride was replaced, 
Krebs was used in Set #1 and NaCI Krebs in Set 112. 
LiCl 
The Krebs solution was further modified, glucose was replaced by 
sucrose. Preincubation in Krebs together with and without KCI was 
carried out. Different tissue was used, instead of rat ileum rat 
muscle was used. All of the modifications were attempted singularly 
and in cOIlbinations. 
2.9 !!YO--IllOSlmI .. SORBlmL & FRUCTOSE ASSAY 
The tissue, rat sciatic nerve, was homogenised in 1ml of distilled 
water containing a-methyl mannoside (30 )1X/ml) as an internal 
standard. A mixture of external standards (30 p.g/mJ.) , myo-inosi tol, 
sorbitol, fructose, also containing a-Dethyl mannoside (30 p.g/ml) was 
similiarly treated in parallel ()(alone 1982; )(ayer & Tom! i nson, 
1983) • 
The homogenised Dixture was boiled in a water bath for 20mins, cooled, 
and then deproteinised by the addition of ZnSOA (O.2m! of O.2X 
solution), and lODins later Ba(OH)2 (O.2m! of O.2X solution). The 
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samples were centrifuged at 800 Xg for 10mins and then the supernatant 
was freeze dried overnight. 
The samples were silyated under a .mixture of pyridine, 
hexamethyldisilaze, and trimethylchlorosilane <10:2:1, V/V; O.5Dl). 
After 24hrs incubation at room temperature <22°C), distilled water 
(2ml) and cylclohexane (0.4Dl spectroscopic grade) were added and the 
samples vortex mixed. After centrifugation at 800 Xs for 2mins the 
cyclohexane phase was separated off for chromatographic analysis. 
The extracts were assayed in duplicate using a Pye Unicam with a 
column 3~ SP2100 on gas chrom Q with mesh size 100/120 and fitted with 
a flame ionization detector. 
The temperature of the colulllll was 190°C when the sample was injected 
and the column was linked to a SP4200 intergrater to give better 
resolution of the peaks. 
The area under the peaks was taken to be proportional to the amount of 
substance present in the samples and this was correlated against the 
external standards. 
2.10 SOPI!!! POTASSIUM: OUABAlN-
SEISITIVE ATPase ASSAY 
The method used was a modification of the procedure described by 
Kjeldsen et al (1986) • The ["HI ouabain obtained was supplied in a 
toluene/ethanol mixture which was immiscible with the buffer used. The 
[~Hlouabain was placed in a scintillation vial in a fume cupboard and 
a pipette fitted to an air pump was used to gently evaporate the 
sol vents off. 
( 113 ) 
The tissue was prewashed twice in ice-cold Tris sucrose buffer for lOmins. 
The composition of the Tris sucrose buffer was Tris Cl lOmM, sucrose 250d, 
KgS04 3mM, and vanadate lmK. 
The tissue was placed in a vial containing the l"ris sucrose buffer, O.l~ 
ouabain, and 0.18-0.21 pCi/ml [3Hlouabain. The mixture was incubated at 
37°C for 3hours. In parallel with this tissue was placed in the same 
mixture as before except that the ouabain (untritiated) concentration was 
increased from 0.1p1[ to Id. Each sample was performed in triplicate. 
During the incubation period the mixture was replaced twice, after the 
first and second hour. 
Following incubation the tissue samples were washed twice (30mins each) in 
ice-cold Tris sucrose buffer, blotted gently dry and weighed. The samples 
were then placed in counting vials together with 5ml of 5~ trichloroacetic 
acid and left at room teD~erature (23°C ) for 24hrs. 
The samples were then counted in a LKB scintillation counter. 
2.11 VAS DEFERENS PREPARATION 
The vas deferens was excised. excess connective tissue was removed, and 
placed in ice-cold DOdified Krebs-Hensleit sol~tion aerated with a mixture 
of 95:1: Ch & 5:1: C[h. The composition of the physiological saline was NaCl 
143.3nK, KCl 15.9mX, XgS04 1.2d, CaCl 2 2.6nK, KB2P04 2.2mM, NaHCQG 24.9mK, 
glucose 10mX, ascorbic acid O.07nX, and B.D.T.A. O.067mK; and this was used 
throughout the study. 
The tissue was suspended ·in a 50Dl organ bath which was filled with 
modified Krebs-Hensleit solution, aerated with the same gaseous 
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mixture as above, and maintained at a constant 37°C. 
A tension of 19 was applied, and the tissue was allowed to equiliberate for 
1 hour until a steady baseline was obtained. 
Following this noradrenaline was added non-culllUlatively to the organ bath; 
the physiological saline was replaced after each dose and the tissue 
allowed to recover ("5-l0mins)' A dose-response curve over a wide range, 
lOnK to O.3mX was obtained. 
Finally the tissue was gently blotted dry and weighed. 
2.12 KATER I ALS 
All radiochemicals used in the experiments were froD Amersham International 
plc., Buckinghamshire, Endgland. 
The drugs were obtained from Signa Chemical Corp., USA. 
Reagents used in the investigation were AliALAR. 
2,13 ANALYSIS OF RE$ULTS 
The E.._~, the maximuD response of the tissue, and the ECso, effective 
concentration required to produce 50~ of the naximal response, were 
calculated using a progralllDe written by Dr P D Lucas on a ZX Spectrum. 
Statistical analysis was carried out also using progralllDes written by Dr P 
D Lucas on a ZX Spectrum computer. 
The significances of differences between groups were assessed initially by 
one-way analysis of varience and, where p values of less than 0.05 were 
obtained, individual groups were cODpared by Duncans multiple comparisons 
tests. 
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CHAPTER THREE 
RESULTS ANALYSIS 
.3, 0 RESULIS AIlALYSIS 
.,1 ANQCQCCYGEUS XUSCLE PREPARAIIOI 
In the first 6-weeks group (table 1) diabetic animals and diabetic 
treated with myo-inositol (DtXI) had significantly elevated blood 
glucose levels (b.g.ls) (pC 01 vs control), whilst the diabetic group 
alone had a significantly reduced body weight (p<.Ol). The D+XI also had 
reduced b.g,ls (p<.02 vs diabetic) and increased body weight gain 
(p<,005 vs diabetic>. 
In the second 6-weeks group the diabetic and diabetic treated with an 
aldose reductase inhibitor (O+ARI) both had signficantly b.g.ls (p<.Ol) 
as well as signficantly reduced body weight gains (p<.Ol). 
In the third 6-weeks group the diabetic and diabetic treated with 
triiodothyronine (Is) and 0 t ARI all had significantly elevated b.g.ls 
(p<,01). In addition these three classes of animals all had 
significantly reduced body weight gains (p<,Ol), 
In the 6-month diabetic aninals (table 2) all groups, diabetic and 0 + 
XI & D + ARI, had significantly higher b,g,ls (p<.Ol). As well as this, 
these three groups all had signficantly reduced body weights (p<. Oll. 
Compared to the diabetic the D+ARI gt;oup had lower b.g,ls (pC05) and 
increased body weight gain (p<. 005) and the O+XI group had increased 
body weight gain (p<.05) 
In the 1 year animals, the diabetic and D + ARI groups both had 
significantly elevated b.g.ls (P<.Ol) and reduced weight gains (p<.Ol). 
Also the D+ARI group had re~uced b.g.ls (p<,02 vs diabetic), 
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TABLE 1 
CONFIRMATION OF DIABETES 
(5 WEEKS ANIMALS 
Blood Glucose Change in Body 
Level (mID Weight (g' s> 
CONTROL, DIABETIC & XI TREATED AlllXALS 
COITROL (6) 4.34±0.75 +63.9±9.3 
DIABETIC (7) 28. 36±2.34B -27.2±8.9A 
DIABETIC + XI (6) 19. 91±1.53BE +17.0±7.6G 
COITROL, DIABETIC 11 AllI TREATED AllIXALS 
COITROL (6) 3. 86±1. 53 +55. 23±25. 62 
DIABETIC (6) 27. 65±4.30B +5. 44±8.35B 
DIABETIC + ARI (6) 26. 48±2.39B -14.33±19.53B 
COlITROL, DIABETIC III !RI III T3 TREATED 
COITROL (12) 4. 79±3. 72 +41. 67±7.65 
DIABETIC (8) 25. 93±1. 93B -5. 33±6.nB 
DIABETIC + ARI (7) 25.34±2.71 B -0. 33±8.38B 
DIABETIC + T3 (9) 26. 69±1. 27 9 +4. 67±12. gg9 
Results are expressed as mean ± s.e. with the number per group 
in parenthesiS. The significance of difference froD the control values 
is indicated by B pC ()1, and significance of difference from the 
untreated diabetic by E pC 02 and G pC 005; when IH is DyO-
inositol, ARI is an aldose reductase inhibitor (ponalrestat) and T3 is 
triiodothyronine. 
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TABLE 2 
CONFIRMATION OF DIABETES 
(3 MONTHS & 1 YEAR ANIMALS 
COJTROL (6) 
DIABETIC (6) 
DIABETIC+ARI (6) 
DIABETIC+XI (6) 
COJTROL (12) 
DIABETIC (7) 
DIABETIC + ARI (8) 
Blood Glucose 
Level (mX) 
6 I!O!ITRS 
7. 32±1. 33 
40. 60±1. 08" 
29.93±4.19BC 
38. 53±2. 90& 
1 YEAR AJjlXALS 
8. 17±1.87 
38. 66±2.44& 
27.25±3.12eE 
Change in Body 
Weight (g's) 
+177±14.50 
+39.80±17"G 
+3. 20±13. 7OSo 
+174. 22±25. 60 
+32.67+11. 93" 
+33. 88±17. 03& 
Results are expressed as :mean ± s. e. with the number per group 
in parenthesis. The significance of differences from the control values 
are indicated by B p<. 01 and significance of differences from the 
untreated diabetic by D pC 05, E pC 02, & G pC 005; when Xl is 
myo-inositol and ARI is an aldose reductase inhibitor 
("ponalrestatff ) • 
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In the first 6-weeks ani_Is group, for responses to noradrenaline; 
(table 3) the diabetic animals had significantly elevated Emax's (p<.05) 
together with a signHicantly higher EC-so range (pC 05>' The D + KI 
group had an Emax significantly lower than the diabetic animals (p<.05). 
whllst the EC-50 ranges were unchanged. There was no significant change 
in the maxillDlm force of contraction in the diabetic and D + XI groups 
compared to the control values. 
TABLE ;3 
6 WEEKS ANIMALS 
"E:..m;wa;a;:x:=.:.·..Js ... _~-----lE=C ..... .!sco RANGES FOR RESPONSES 
TO NORADRENALINE & MAXIMUM FORCE OF 
CONTRACTION DUE TO FIELD STIMULATION 
CONTROL DIABETIC DIABETIC + XI 
(6) (7) (6) 
EC-so Ranges 0.50 (0.1-1. 5) 1. 30(0. 7-2. 4)A 1. 80 (1. 2-2. 9) 
(flK) 
EDax (mg/ten. 520:1:59 738±81A 505±35° 
n'8 wet weIght) 
Kax Con. (mg/ten 259±.39 240±32 191:1:52 
mg wet weight) 
Resul ts are expressed for the Emax' sand Kaxlmum force of 
contraction as mean ± s.e. and for the EC ranges as geometric means 
with 95~ conf1dence liDits when the nun,ber of ani_Is per group 
is in parenthesls. Tbe slgnificance of difference from tbe control 
values is indicated by A pC 05 and from the untreated dlabetlc 
values by D p(.05 ; when XI is myo-inositol. 
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QRApH 1 
Dose-response curves of rat anococcygeus muscle to Igradrenaline froD 
6-weeks STZ diabetic, control, and diabetic treated with myo-inositol. 
, 
Each point represents an average of at least six observations and 
vertical lines denote SEK. 
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In the second 6-weeks animals group (table 4) responses to three 
exogenous drugs were evaluated, noradrenaline, phenylephrine and 
clonidine ( in the presence of prazosin). For noradrenaline the EC-so 
ranges of the diabetic and treated animals were unchanged. However the 
diabetic animals' Emax was significantly higher (p<.05) and the D + ARI 
group had a significantly lower Emax <pC 01 vs diabetic)" 
For phenylephrine once again the EC-so ranges were unchanged whilst the 
diabetic Emax was significantly higher (pC 05>' The D + ARI group Emax 
was significantly lower (p<.Ol vs both Control & Diabetic). 
For clonidine (in the presence of prazosin) the EC-so ranges for the 
diabetic group was lower, whilst the D + ARI group was significantly 
lower (p<.Ol vs the control group). The Emax for the diabetic group was 
significantly higher (p<.05) and the D + ARI groups Emax was 
significantly lower (p<.05 vs the diabetic group). 
In the third 6-weeks animals group (table 5) there were no changes in 
responses to noradrenaline and phenylephrine, in both EC-so ranges and 
Enax's; though the Emax's for the diabetic were higher they were not 
significantly so. For clonidine (in the presence of prazosin) the D + 
ARI group's EC-50 range was significantly different (p<.05 vs control & 
diabetic values). The diabetic EDax was significantly higher (pC 01), 
whilst the Emax's for the D + ARI and D + T3 were significantly lower 
(both p<.Ol) compared to the diabetic value. 
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TABLE 4 
6 WEEKS ANIMALS 
Ema;x;' 6 & EC .'5<> RANGES 
EC-.. o Enax 
Ranges mg!ten. ~ wet weight 
lfORADREJrALIHE 
COJrTROL (6) 3.8(2.1-6.9) pX 822±54 
DIABETIC (5) 3.8(2.1-'7.0} pX 1142±6'lA 
DIABETIC + ARI (6) 6.3(3.9-10.3} ~K 'l40±4'lF 
PHEIYLEPHRIHE 
COJrTROL (6) 2.2(1.4-3.3} pX 'l'l3±58 
DIABETIC (5) 1.8(1.0-2.9} pX 1199±89A 
DIABETIC + ARI (6) 1.'7(1.1-2.8) pX 468±'lOBF 
CLOJrIDIHE (+PRAZOSIJr) 
COJi"TROL (6) 0.1(0.08-0.1) ~K 'l14±43 
DIABETIC (5) 52(2'l-99} nK 10'l'l±9'lA 
DIABETIC + ARI (6) 32(1'7-59} n]{B 
Resul ts for Emax are expressed as mean ± s. e. and for the EC-so 
ranges as geometric means with 95~ confidence limits, with the 
number per group in parenthesis. The significance of difference 
from the control Dean values is indicated by A p<.05 & B p<.Ol & 
from the untreated diabehc values is indicated by D pC 05 & F 
pC 01; when ARI is an aldose reductase inhibitor ("ponalrestat"). 
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GRAPH 2 
Dose-response curves of rat anococcygeus DUscle to Igradrenaline from 6-
weeks STZ diabetic, control, and diabetic treated with an, aldose 
reductase inhibitor <ponalrestat). Each point represents an average of 
at least five observations and vertical lines denote SEll, when D 
<p<0.05) indicates a significant difference froll the untreated diabetic 
values. 
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GRAPH 3 
Dose-response curves of rat anococcygeus muscle to Phenylephrine froll 6-
weeks STZ diabetic, control, and diabetic treated with an aldose 
reductase inhibitor <ponalrestatl. Each point represents an average of 
at least five observations and vertical lines denote SEX, when D 
<p<0.05) and F <p<O.01) indicate a significant difference frOll the 
untreated diabetic values. 
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GRAPH 4 
Dose-response curves of rat anococcygeus Dllscle to Clonidine in the 
presence of Prazosin from 6-weeks STZ diabetic, control, and diabetic 
treated with an aldose reductase inhibitor <ponalrestat). Each point' 
represents an average of at least five observations and vertical lines 
denote SEX. 
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TABLE 5 
6 WEEKS ANIMALS 
Emax·s & EC RANGES 
EC-so EDax 
Ranges mg/ten mg wet weight 
JiORADREJULIIE 
COflROL (6) 2.4(1.6-3.6) pJI 398±38 
DIABETIC (7) 1. 2 (0. 4-3.1) pJI 634±126 
DIABETIC + ARI (5) 4.5(2.4-8.3) pJI 341±92 
DIABETIC + T3 (6) 4.3(2.4-7.6) pJI 468±98 
PHEJlYLEPIIR I IE 
COITROL (6) 7.4(2.5-21.4) pJI 404±30 
DIABETIC (7) 10.3(3.4-31.7) pX 651±127 
DIABETIC + ARI (5) 3.9(2.0-7.5) pX 413±124 
DIABETIC + T3 (6) 3.9(2.1-7.1) pX 426±127 
CLOIIDIIE (+PRAZOSII) 
CONTROL (6) 1.5(0.5-4.4) pX 288±27 
DIABETIC (7) 1.0(0.2-4.6) pX 782±130B 
DIABETIC + ARI (5) 11.5(10.2-12.9) pXAD 331±125F 
DIABETIC + T3 (6) 3.3(1.7-6.6) pX 154±10F 
Results for Emax are expressed as mean ± s.e. and for the BC-so 
ranges as geometriC means with 95~ confidence limits, , with the number 
per group in parenthesis. The significance of difference from the 
control values by A p<.05 & B p<.01 and from the untreated diabetic 
values by D p<.05 & F p<.Ol; when ARI is an aldose reductase inhibitor 
(ponalrestat) and T3 is tri-iodothyronine. 
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GRAPH 5 
Dose-response curves of rat anococcygeus DUscle to Ipradrenaline from 6-
weeks STZ diabetic, control, diabetic treated with an aldose reductase 
inhibitor (ponalrestat), and diabetic treated with triiodothyronine 
(T3). Each point represents an average of at least five observations and 
vertical lines denote SE., when A <p<O.05)indicates a significant 
difference from the control values, and D (p<O.05) 
significant difference from the untreated diabetic values. 
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GRAPH 6 
Dose-response curves of rat anococcygeus DUsCle to Phenylephrine from 6-
weeks STZ diabetic, control, diabetic treated with an aldose reductase 
inhibitor (ponalrestat), and diabetic treated with triiodothyronine 
(T3). Each point represents an average of at least five observations and 
vertical lines denote SEX. 
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GRAPH 7 
Dose-response curves of rat anococcygeus Dllscle to CIgnidine in the 
presence of Prazosin from 6-weeks STZ diabetic, control, diabetic' 
treated with an aldose reductase inhibitor (ponalrestat), and diabetic 
treated with triiodotbyronine (T3). Each point represents an average of 
at least five observations and ,vertical lines denote SEX, when A (p<.05) 
and B (p<.Ol) indicate a significant difference from the control values 
and D (p<. 05) and F (p<. 01) indicate a signifcant difference from the 
untreated diabetic values. 
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For tbe 6 m:mtb animals (table 6) the diabetic group's EC-eo" ranges 
were significantly different ( p<.Ol) from the control values. The D + 
!RI group was significantly different from the control (p<.05) and the 
diabetic values (pC on. Tbe D + XI group was also significantly 
different from the control (pC 01) and diabetic va 1 ues (pC Oll. The 
diabetic Emax was significantly higher (p<.05) than the control, whilst 
the D + ARI .,. D + XI groups bad a significantly lower values (p<. 05) 
compared to the diabetic. 
TABLE 6 
6 MONTHS ANIMALS 
Emax's & EC ~~ RANGES FOR RESPONSES 
TO NORADRENALINE 
EC_so EDax 
Ranges ms/ten ~ wet weight 
COnROL (6) 4.6(2.7-7.9) )IX 507±97 
DIABETIC (6) 0.5 <0. 3-0. 6) )Ill" 1774±384A 
DIABETIC + Xl (6) 1.6(1.1-2.5) )lXAF 657±167D 
DIABETIC + ARI (6) 1. 3 <0. 6-2. 6) )lII"F 620±64D 
. 
Resul ts are expressed for the Emax's as Dean ± s. e. and for the 
BC-so ranges as geometric means with 95~ confidence limits with the 
number of animals per group in parenthesis. The significance of 
difference from the control values is indicated by A p<.05 & 
B p<.Ol and from the untreated diabetic by D p<.05 F f p<.Ol; when XI 
is Dyo-inositol and ARI is an aldose reductase inhibitor 
<"ponalrestatU ) • 
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GRAPH 8 
Dose-response curves of rat anococcygeus muscle to Noradrenaline froD 6-
months STZ diabetic, control, diabetic treated with an aldose reductase 
inhibitor <ponalrestat>, and diabetic treated with myo-inositol. Each 
point represents an average of at least six observations and vertical 
lines denote SEX, when A <p<O.05) and B <p<O.Ol} indicate a significant 
difference from ·the control values, and D <p<O.05) indicates a 
significant difference from the untreated diabetic values. 
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In the 1 year aninals (table 7) sensitivity to noradrenaline, 
phenylephrine, and clonidine were all unchanged in the untreated diabetic 
and D + ARI groups compared to the control values. For noradrenaline the 
diabetic Emax was significantly lower (p<.01>, whilst the D + ARI group 
animals were significantly lower (p<.Ol vs diabetic values). For 
pbenylephrine the diabetic Emax was significantly lower (pC 01); as was 
the D + ARI groups' Ema:>: (p<. 05) cOD'P"red to the control values. For 
clonidine only the diabetic EDax value was significantly lower (p<.05). 
TABLE 7 
1 YEAR ANIMALS 
Emax'$ & EC ~~ RANGES 
EC-so E,...:>: 
Ranges mg/ten mg wet weight 
1I0RADREJrALIlrE 
COITROL (6) 1.6(1.5-1.7) fill 1439±35 
DIABETIC (5) 3.2(2.3-4.4) fill 608±24s 
DIABETIC + ARI (6) 3.6(2.0-6.3) fiX 1295±25F 
PHElIYLEPHRIlrE 
COIrTROL (6) 2.5(2.1-2.9) fiX 1584±60 
DIABETIC (5) 2.8(2.3-3.5) fiX 498±36s 
DIABETIC + ARI (6) 3.4(3.0-4.0) fiX 775±49A 
CLOIfIDIlrE (+PRAZOSIN) 
COITROL (6) 0.20(0.10-0.35) fill 503±63 
DIABETIC (5) 1. 0(0. 7-1. 5) fiX lO9±16A 
DIABETIC + ARI (6) 0.4(0.3-0.5) IlX 419±44 
Results for Ema:>: are e:>:pressed as mean ± s.e. and for the EC-5 o ranges 
as geoJDetric means with 95% confidence limits, with the number per 
group in parenthesis. The signifcance of difference from the control 
values is indicated by A p<.05 .\ B p<. 01 and from the untreated diabetic 
values by F p<.Ol; • when ARI is an aldose reductase inhibitor 
("ponalrestat") . 
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GRAPH 9 
Dose-response curves of rat anococcygeus DUscle to Noradrenaline froD 1 
year STZ diabetic, control, and diabetic treated with an aldose 
reductase inhibitor <ponalrestat). Each point represents an average of 
at least five observations and vertical lines denote SEK, when A 
<p<0.05) and B <p<O.Ol) indicate a significant difference frOD the 
control values, and D <p<O.05) and F <p<O.01) indicate a significant 
difference from the untreated diabetic values. 
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GRAPH 10 
Dose-response curves of rat anococcygeus DUscle to Phenylephrine froD 1 
year STZ diabetic,· control, and diabetic treated with an aldose 
reductase inhibitor <ponalrestat). Each point represents an average of 
at least six observations and vertical lines denote SEX, when A <p<0.05) 
and B <p<O.Ol) indicate a significant difference froD the control 
values, and D <p<O.05) indicates a significant difference fron the 
untreated diabetic values. 
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GRAPH 11 
Dose-response curves of rat anococcygeus muscle to Clenidine in the 
presence ef Prazosin from 1 year STZ diabetic, control, and diabetic 
treated with an aldose reductase inhibitor <ponalrestat). Each point 
represen~ an average of at least six observations· and vertical lines 
denote SEX, when A <p<O.05) and B <p<O.Ol) indicate a significant 
difference from the control values. 
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In the anococcygeus muscle preparation (table 8) for the variable 
tension set-up diabetes was confirmed by the significantly elevated 
blood glucose levels ( p<.Ol) and significantly reduced body weight gain 
(pC 01), At 19 tension the EDax's for the diabetic group were higher, 
but not significantly so, compared to the control group. At the optiDUm 
tension, which varied between 0.5 and 0.25g, the diabetic Emax's were 
once again higher but not significantly so. There was no change in 
sensativity to noradrenaline in the diabetic groups for both the fixed 
(lg) and variable tension. Responses to field stimulation were similiar 
in both the control and diabetic groups with no significant variation. 
TABLE e 
CONFIRMATION OF DIABETES 
COITRaL (6) DIABETIC (6) 
Blood Glucose 6. 92:1:1. 15 22.61±8.36B 
Level (mM) 
Change in Body +78. 5±3. 90 +17. 56±11. 991> 
Weight (g's) 
EDax (1g tension) 414:1:91 489±82 
EDax (xg tension) 410±88 546±147 
EC"o 0.5(1. 1-0. 3)jJX 1. 1 (3. 2-0. 4) jJX 
(1g Tension) 
EC"o 0.4(1. O-O.l)jJX 1. 0(2. 4-5. 6)jJX 
(xg Tension) 
Results are expressed as mean ± s.e. with the number per group 
in parenthesiS. The significance of difference from the control values 
is indicated by B p<.Ol; when XI is myo-inositol, ARI is an 
aldose reductase inhibitor (ponalrestat). In the second phase of the 
experiment the tension (Ig) was varied until the optimum tension 
waS reached and a maximal response was obtained. 
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GRAPH 12 
Dose-response curves of rat anococcygeus muscle at a fixed tension of 
18 to loradrenaline frOD 6-wee:k:s STZ diabetic and control rats. Each 
point represents an average of at least six observations and vertical 
lines denote SEX . 
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GRAPH 13 
Dose-response curves of . rat ano=ygeus muscle at an opti ... l tension 
to ipradrenaline froD 6-weeks STZ diabetic and control rats. Each point 
represents an average of at least six observations and vertical lines 
denote SEX. 
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GRAPH 14 
Response curves of rat anococcygeus muscle to field stimulation with 
varying frequency froD 6-weeks STZ diabetic and control rats. Each point 
represents an average of at least six observations and vertical lines 
denote SEX. 
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In the tritiated noradrenaline overflow and stimulated release experiments 
in the anococcygeus muscle diabetes was confirmed in all three groups. In 
the first 6 week group (table 9) the diabetic and D + ARI groups all had 
significantly elevated blood glucose levels (p<. 01) and reduced body 
weight gain (p<. 01). This pattern of diabetes was also confirmed in the 
second six weeks animals with the diabetic , D + ARI and D + T3 groups all 
having significantly elevated blood glucose (p<.Ol) and reduced body weight 
gains (p<. 01) compared to the control values. In the first 6-wee1<s group 
basal release of tritium and stimulated release (table 10), in the absence 
of drugs, were similiar in all groups; namely control, diabetic & D + ARI. 
The addition of desipramine (0.2)110 elevated the tritium release due to 
stimulation to a markedly lesser degree in the diabetes group compared to 
the control values (p<.05). This effect was rectified in the D + ARI group 
which was significantly different from the diabetic values (p<.Ol). Further 
potentiation of release by the addition of yohimbine (1J1X) was equivalent 
in all groups. Tissue 3H- NA uptake was similar in all three groups. 
In the second 6-wee1<s group (table 10 ) the same pattern of results were 
observed. The basal release and stimulated release, in the absence of 
drugs, was similiar in all groups. Tritium release was potentiated by the 
addition of desipramine (0.2)lX); but once again significantly to a lesser 
degree in the diabetic group compared to the control values (p<. 05). 
Treatment with an aldose reductase inhibitor and triiodothyronine produced 
a significant positive effect (p<.05 vs the diabetic values); and restored 
values comparable to the control value. The addition of yohimbine (1)1.10 
caused a potentiated release higher in the control group compared to the 
diabetic, but not significantly so. 
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In a further set of overflow and stimulated release of tritiated 
noradrenaline experiments in 6-months streptozotocin-induced diabetic 
rats, carried out hy a co-researcher, there was no difference between basal 
and stimulated release both in the absence and presence of drugs, 
desipramine and yohimbine (unpublished data). 
OVERFLOW & STIMULATED RELEASE OF""'[NAJ 
BY ANOCOCCYGEUS MUSCLE 
CONFIRMATION OF PIABETES 
aJJrrROL (6) 
DIABETIC (6) 
DIABETIC + ARI (6) 
aJITROL (6) 
DIABETIC (6) 
DIABETIC + ARI (6) 
DIABETIC + T3 (6) 
TABLE 
Blood Glucose Level 
(mII) 
9 
Change in Body 
Veight (g's) 
6 Weeks Animals (l-~ Set) 
4.36±1. 83 +63. 9±22. 8 
28.39±5.72B -27. 2±21. 8B 
27. 12±6. 149 -19.8±18.9B 
6 Weeks Animals (2nd Set) 
6.91±1.24 +78.5±3.9 
22. 64±8. 4ZB +l7. 6±11. 9 B 
Z3.27±9.23B +lO.Hl3.5B 
Z5.9H8.47B +30.6±12.4B 
Results are expressed as mean ± s.d. with the number per group in 
parenthesis. The significance of difference from the control values is 
indicated by B pC 01; when ARI is an aldose reductase illhlbitor 
('ponalrestat') , ](1 is myo-inoslt.ol and T3 is trUodothyronine. 
( 143 ) 
OVERFLOW & STIMULATED RELEASE OP=[NAl 
BY ANOCOCCYGEUS MUSCLE 
STIMULATED rH"'"] OVERFLOW <pmal/g> 
TABLE lQ 
6 WEEKS AJ[IJIIAI.S o-t. Set> 
No Drugs 
+ Desiprallline 
:£ Increase 
COlfIROL 
(6) 
30.8±4.2 
39.1±5.9 
26.6±4 .. 7 
+Des.+Yohimbine 58.4±9.5 
:£ Increase 50.8±8.4 
Tissue 3H- NA (nmol/g) 
@t=O 2.32!O.49 
after superfusion l.9l!O.42 
Q. 
No Drugs 
+Desipramine 
:£ Increase 
+Des+Yohimbine 
'.t Increase 
CONTROL 
(6) 
61. 3±16. 7 
77.4±18.8 
35. 2±22. 2 
131. 5±26. 5 
96.8±29.3 
DIABETIC DIABETIC + ARI 
(6) (6) 
31.1±6. ° 35.8±6.5 
31. 6±5. 9 49.7±8.Q 
2.8±4.0A 40.1±7.2F 
44.9±7.4 69.4±10.4 
47.3±10.5 40.5±10.6 
2.l0!O.34 2.2l!O.17 
1.53!O.65 !.77!O.18 
WEEKS ANIMALS ~ Set) 
DIABETIC DIABETIC+ARI 
(6) (6) 
61. 4±17. 6 64.7±22.6 
64.3±18.7 79.2±22.3 
10. 1±9. 5A 38.3±22.3° 
99.6±27.8 102.5±22.1 
36.6±16.3 60.8±17.9 
DIABETIC+T" 
(6) 
56.9±22.7 
61. 3±27. 6 
30.7±11.7° 
112.6±3Q.6 
45.8±14.7 
Results are expressed as mean ± s.e. with the number per group in 
parenthesis. The significance of difference from the control val ues is 
indicated by A p(.05 and from the untreated diabetic values by D p(.05 & F 
p(.Ol, when ARI is an aldose reductase inhibitor (·ponalrestat·). XI is 
myo-inositol. and T3 is triiodothyronine. 
Tissue 3H- NA at time 0 i.e. tissue 3H- NA uptake was estimated by 
addinq total basal 3H release (calculated, assuming 1st order 
kinetics) and the stimulated release to the 3H measured in the 
tissue after superfusion. 
( 144 ) 
GRAPH 15 
Effects of desipraDine (O.2~K) and desipramine with yohimbine (1~) on 
stimulated [3H]-Noradrenaline release in rat anococcygeus muscle from 6-
weeks STZ diabetic, control, and diabetic treated with an aldose 
reductase inhibitor (ponalrestat). Each bar represents the average of at 
least of six observations and vertical bars denote SEX. 
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GRAPH 16 
Per centage increase of stimulated [3Hl-Jroradrenaline release in rat 
anococcygeus DUscle due to desipramine (O.2pX) and desipramine with 
yohimbine (lpX) from 6-weeks STZ diabetic, control, and diabetic treated 
with an aldose reductase inhibitor (ponalrestat). Each bar represents 
the average of at least of six observations and vertical bars denote 
SEX, when A <p<O.05) indicates differences from the control values and 
D <p<O.05) indicates differences frOD the diabetic values. 
INCREASE IN TRITIATED NORADRENAUNE RELEASE DUE TO DRUGS 
120 
100 
80 
60 
40 
20 
o 
+ DESIPRAMINE + DESIPRAMINE 
+ YOHIMBINE 
Legend 
_ CONTROL 
CDIAUTIC 
221 DIABeTIC + poncllrutat 
GRAPH 17 
Effects of desipramine (0.2j1X) and desipramine with yohillbine (1pX> on 
stimulated ["'H]-Jloradrenaline release in rat anococcygeus muscle frem 6-
weeks STZ diabetic, control, diabetic treated with an aldose reductase 
inhibitor (ponalrestat) and diabetic treated with triiodatbyronine (T3. 
Each bar represents the average of at least of six observations and 
vertical bars denote SEX . 
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GRAPH 18 
Per centage increase of stimulated [:>Hl-]I'oradrenaline release in rat 
anococcygeus muscle due to desipramine (O.2pJl) and desipramine with 
yohimbine <lJ1K) froD 6-weeks STZ diabetic, control, diabetic treated 
with an aldose reductase inhibitor (ponalrestat) and diabetic treated 
with triiodothyronine· (T3. Each bar represents the average of at least 
of six observations and vertical bars denote SEX, when A (p(O.05) 
indicates differences from the control values and D <p<O.05) indicates 
differences from the diabetic values. 
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,2 AQRTIC RING PREPABATIQI 
In the aortic ring experiDents (table 11) diabetes was confirmed in the 
diabetic D + ARI and D + XI,in 6-week, 6-month, and 1 year animals, by the 
significantly elevated blood glucose levels (p<.01) and reduced body 
weight gains (p<.Ol). 
TABLE 11 
CONFIRMATION OF DIABETES 
COll'TROL (8) 
DIABETIC (10) 
DIABETIC + XI (7) 
DIABETIC + ARI (6) 
COll'TROL (6) 
DIABETIC (6) 
DIABETIC + XI (6) 
DIABETIC + ARI (6) 
conROL (12) 
DIABETIC (7) 
DIABETIC + ARI (8) 
Blood Glucose 
Level (mID 
6 WEEKS AJllXALS 
6. 89±1. 05 
26. 48±2. 21" 
30.51±2.65" 
32.70±2.03" 
6 JIIOIITHS ANlXALS 
7. 32±1. 33 
40. 60±1. 08" 
29.93±4.19BO 
38.53±2.90" 
1 YEAR AJllXALS 
8. 17±1. 87 
38.66±2.44" 
27. 25±3. 12"E 
Change in Body 
Weight (g's) 
+60. 48±9. 56 
-22. 68±11. 70" 
-33.70±8.90" 
-27.90±13.70" 
+l77±14.5 
-34.80±9.10" 
+39. 80±17. 90"G 
+3. 20±13. 70"0 
+174. 22±25. 60 
+32. 67±11. 93" 
+33. 88±17. 03" 
Results are expressed as mean +/- s.e. with number per group in 
perenthesis. The significance of difference from the control group 
values are indicated by B p<O.Ol and from the untreated diabetic by D 
p<.05, E p<.02 & G p<.005; where XI is myo-inositol, and ARI is 
an aldose reductase inhibitor ("ponalrestat"). 
( 149 ) 
In the 6-week animals <table 12) there was no change j n sensi ti vi ty and 
EDax's in response to noradrenaline in both rubbed and unrubbed aorta. 
Sensitivity to 5-hydroxytryptamine <5-HT) in the rubbed aorta in the 
diabetic, D + XI and D + ARI groups was significantly different from the 
control values <pC 01); whereas in the' unrubbed aorta only the D + XI 
group was significantly different from the control values <p<.05). 
The Emax's for 5-HT, for both rubbed and unrubbed, were unchanged in the 
untreated diabetic and the treated groups. 
In the 6 month animals <table 13) only rubbed aorta was used. Sensitivity 
to noradrenaline and 5-HT, both in the absence and presence of desipramine, 
was neasured. Diabetic and D + 'XI animals both bad signficantly increased 
sensitivity to noradrenaline, < pC 01 and pC 05 respectivly), whilst the 
sensitivity· of the D + ARI group was significantly restored Cp<.05 vs the 
diabetic values). Emax's for the diabetic group were significantly 
increased <p<. 05 vs control values), whereas those for the D + XI group 
were significantly reduced <p<.01 vs the diabetic values). The Emax's for 
the D + ARI group were significantly different Cp<.05 vs control & p<.01 
vs diabetic). 
There was no change in sensitivity to 5-HT in the diabetic and treated 
groups in the absence of desipramine. The diabetic Elnax was significantly 
higher Cp<O. 5), whllst the D + XI group Emax was significantly lower 
<p<0.5 Vs control and p<.Ol Vs diabetic); as was the Emax for the D + ARI 
<p<.01 Vs both control & diabetic values). 
Sensitivity to 5-HT in the presence of desipramine was unchanged. Emax's 
however, for the diabetic group were significantly higher <p<.01) and for 
the D + XI group significantly lower <p<. 01 Vs control & diabetic 
values). An interesting feature was that the responses for the D + ARI 
group were so reduced as to be unneasureable. 
< 150 ) 
AORTIC RING SENSITIVITY TO DRUGS 
Em.>: (I!g/ten 
",g .et weight) 
EC-to 
(nM) 
Emax (~g/ten 
mg wet weight) 
EC-&o 
(nM) 
E",x (mg/ten 
mg wet weight) 
EC-so 
(~M) 
E~,>: (.gjlen 
og .et .eight) 
EC-s<' 
(~M) 
TABLE 12 
6 WEEKS ANIMALS' 
Emryx'5 & EC ~~ Ranges. 
CONTROL 
393±43 
(8) 
2,2(1,2-3,S) 
(8 ) 
209.20 
(8 ) 
21(10-43) 
(8) 
303t38 
(9) 
0,3(0,1-0,7) 
(9 ) 
184t21 
(9) 
3,1(1,9-5,3) 
(9) 
DIABETIC DIABETlCtMI 
NORADRENALl NE 
Rubbed Ae,r\·iI 
433t96 446<59· 
( 6) (6) 
2,6(1,2-5,5) 5,8(3,9-8,9) 
(6) (6) 
Un rubbed Aor\.iI 
247t28 36U78 
(7) m 
15(4,6-50) 49(21-100) 
(7) (7) 
5-HYDROXYTRYPTAMINE 
Rubbed Aorta 
358t62 350t53 
(9) (6) 
2,3(1,6-3,3)" 4,1(2,2-7,7)" 
(9) (6 ) 
Unrubbed Aorh 
143t27 193<51 
( 9) m 
6,7(3,5-13) 10,3(5,8-1S)" 
(1O) (7) 
DIASETlC+ARI 
408t62 
(6) 
3,4(1,6-6,3) 
(6) 
25Bm 
(6) 
24(7-49) 
(6 ) 
363<59 
(6) 
I,S(0,3-5,3)" 
( 6) 
126.32 
(6 ) 
5,6(3,8-19) 
(6) 
Results are expressed as mean ± s.e .• with the number per group in 
parenthesis, The significance of difference from the control values is 
indicated by A pC 05 & B pC 01 ; when XI is myo-inositol and ARI is an 
aldose reductase inhibitor ("ponalrestat") 
( 151 ) 
AORTIC RING SENSITIVITY TO DRUGS 
COlITROL (6) 
DIABETIC (6) 
DIABETIC + XI (6) 
DIABETIC + ARI (6) 
COlITROL (6) 
DIABETIC (6) 
DIABETIC + XI (6) 
DIABETIC + ARI (6) 
COlJTROL (6) 
DIABETIC (6) 
DIABETIC + XI (6) 
DIABETIC + ARI (6) 
TABLE 33 
6 MONTHS ANIMALS 
EC-so EDax 
Ranges mg/ten mg wet 
1l0RADREJlALln: 
44 (15-100) nil 167±14 
3.5(2.3-5.3) nP 243±43A 
8.7(5.8-13) nJ(A 79±5F 
21(9.8-48) nJ!" 141±5AF 
5-HYDROXYTRYPTAXlNE 
0.8(0.2-3.4) pll 153±15 
2.1 (1.1-4.1) jJJ!: 196±17A 
0.6 (0. 2-1. 4) pll 86±13AF 
1. 2 (1. 0-1. 5) pll 111±9eF 
5-HYDROXYTRYPTAXIJIE (+ DESIPRAIIIllE) 
7.3(3.1-16.8) ~ 
4 <1. 8-8.8) pX 
2.2(1-4.7) pX 
136±13 
232±156 
52±106F 
weight 
Results for Emax's are expressed as mean ± s.e. and for EC-so Ranges as 
geometric means with 95Z confidence limits, with the number per group 
in parenthesis. The signfficance of difference from the control values 
is i nd! c.ated by A p<. 05 & B p<. 01 and from the untreated 
diabetic values by D p<.05 & F p<.Ol; when III is myo-inositol & ARI 
an aldose reductase inhibitor ("ponalrestat"). 
( 152 ) 
GRAPH 19 
Dose-response curves of rubbed rat aortic rings to Noradrenaline froD 6-
months STZ diabetic, control, diabetic treated with an aldose reductase 
inhibitor <ponalrestat), and diabetic treated with DYo-inositol. Each 
point represents an average of at least six observations and vertical 
lines denote SEX, when A <p<O.05) and B <p<O.Ol) indicate a significant 
difference from the control values, and D <p<0.05) and F <p<O.01> 
indicate a significant difference froD the untreated diabetic values. 
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GRAPH 20 
Dose-response curves of rubbed rat aortic rings to 5-Hydroxytryptam1 ne 
fro,. 6-JaOnths STZ diabetic, control, diabetic treated- with an aldose 
reductase inhibitor <ponalrestat), and diabetic treated with ,.yo-
inositol. Each point represents an average of at least six observations 
and vertical lines denote SEX, when A (p<0.05) and B <p<O.Ol) indicate a 
significant difference frail the control values, and D (p<0.05) and F 
<p<O.Ol) indicate a significant difference fro,. the untreated diabetic 
values. 
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GRAPH 21 
Dose-response curves of rubbed rat aortic rings to 5=llydroxytr~ptamjne 
in tbe presence Of desipran!»a from 6-months'STZ diabetic, control, and 
diabetic treated with myo-inositol. Each point represents an average of 
at least six observations and vertical lines denote SEX, when A <p<O.05) 
and B <p<O.01) indicate a significant difference frOD the control 
values, and D <p<O.05) a~d F <p(O.Ol) indicate a significant difference. 
from the untreated diabetic values. 
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In the 1 year aniDals (table 14) the sensitivity to noradrenaline in the 
diabetic group was significantly higber compared to the control values 
(pC 05), The senstivity to noradrenaline of the D + ARI group was 
significantly lower ( p<.05 Vs diabetic & p<.Ol vs control). There was 
DO change in the En&x's for the diabetic and D + !RI groups. Emax's and 
Bensitivity to 5-HT, in the absence and presence of desipramine, were 
u~changed in the diabetic and D + !RI groups. An anomaly was the fact 
that the diabetic group's response was so low as to be unmeasureable. 
TABLE 14 
1 YEAR ANIMALS 
Emax's & EC ~~ Ranges 
Emax EC-OoO 
Ranges mg/ten. mg wet weight 
NORADRENALIIE 
COJrTROL (6) 0.1(0.2-0.1) fiX 228±54 
DIABETIC (5) 1. 2 (S. 8-0. 3) fill1A 170±15 
DIABETIC + ARI (5) 47<85-26) nl'lAF 204±38 
5-HYDROXYTRYPTAXlIE 
COJrTROL (6) 1. 6 (3. 8-0. 7) fiX 121±32 
DIABETIC (5) 0.7(S.2-0.1) fiX 110±22 
DIABETIC + ARI (6) 0.4 (1.1-0. 1) fiX 151±36 
5-HYDROXYTRYFTAXINE (+ DESIPRAXlIE) 
COJrTROL (6) 0.5 (1. 7-0.1) fiX 
DIABETIC (5) --.,..-
DIABETIC + ARI 0.6(1.2-0.3) fill1 
Results for Emax's are expressed as Dean 
as geometric Deans with 951. confidence 
group in parenthesis. The significance of 
values is indicated hy A pC 05 
diabetic values by F p<.Ol; WbP.D XI is 
reductase inhi bi tor ("ponalrestat" >. 
( 156 ) 
117±26 
lS9±21 
± s.e. and for EC-so Ranges 
limits, with the number per 
difference from the control 
and from the untreated 
myo-inositol & ARI an aldose 
GRAPH 22 
Dose-response curves of rubbed rat aortic rings to Mgradrenaline frOD 1 
year STZ diabetic, control, and diabetic treated with an aldose 
reductase inhi bi tor <ponalrestat). Each point represents an average of 
at least six observations and vertical lines denote SEX. 
· _w._" 
::"f:r~··'-" 
"" 
RESPONSES TO NORADRENALINE 
220 
200 
180 
160 
140 / 
120 
100 
80 
60 
40 
20 
• 
O+-~~-.-----.-----.------.-----. 
-8 -7 -6 -5 -4 -3 
log [noradrenaline] 
Legend 
o CONTROL 
• p!~~mC ___________ _ 
• Q.!.!.!!T.!.2.:!:..P~'.!!2.t 
I 
I 
. I 
GRAPH 23 
Dose-response curves of rubbed rat aortic rings to 5-Bydroxytq[ptamine 
from 1 year STZ diabetic, control, and diabetic treated with an aldose 
reductase inhibitor <ponalrestat). Each point represents an average of 
at least five observations and vertical lines denote SEK, when A 
<p<0.05) indicates a significant difference from the control values, and 
D <p<0.05) and F <p<O.01) indicate a significant difference from the 
untreated diabetic values. 
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GRAPH 24 
Dose-response curves of rubbed rat aortic rings to 5-Hydroxytr~tamine 
in the presence pf desipramine from 1 year STZ diabetic and control 
animals. Each point represents an average of at least five observations 
and vertical.lines denote SEX, when A <p<O.05) and B <p<O.Ol) indicate a 
significant difference from the control values. 
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,:,\ VAS nEFEREIm PREPARATION 
In the vas deferens preparation (t.able 15) diabetes was confirmed by the 
significantly elevated blood glucose levels (p<.Ol) and reduced body weight 
gain (p<.Ol) of the diabetic and treated groups, in both 6 month and 1 year 
animals. 
TABLE J5 
CONFIRMATION OF DIABETES 
Blood Glucose 
Level (mID 
Change in Body 
'Weight (g's) 
6 XORTBS ANIMALS: CORTROL, DIABETIC & ARl & XI TREATED 
COKTROL (6) 7. 32±1.33 +177±14.5 
DIABETIC (6) 40. 60±1. 08" -34.80±9.10" 
DIABETIC + XI (6) 29. 93±4. 19"D +39. 80±17. 90BG 
DIABETIC + ARI (6) 38. 53±2. 90" +3.20±13.70BD 
1 YEAR AlrIXALS: CORTROL, DIABETIC & ARI TREATED 
COJTROL (12) 8. 17±1. 87 +174. 22±25. 60 
DIABETIC (7) 38. 66±2. 44" +32. 67±11.93" 
DIABETIC + ARI (8) 27.25±3.12"E +33. 88±17. 03" 
Results are expressed as mean +/- s.e. with number per group in 
perenthesis. The significance of difference from the control group 
values are indicated by B p<O.Ol and from the untreated diabetic values by 
D p<.05, E p<.02 & G p<.005; where XI is myo-inositol, and ARI is 
an aldose reductase inhibitor ("ponalrestat"). 
( 160 ) 
Sensitivity to noradrenaline (table 16) was unchanged in both 6 DOnth and 1 
year aniIoals. In the 6 ~nth animals the Emax for the diabetic group was 
significantly higher (p<.05). The Emax for the D + XI group was 
significantly lower (p<.05 Vs diabetic). There was no change in the Emax 
for the 1 year animals. 
COITROL(6) 
DIABETIC(6) 
DIABETIC+XI (7) 
DIABETIC+ARI (6) 
COITROL(7) 
DIABETIC (6) 
DIABETIC+ARI(6) 
TABLE 16 
Emax's & EC ~~ RANGES 
Euax EC-so 
Ranges ms'slten ms wet weight 
6 J(QNTI!S AIIIfAI.8 
1. 9 (0. 7-2. 7),.,x 
3.3(2.4-4.5),.,x 
2.5(0.4-15.0)fJX 
1. 4 (1. 0-2. O),.,x 
1 YEAR AllIJ!ALS 
1. 4 (O.7-2.7),.,x 
1. 4 (0. 5-3. 4),.,x 
1.2(0.4-3.4),.,x 
41. 0±4. 9 
67. 0±10. 1" 
41. 0±2. 5° 
54.3±4.7 
22.5±1. 8 
25. 9±4. 2 
23.0±3.3 
Results for Emax's are expressed as mean ± s.e. and for EC-so Ranges as 
geometric means with- 95~ confidence Units; with the number per group in 
parenthesis. The significance of difference from the control values is 
indicated by A pC 05 and from the untreated diabetic values by D pC 05; 
when IH is myo-inositol & ARI is an aldose reductase inhibitor 
("ponalrestat") . 
( 161 ) 
GRAPH 25 
Dose-response curves of rat vas deferens to !oradrena)ine from 6-months, 
STZ diabetic, control, diabetic treated with an aldose reductase 
inhibitor (ponalrestat), and diabetic treated with myo-inositol. Bach 
point represents an average of at least six observations and vertical 
lines denote SEll, when A <p<0.05) indicates a significant difference 
from the control values, and D <p<0.05) and F <p<O.Ol) indicate a 
significan~ difference from the untreated diabetic values. 
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GRAPH 26 
Dose-response curves of rat vas deferens to ioradrenaline from 1 year 
STZ diabetic, control, and diabetic treated with an aldose reductase 
inhi bi tor <ponalrestat). Each point represents an average of at least 
six observations and vertical lines denote SEX. 
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4 mDIIDI-fCTUSSIlTX ATPase & TRUODOTHYROlrIlfE M~AY 
In the Na+-K+ oubain-sensitive ATPase and triiodothyronine assay in the rat 
diaphragm the blood glucose and body weight data confirming diabetes are 
given in table 17. 
Levels of triiodothyronine were measured (table 17) and found to be 
significantly reduced in the diabetic group and the diabetic treated with 
an aldose reductase inhi bi tor group (both were pC 01). Levels of the 
hormone were however restored in diabetic rats treated with 
triiodothyronine (p<.05). 
SodiUR"potassium ATPase levels were significantly reduced in the diabetic 
group conpared to the control group values (p<.Ol). The enzyme levels were 
restored in the diabetic treated with an aldose reductase inhibitor group, 
but whilst higher than the diabetic group the levels were not restored to 
the control values. In the diabetic treated with triiodothyronine group the 
enzyme levels were significantly higher (p<.05) than the untreated diabetic 
group values. 
TABLE J7 
CONFIRMATION OF DIABETES & T"", LEVELS 
(3 WEEKS ANIMALS 
Blood Glucose Change in Body T" Levels 
Level (nJ{) Weight (g's) I'gll 
COnROL (12) 4.79±3.72 +41. 67±7 . 65 2.68±0.26 
DIABETIC (8) 25. 93±1. 939 -5. 33±6. 72" 0.64±0.349 
DIABETIC + ARI (7) 25.34±2.71B -0.33±8.38B 0.35±0.13E> 
DIABETIC + T", (9) 26. 69±1. 2'7'" +4.67±12.99B 1. 94±0. 74 D 
Results are expressed as mean ± s.e. with the number per group in 
parenthesiS. The significance of difference from the mean control values is 
indicated by B p<. 01 and fronl 1:he untreated diabetic vallles by D 
p<.05; when XI is myo-inositol, ARI is an aldose reductase 
lnhibitor (ponltlrestat) and T" is triiodothyronine. 
( 164 ) 
GRAPH 27 
Levels of ouabain-sensitive sodiuDrpotassium ATPase in the rat diaphragm 
of 6-weeks STZ diabetic, control, diabetic treated with an aldose 
reductase inhibitor <ponalrestat) , and diabetic treated with 
triiodothyronine T3). Each bar represents the average of at least seven 
observations, each observation being triplicated, and vertical lines 
denote SEX, .when B <pO.01) indicates significant difference from the 
control values and D <p<O.05) indicate significant difference from the 
diabetic values. 
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In the second sodium-potassi un ATPase and triiodothyronine assay various 
tissues were used, namely the rat heart, superior cervical gangli on and 
sciatic nerve. Diabetes was confirmed in the untreated diabetic group, and 
diabetic treated with an aldose reductase inhibitor and triiodothyronine by 
the significantly elevated blood glucose levels (p<.Ol) and significantly 
reduced body weight gains (p<.Ol) (table 18). 
Triiodothyronine levels (table 18) were found to be significantly reduced 
in the untreated diabetic group (p<.Ol) and in the diabetic treated with an 
aldose reductase inhibitor (p<.Ol). The levels of this hormone were 
restored in the diabetic rats treated with triiodothyronine (p<.Ol). 
In the superior cervical ganglion and sciatic nerve insufficient number of 
samples were available to test for significance of difference fron the 
control values (table 19). 
In the superior cervical ganglion mean sodium-potassium ATPase levels for 
the diabetic group was, however, much lower than the control group. In the 
diabetic groups treated with an aldose reductase inhibitor and 
triiodothyronine the mean levels of the enzyme were higher but not restored 
to the control levels. 
In the sciatic nerve the diabetic group mean level of enzyre was higher 
than the cl)ntrol. The rean levels of the diabetic groups treated with an 
aldose reductase inhibitor and triiodothyronine were similiar to the 
control. 
In the heart the sodium-potassium ATPase level of the diabetic group was 
si&nificantly reduced compared to the control values (p<.05). The diabetics 
groups treated with an aldose reductase inhibitor and triiodothyronine 
groups both had significantly lower values than the control (both pC 05) 
whilst the DtARI group had increased levels compared to the diabetic values 
(pC 05) 
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ASSAY OF Na- K- ATpase & T,... LEVEI.S 
IN VARIOUS RAT TISSUES 
TABLE lB 
CONFIRMATION OF PIABETES & T"", LEVELS 
6 WEEKS ANIMALS 
Blood Glucose Change in Body T3 Levels 
Level (nlD Weight (g's) I'gll 
COITROL (6) 6. 9±1. 2 +78.5±3.9 1. 95±0.12 
DIABETIC (6) 22. 6±B. 4'" +l7.6±l1.9'" O.79±0.11'" 
DIABETIC + ARI (7) 23. 2±9. 2'" +l0.1±l3.5'" 0.91±0.07'" 
DIABETIC + T3 (B) 25. 9±B. 4'" +30. 6±12. 4'" 2.26±0.73F 
Results are expressed as mean ± s.e. with the number per group in 
parenthesiS. The significance of difference from the mean control values is 
indicated by B p<.01 and from the untreated diabetic values by F p<.01; 
when KI is myo-inositol, ARI is an aldose reductase inhibitor 
(ponalrestat) and T3 is triiodothyronine. 
TABLE 19 
Na- K- A:I:Pase LRVRI.R 
(pmol/g wet weight) 
Superior Cervical Heart Sciatic Nerve 
Ganglion 
COITROL 219±98 82±9 27±10 
(5) (9) (6) 
DIABETIC 79±22 15±7A 92±53 
(4) (5) (4) 
DIABETIC + ARI 121±37 45±9"D 32±12 
(3) (B) (4) 
DIABETIC + T3 149±68 39±13A 12±5 
• (3) (5) (4) 
Results are expressed as mean ± s.e. with the nUll,ber per group in 
parenthesis. The significance of difference from the control values is 
indicated by A p<. 05 and from the untreated diabet.ic values by D p<. 05; 
when ARI is an aldose reductase inhibitor ('ponalrestat') and T3 is 
triiodothyronine. 
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.5 OESOPHAGUS PREPARATION 
In the oesophagus preparation diabetes was confirmed (table 20) by the 
significantly elevated blood glucose levels (p<.01) of the diabetic and D + 
KI groups and reduced body weight gain (p<.01) of the diabetic group in the 
6-weeks animals. In the 6 month, and 1 year animals diabetes was confirmed 
by the significantly elevated blood glucose (p<.01) and reduced body weight 
gain (p<.01) of the diabetic and treated animals. 
TABLE 20 
CONFIRMATION OF DIABETES 
COJI'TROL (6) 
DIABETIC (7) 
DIABETIC+XI (6) 
Blood Glucose 
Level (DIn 
Change in Body 
Weight (g's) 
6 WEEKS: CONTROL, DIABETIC & XI TREATED. 
4. 34±0.75 +63.9±9.3 
28. 36±2.34'" -27. 2±8. 9'" 
19. 91±1.53"'E +17.0±7.6G 
6 JIONTHS AJrIIlALS: CONTROL, DIABETIC & ARI & KI TREATED 
COll'TROL (6) 7. 32±1.33 +177±14.5 
DIABETIC (6) 40. 60±1. 08'" -34.80±9.10'" 
DIABETIC + XI (6) 29. 93±4. 19BO +39. 80±17. 90BG 
DIABETIC + ARI (6) 38. 53±2.90" +3.20±13.70Bd 
1 YEAR AKIKALS: CONTROL, DIABETIC & ARI TREATED 
COJI'TROL (12 ) 8. 17±1.B7 +174. 22±25. 60 
DIABETIC (7) 38. 66±2.44B t32.67±11.93B 
DIABETIC + ARI (B) 27. 25±3. 12aE t33. 88±17. 03B 
Results are expressed as mean t/- s.e. with number per group in 
perenthesis. The significance of difference from the control group 
values are indicated by B p<O.Ol and from the untreated diabetic values by 
D p<.05, E p<.02 & G p<.005; where KI is myo-inositol, and ARI is 
an aldose reductase inhibitor (Hponalrestat"). 
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In the 6 weeks animals (table 21) sensitivity to acetylcholine was 
unchanged, whilst the Emax for the D + XI group was significantly lower 
(p<.Ol vs diabetic). 
In the 6 DDnths animals only sensitivity to acetylcholine in the D + XI 
group was significantly different ( p<.05 vs diabetic). The Emax's for 
the D + IH and D + ARI groups were significantly lower (pC 05 vs 
diabetic) . 
In the 1 year animals sensitivity to acetylcholine was unchanged, only 
the D + ARI group Emax was significantly lower (p<.05 vs diabetic). 
COlITROL (7) 
DIABETIC (6) 
DIABETIC + XI (6) 
TABLE 21 
EC-SQ 
Ranges mg/ten 
6 \lEEKS AJUKAlS 
2.5<o.2-3.2} p.X 
7.4(6.3-8.6) p.X 
3.5(3.2-3.9} p.X 
6 J{OlITHS AlUIALS 
COlITROL (6) 0.2(0.1-0.2} "I 
DIABETIC (6) 0.10(0.10-0.15) p.X 
DIABETIC + XI (5) 0.3(0.2-0.6} ,,10 
DIABETIC + ARl (6) 0.1(0.1-0.4} p.X 
COlITROL (12) 
DIABETIC (8) 
DIABETIC + ARl (7) 
1 YEAR AJUIAI S 
0.6(0.5-0.8} "X 
0.5<0.4-0.7) p.X 
0.4<0.3-0.4) p.X 
EDax 
mg wet weight 
31. 7±3. 0 
37.6±4.5 
46.8±4.4F 
132±13 
151±23 
97±18° 
72.5±12.1 
73. 6±8. 0 
45. 3±8. 8° 
Results for Emax's are expressed as nean ± s.e. and for the EC_sQ Ranges 
as geollEtric means wi 1:h 95~ confidence li mits; with the number per 
group in parenthesis. The significance of difference from the 
untreated diabetic values is indicated by D p<. 05 &. F pC 01; when Kl 
is myo-inositol and ARI an aldose reductase inhibitor ("pona1restat"). 
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GRAPH 28 
Dose-response curves of rat oesophageal lIIlscularis DUcosa to 
Acetylchgline fro", 6-weeks STZ diabetic, control, and diabetic treated 
with myo-inositol. Each point represents an average of at least five 
observations and vertical lines denote SEX, when D <p<O.05) and F 
<p<O.01> indicate a significant difference froD the untreated diabetic 
values. 
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GRAPH 29 
Dose-response curves of rat oesophageal DUscularis mucosa to 
Acetylcholine froD 6-DOnths STZ diabetic, control, diabetic treated with 
an aldose reductase inhibitor <ponalrestat), and diabetic treated with 
myo-inositol. Each point represents an average of at least five 
observations and vertical lines denote SEX. 
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GRAPH 30 
Dose-response curves of rat oesophageal DIIscularis DlI=sa to 
Acetl'lcbal ine froll 1 year STZ diabetic, control, and diabetic treated 
with an aldose reductase inhibitor <ponalrestat). Each point represents 
an average of at least seven observations and vertical lines denote 
SEI, when A <p<0.05) indicates a significant difference from the control 
values, and D <p<0.05) indicates a significant difference from the 
untreated diabetic values. 
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Lxim~D1 furce of contraction to field stiDlulation in 6-weeks aninals was 
unchanged in both the presence and absence of atropine (table 22). 
There was DO change in the maximum force of contraction in 6-months 
ani:mals in the absence of at.ropine. 
TABLE 22 
MAXIMUM FORCE OF CONTRACTION 
DUE TO FIELD STIMULATION 
(mg t.enslonf mg wet weight) 
6 WEEKS AIUX61,S 
WITH ATROPINE WITHOUT ATROPINE 
CONTROL (7) 62.3±16.8 70.2±11.0 
DIABETIC (6) 77.5±19.4 132.5±35.7 
DIABETIC + XI (6) 53.0UO.3 GG.3±12.6 
6 XONTHS AIrIXAI.S 
WITHOUT ATROPINE 
CONTROL (6) 42.4±10.4 
DIABETIC (6) 32.5±6.9 
DIABETIC + XI (5) 33.1±5.0 
DIABETIC + ARI (6) 38.3±9.8 
Results are expressed as nean±s.e.j when XI is myo-inositol and ARI is 
an aldose reductase inhibitor, 'ponalrestat'. 
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.6 LO'NGIIQDINAI. JlUSCLE PREPARATIO][ 
In the 6-mDDth diabetic longitudinal DUscle preparation (table 23) 
diabetes was confirmed by the significantly elevated blood glucose 
levels (p<.Ol) and reduced body weight gain (p(.Ol). 
The EC .. o ranges were unchanged (table 24), whilst the EDax's for the 
diabetic and D + ARI groups were significantly lower (p<.Ol vs control 
values) . 
TABLE 23 
CONFIRMATION OF DIABETES 
6 MONTH ANIMALS 
aJlTROL (6) 
DIABETIC (6) 
DIABETIC + ARI (5) 
Blood Glucose 
Level (mlO 
6. 92±1. gO 
35. 62±6.40" 
36.94±6.70" 
Results are expressed as mean ± s.e. 
in parenthesis. The significance of 
values is indicated by B pC 01; 
reductase inhi bi tor ("ponalrestat"). 
Change in Body 
Weight (g's) 
+l71±28 
-38. 3±12. 6'" 
-20.2±10.3'" 
with the nunber per group 
difference from the control 
when ARI is an aldose 
TABLE 24 
E:rna.x's & EC-== Ra.nges 
EDax 
(JIlcJIi2) 
Ec....so 
,.,.x 
aJIITROL (6 ) 1. 6309±0. 1715 4.7(2.3-9.2) 
DIABETIC (6) 0. 8492±0. 0734'" 12.0(2.4-58.8) 
DIABETJC+ARJ (5) 1. 094%0. 1017'" 9.7(3.0-30.9) 
All results for Emax 
ranges as geo:metric 
The significance of 
indicated by B p<. 01 ; 
"ponalrestHt", and XI is 
are e%pressed as mean ± s.e. and for EC-so 
Deans wi th 95~ confidence Hmi ts. 
difference from the control values is 
when ARI is an aldose reductase inhibitor, 
lIyo-jnositol. 
( 174 ) 
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GRAPH 31 
Dose-response curves of rat terminal ileum longitudinal muscle to 
Acetylcboline from 6-months srz diabetic, control, and diabetic treated 
with an aldose reductase inhibitor <ponalrestat). Each point represents 
an average of at least five observations and vertical lines denote SEX, 
when B (p<O.Ol) indicate a significant difference from the control 
values. 
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·.7 CHOLJKE ACETYI.TRAlfSFERASE ASSAY (CHAT> 
Diabetes in 6-weeks diabetic animals was confirmed (table 25) by the 
elevated blood glucose levels (peOl) and the reduced body weight gain 
(pC 01>. 
TABLE 25 
CONFIRMATION OF DIABETES 
COlITROL (8) 
DIABETIC (10) 
DIABETIC + XI (7) 
DIABETIC + ARI (6) 
Blood Glucose 
Level (mID 
6. 89±1. 05 
26.48±2.21B 
30.51±2.65B 
32.70±2.03B 
Change in Body 
Weight (g's) 
+60. 48±9.56 
-22. 68±11. 7 B 
-33.70±8.90B 
-27. 90±13. 70B 
Results are expressed as Dean +/- s. e. with number per group 
inperenthesis. The significance of difference from the control group 
values are indicated by B p<O.Ol, where XI is nyo-inositol, and ARI is an 
al dose reductase i nhi bi tor (~' ponalrestat" ) . 
There was no significant difference in levels of ClIAT between the control 
group and. the untreated diabetic group. Though mean levels of ClIAT in both 
the XI and ARI treated groups were higher than the control and untreated 
diabetic groups, this mean elevation was not significant. 
The levels of CHAT in control animals was measured in both the brain and the 
ileum and the mean level in the brain was found to be 100X greater than the 
mean level in the ileum. 
TABLE 26 
Levels Of Choline AcetyJtransferaae 
<pM/ g prote~=/ hour) 
COJITllllL 
(8) 
l7.5±4.9 
Rat Brain Tissue (4) 
Rat Ileum Tissue (3) 
RA!. lLE!!ll TI SSUR 
DIABETIC DIABETIC+!U 
(10) (7) 
19. 5±4. 6 37. 4±9. 6 
COJITROL II SS!!E 
1.63±0.14 nXI g protein/ hour 
25.53±8.27 pXI g protein/ hour 
DIABETIC+ARI 
(6) 
36.7±10.2 
Results are expressed as mean ± s.e. with the number per group in 
parenthesis. 
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',8 )fYQ-TllOOITOL, OORBTTOI," FRUCTOSE ASSAY IJ[ RAT SCIAIlC llERYE 
Diabetes was confirmed in 6-weeks diabetic rats (table 27) by the elevated 
blood glucose levels (p<.Ol) and the reduced body weight gain (p<.Ol). 
TABLE 27 
CONFIRMATION OF DIABETES 
Blood Glucose Change in Body 
Level (mX) Weight (g's) 
CONTROL (6) 4. 34±0. 75 +63.9±9.3 
DIABETIC (7) 2B. 36±2. 34s -27.2±B.gs 
DIABETIC + XI (6) 19. 91±l. 53"" +17. 0±7. 6·'" 
DIABETIC + ARI (6) 32. 62±0.86" -19.7±7.7B 
Results are expressed as Dean ± s.e. with the number per group in 
parenthesis. The significance of difference from the control values is 
indicated by B p<.Ol and from the untreated diabetic values by E p<.02 & G 
p<.005; when II is myo-inositol, ARI is an aldose reductase inhibitor 
(ponalrestat) . 
Levels of Dyo-inositol in untreated diabetic sciatic nerve were 
significantly reduced compared to the control values (p<.Ol). In the 
diabetic group treated with XI the level was significantly elevated compared 
to both the control and untreated diabetic group (both p<. 01). Levels of 
myo-inositol were normalized in the ARI treated group and were significantly 
higher than the untreated diabetic group (p<.Ol). 
Levels of sorbitol were significantly increased in the untreated diabetic 
group coupared to the control values (pC 01). The XI treated group had 
elevated levels compared to the control (p<.Ol) and the untreated diabetic 
(p<.05) values. Levels of sorbitol were normalized in the ARI treated group 
and were significantly reduced compared to the untreated group (p<.Ol). 
Levels of fructose were significantly elevated only in the untreated 
diabetic group compared to control values (p<.Ol). In the ARI treated group 
levels were significantly lower than the untreated diabetic group (p<. 01). 
Kean fructose levels in the D + XI group were lower, but not significant. 
( 177 ) 
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GRAPH 32 
Levels of myo-inositol, sorbitol and fructose in the rat sciatic nerve 
of 6-weeks STZ diabetic, control, diabetic treated with an aldose 
reductase inhibitor <ponalrestat), and diabetic treated with myo-
inositol. Each bar represents the average of at least six observations, 
each observation being triplicated, and vertical lines denote SEX, when 
B <pO.Ol) indicates significant difference from the control values and D 
<p<O.05) and F <p<O.Ol) indicate significant difference from the 
diabetic values. 
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CHAPTER FOVR 
4. 1 DISC!!SSIOII 
The purpose of this study >fas to investigate the effects of different 
periods of streptozotocin-induced diabetes in the rat on nervous and 
vascular function using a range of tissues. The main ain was to 
establish whether neuropathy or vascular changes could be detected. Such 
changes night provide more appropriate models of diabetic complications 
than those currently in use. 
Various mechanisms have been proposed, such as sorbitol accunwlation, 
polyol pathway dysfunction, hypothyrOidism, anoxia, blood lipid and 
fibrinogen changes, alterations in eicansoid :metabolism, sympathetic 
neuropathy, ganglioside depletion, 
protein glycosylation and excess 
vitamin C depletion, non-enzymatic 
development of diabetic 
introduction) . 
free 
conplications 
radicals, to explain 
(as described in 
the 
the 
We decided to investigate the effects of dietary suppleuents of nyo-
inositol, an aldose reductase inhibitor (ponalrestat> and 
triiodothyronine to assess whether the proposed mechanisms, excess 
polyol pathway flux and hypothyrOidism, were involved in any diabetes 
induced changes. 
4,2 AORTA 
Cardiovascular dysfunctions are IWre common among diabetics than the 
general public ('Chrlst:lieb Cl.1973Sb,). These· dysfunctions, such as 
postural hypertension, disturbances in regional blood flow, and changes 
in elasticity of blood vessels, may be caused by changes in sensitivity 
to neurotransnitters in blood vessels (Chriestlieb et aI, 1976; Weidmann 
( 180 ) 
et aI, 1979), 
ltany workers have tested this hypothesis by using various vascular 
preparations from rats with induced diabetes (Brody & Dixon, 1964; Foy & 
Lucas, 1976; Owen & Carrier, 1980; Cav41iere et aI, 1980; Turlapaty et 
aI, 1980; PfaffDan et aI, 1982; Jackson & Carrier, 1981; Hac:Leod & 
Ilclfeill 1985). The aorta is a very reliable preparation as a oodel for 
measuring vascular responses in experimental diabetes, but it is not 
known how relevant these changes are to diabetic dysfunction. An 
advantage of the preparation is that it is larger that other arteries 
and is therefore easier to handle. It is usually prepared as helical 
strips or rings, though helical preparations usually damage the 
endothelium cells; in this particular study aortic rings were used. 
The present study indicates little or no evidence for vascular changes 
in the streptozotocin-induced diabetic rat aorta. 
In the six-weeks diabetic rat study, the untreated diabetic rubbed aorta 
was desensitised to 5-hydroxytryptamine (5-HT> compared to the control 
(pC 01>. Treatment with ponalrestat and myo-inositol Oil) 
supplementation failed to rectify this abnornality; both of these groups 
remained desensitised (pC 01>. In the unrubbed aorta only the diabetic 
treated with III was desensitised (p<'05)' Sensitivity to noradrenaline 
(HA) was unchanged in both rubbed and unrubbed aorta. 
The variable duration of induced diabetes used by workers to represent 
the short-terD state Bakes cODparisons between studies difficult. 
Workers found no change in sensitivity to a range of agonists, such as 
][A, 5-HT and KC1, in rats with 7 days induced diabetes; for both 
streptozotocin and alloxan induced animals (HacLeod & JlcBeill 1985"; 
Turlapty et aI, 1980). This short period of diabetes doesn't offer a 
valid comparison with the aninals used in our study. Our data on changes 
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in sensitivity agreed with studies which found a reduction in 
sensitivity in 8-weeks alloxan induced diabetic rats (l'urlapty et aI, 
1980; Pfaffman et aI, 1982). Studies by these workers on 12-weeks 
alloxan induced diabetic rats showed similiar reductions in 
sensitivity. 
In the 6-DOnths diabetic rat rubbed aorta sensitivity to BA was 
increased; this contradicted a study which showed no change in 6-months 
animals (Kac Leod '" Xclleill, 1985). In 3-JI<)nths diabetic aniJDals they did 
however find an increase in sensitivity to IIA with no alteration in the 
EDax's. Treatment of diabetic rats with IH produced no change in the 
al tered sensi ti vi ty to BA, though it did lower the JDaXi_l response 
<p<.Ol vs diabetic). Treatnent with ponalrestat significantly decreased 
sensitivity to BA <p<.05 vs diabetic). The maximal response was 
significantly lowered ( p<.Ol vs diabetic), though it did not return to 
the control value <p<.05). 
We did not detect a decrease in responsiveness to 5-HT as these workers 
did, but increases in maximal response did agree with this study. The 
maximal response of the untreated diabetic was increased <p<.05), whilst 
treatnent with XI considerably reduced the maximal response (pC 05 vs 
control '" p<.01 vs control) and ponalrestat treatment did not restore 
this response <p<.01 vs control). 
Sensitivity to 5-HT in the presence of desipramine, a patent HA Uptake, 
blocker, was unchanged in the diabetic and KI treated animals. Xaximal 
responses in the diabetic rat were increased <p<.01), and treatment with 
IH considerably lowered these responses <pC 01 vs diabetic '" pC 01 vs 
control). We were unable to obtain any responses in diabetic aniuals 
treated with ponalrestat. It may be that ponalrestat was having an 
adverse effect; however further work was not carried out to verify this. 
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The increased Emax values for both JlA and 5-lfT in the 6 DDnth study 
suggest a post-receptor change. The partial prevention by ARI/XI 
indicates an involvement of a polyol pathway dependent HI depletion. A 
measurellllmt of sorbitol and Xl in aortic slllCloth Dllscle might provide 
evidence to support this. A role for the polyol pathway in diabetes 
induced changes in smooth muscle, as well as in nervous tissues, would 
be of considerale interest. Diabetes induced changes in autonomic 
control of a tissue tend to be ascribed to nervous changes, they could 
equally be due to effector tissue changes. It has been pointed out that 
decreased responses in the ileum of streptozotocin-induced diabetic rats 
to acetylcholine could contribute to lack of proper gut DRJscle tone 
(Lucas & Sardar, 1991). 
In the 1 year animals sensi ti vi ty to lrA in the diabetic state was 
decreased whilst the maximal response was unchanged. This finding 
disagreed with earlier studies which showed supersensitivity to KA in 
the 1 year diabetic rat aorta (XocLeod a KcKeill, 1985); and to HA in the 
42-43 weeks diabetic mesenteric arteries (Jackson & Carrier, 1981). Ve 
did not find an increase in sensitivity to 5-lfT as other workers did 
ObcLeod & KcHeiU, 198'5) 
The diabetic treated ",i th ponalrestat was found 
to be supersensitive to JlA with an unchanged nlaximal response. This 
indicated that decreased sensitivity was ameliorated by this treatment 
and that the polyol pathway was involved in decreasing sensitivity to HA 
in the 1 year animals. 
Responses to 5-8T were unchanged in the diabetic and ponalrestat 
treated animals, this contrasted with a study which found 1 year 
streptozotocin diabetic rats supersensitive to 5-8T (1!iI<Leod & I!cKeill, 
1985) • The diabetic response to 5-81', with desipramine, was conpletely 
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absent. whereas it was present in the ponalrestat treated animals. 
The contradiction between our results of the 1 year induced diabetic 
animals with the previous studies could be due to differences in the 
severity of the induced diabetes, a common problem in this field. It may 
be related to the sex of the animals used, our study used male rats 
whereas !bLeod and J!cHeill used fe_le rats. 
Our results show little evidence to suggest aenervation is occurring in 
the diabetic rat aorta. Changes in sensitivity. to 5-HT in the 6 weeks 
animals and to HA in 6 months and 1 year animals, are probably due to 
SDOoth muscle changes. The degree and consistancy of changes occurring 
in the rat aorta is difficult to assess. 
Workers found increased maximal responses to lA and KCI in the 1 year 
rat only when they assumed a proportionate decrease in all the 
components of the diabetic aorta and calculated results by dividing the 
tension developed by the cross-sectional area <Kcl.eod & J!cJreill 1985">. 
It could be that the difference in results between the two studies was 
due to inconsistant smooth muscle changes occurring in the diabetic rat 
aorta. 
It would appear from our study that the polyol pathway is not implicated 
directly in any changes occurring in the rat aorta in the early stages. 
It however. does play a role in the 1 year rat where ponalrestat was 
responsible for reversing diabetic-induced changes. 
In the 6 weeks animals decreased sensitivity to 5-HT was not ameliorated 
by treatment with either XI or ponalrestat. In the 6 lIJOnth ani_Is 
sensitivity to HA was increased and treatment with XI had no effect on 
this change. Ponalrestat treatment was effective in restoring 
sensitivity, but sensitivity was still higher in these animals compared 
to the controls. 
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DecreaS<'d sensitivity to HAD in 1 year anim"ls was r-eversed by treatment 
with ponalrestat pro<lucing ECso values of tbe same magnitude as those 
for the 6 month animals. Ponalrestat may have bad a sensitizing p.ffect 
on the tissue, suggesting a mechanism not dependent on aldose reductase 
i nU biti on, in which case furU,er i nvestigaU on of a control + 
ponalrestat group would be beneficial. 
The absence of responses to 5-HT with desipramine in tbe 1 year diabetic 
group may suggest total desensitisation, and tbe normal responses in 
the ponalrestat treated animals could indicate reversal of this 
desensitisation. However tbere was no difference in responses to 5-3T, 
without deSipramine, in the diabetic state. It is worth noting though 
that 5-HT acts both directly on the aortic smooth muscle and indirectly 
via the release of catecholamines, the latter being prevented by 
desipramine. It seems that the direct effects were impaired in the 
diabetic treated animals but not in the ponalrestat treated animals. 
A decrease in sensitivity to lA in control groups gOing from 6 months 
to 1 year animals, whereas tbere was no cbange to 5-HT. This concurs 
wi th other stud_ies which found a nonspecific loss in the responsiveness 
of aortae to agonists with increasing age (Cohen &. Berkowitz, 1976; 
JIod.eod & XcHeiIl 1985); tbe DechaniSllS for these changes have not been 
elucidated. 
The changes in the rat aorta to external agoni sts are not progr-essi ve 
and postulating any mechanism is difficult. It may be that specific 
changes are occurring in the receptors for tbese agonists, or in the 
coupling of these receptors to the mohilisaUon of calcium ions. But 
these changes are not ~rmanent as tbey vary between the different 
durations of diabetes investigated. 
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In conclusion it would seem that vascular changes were seen but they 
didn't follow a clear progressive pattern. They don't appear to offer 
suitable models of diabetic neuropathy or vasculopathy. 
4.3 THE AIIDCOCCYGEUS KllSCLE 
As described in the introduction, autonomdc neuropathy frequently occurs 
in hUDan diabetes (Clarke et aI, 1979; Harati et aI, 1987). The severity 
and degree of neuropathy depends on several factors, OIle of which is the 
duration of diabetes (JereDY et aI, 1986). Loss of autonomdc function 
has been reported in sciatic nerves from long-terD diabetic rats 
CTomlinson ... Yusof, 1983; Yagihashi & 8ioo, 1985; Schmidt & Plurad, 
1986). Alterations in nervous tissue responses to agonists and field 
stimulation have been reported in short term diabetic studies. (Brody & 
Dixon, 1964; JoIa<Leod & XcNeill 1985; 8carborough & Carrier, 1984; Chang 
et aI, 1986; Nowak et aI, 1986). 
Profound changes occur in tissue eXhibiting sympathetic denervation, 
such as reduced responses to nervous stimulation and increased 
sensitivity to agonists, such as noradrenaline, either of these would be 
ind.icati ve of neuropathy (Scar borough & Carrier, 1984; ;JO.cKSOi\ g,. ~rrierr~&I) 
. _~ _ ,--.", Increased sensiti vi ty 
to HA in neuropathic tissue would JOClst likely be due to a combination 
of receptor up regulation, i.e. increased receptor number, and reduced 
HA uptake by neurones (Brody & Dixon, 1964; Foy & Lucas, 1976; XaCLeod & 
Kdrei11 1985; Chang et aI, 1986; Nowak et aI, 1986). 
Several mechanisms have been proposed to explain the neuropathy 
prevalent in the diabe~ic state; we decided to investigate the 
involvement of two, the polynl pathway and hypothyroidism in diabetes 
induced changes. Ve examined the effects of different periods of 
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diabetes on tissue responses to electrical stimUlation and to exogenous 
HA and the overflow and stimulated release sH-HA. 
The tissues were considered suitable for a study of sympathetic 
innervation since they have a dense adrenergic innervation distributed 
throughout the lIUscle but apparently no cholinergic innervation, also 
the tissues exist as a pair and this offers certain advantages in some 
studies. 
Sensi ti vi ty was de.creased to HA and Emax values were increased in the 6 
weeks untreated ·diabetic rats Whilst the maxilIl.lm force of contraction 
due to field stimulation was unchanged. However we were unable to show 
this defect when the experiment was repeated three tiDeS with HA and 
other agonists, phenylephrine and clonidine. Sensitivity to HA was 
increased in 6 IIDnths diabetic animals and treatment with XI and 
ponalrestat significantly desensitised the tissue but did not normalize 
it. 
In the 1 year animals there was a mean decrease in sensitive to HA and 
phenylephrine from control to diabetic and ponalrestat treated 
diabetics, hut this was not significant. 
Failure to replicate the decrease in sensitive to HA in 6 weeks diabetic 
rats, even though this experiment was repeated three times, suggests the 
initial result was an abberation. Also there was no difference in the 
force of maximum contraction to field stimulation between control and 
diabetic animals. Any changes in the force of contraction are likely to 
refl .. ct smooth muscle changes; changes in neuropatLy should have a 
greater impact on sensitivity, in that it should have been increased. 
The increase in sensi ti vi ty to HA in 6 months diabetic rats may 
• 
indicate the presence of neuropathy, however treatment with KI and 
ponalrestat failed to normalise this defect. Also the failure to 
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detect neuropathy, Le. increased sensitivity to HA, in 1 year animals 
indicates this effect is not progressive and is self-correcting. The 
mean decrease in sensitivity in 1 year animals Day have been due to a 
reduction in receptor population. studies have shown a reduced 
sensitivity to agonists following prolonged exposure and implicitly 
linked this to reduced receptor nUDlbers (Vadlamundi & Xclleill, 1983; 
Kofo-AbeyoDli 11 Lucas, 1988), and tbis =y have been responsible for the 
observed reduction in sensitivity to HA in 1 year diabetic rats. If 
so, then this is the opposite change to that expected to follow 
neuropathy. 
Diabetes could have been responsible for the reduction in sensitivity to 
HA by increasing tissue exposure to HA It bas been proposed that 
excess flux through the polyol pathway, leading to a=ulRUlation of 
sorbitol within neurones, =y cause a reduction in lla-K- ATPase 
activity, and this defect is responsible for subsequent cell damage 
(Greene et aI, 1983; Greene, 1986). A depression of H,,-K- ATPase 
activity in sY1llPathetic nerve endings might be expected to affect Ha-
gradient dependent transport, such as Uptake, responsible for the uptake 
of HA back into neurones. Such an effect might contribute to increased 
NA turnover, which has been found in various tissue of short-term (6 
___ eks) diabetic rats (Lucas 11 Qirbl, 1989; Ganguly et. aI, 1987). The 
prolonged presence of extraneuronal HA would be likely to lead to 
desensitization. 
Alternatively reduced sensitivity to HA, may be due to a depression of 
post-receptor mechanisms, such as reduced secondary messengers, ego 
pllOsphoinositides. It has peen proposed that diabetes is responsible for 
a reduction in phospboinosi tj des by causing a decrease in levels of myo-
inositol, an essential substrate for tbe synthesis of 
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phosphotidylinositol. Studi.,s have shown a reduction in the levels of 
phosphatidylinositol (PI>, phosphRtidylinositol 4-phosphate (PIP) , 
phosphatldylinositol 4,5-bisphosphate (PIP"" as well as reduced activity 
of CDP-diacylglycerol and PIP kinase in the nerves of diabetic rats 
:'; (Dyck et aI, 1980; Tomlinson et aI, 1984>' Reduced 
myo-inositol levels leading to decreased turnover of phosphoinositides 
would produce a decrease in cell sensitivity to agonists, and this n~y 
be responsible for the mean reducti on in sensitivity to !lA in 1 year 
diabetic rats. A longer period of diabetes, such as 18 lIIOnths, may 
establish whether the observed mean difference was significant or not. 
Whether this defect is mirrored in humans is not clearly established. 
Werve tissue myo-inositol content is reduced by 20-301; in diabetic 
patients (Hale et aI, 1987), but a recent study found increased membrane 
concentration of total phospholipids in the platelets of diabetic 
patients (Xazzanti et aI, 1990). Studies have found reduced nerve myo-
inositol in conjunction with unchanged plasma myo-inositol levels in 
dIabetic rats .. ' :". (Dyck et aI, 1980; Tomlinson et aI, 
1984). It may be that plasma levels of myo-inositol are elevated by 
diabetes since tissue levels are reduced and less myo-inositol is being 
taken up. In which case reduced neuronal phospholipids could coexist 
with increased platelet nembrane phospholipids. 
The data collected from 6 months animals suggests that naybe a 
significant change is occurring at this stage of diabetes. But the 
disappellrance of these changes in 1 year diabetic anilR111s implies that 
this change is not progressive and therefore its relevence to human 
diabetic neuropathy, which shows a consistant increase with the 
duration of the disease, is uncertain. 
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'\le found that Emax' s for untreated diabetic aIlinals were conslstantly 
higher than the control values, in SOD'" cases significantly so. t.his 
data suggested that changes in the effector component of the responses 
was occurring in diabetic anillals. Structural al terations in diabetic 
animals are well documented (Schmldt et aI, 19$1 and it could be that 
there are smooth muscle changes occurring in diabetes. It maybe that the 
diabetic animals preparations were closer to the optimum tension than 
tIle control animals. Since diabetic tissues are smallE'T, it maybe that 
subjecting them to the same total tension would have resulted in greater 
resting force/unit cross sectional area. Considering this we varied the 
tension used, so that responses at the optinrum tension were recorded. 
However EC-so values for the diabetic animals were unChanged and EDBX'S 
at variable tension remained high, though not significantly so, compared 
to the control values. The lack of significance suggests that the 
differences previously observed were due to the diabetic tissues being 
close to their optimum tension. 
The results of a previous study of NA overflow and stimul ated release 
into sympathetic neurones of anocDCcygeus muscles and Its inhibition by 
various blockers (Doggerell & Voodruff, 1978) found the ECso of 
desipramlne to be about 10nM and suggested that 0.2 fiX desipramlne 
should produce near complete inhibition of Uptale,. The flnding lD the 
present study of a reduction in the ahility of this cClDcentration of 
desipramine to potentiate "'H overflow in the t,ssues from the untreated 
diabetic group $uggests an impalrment of this tran'3port. The 
potentiation by transmural nerve stimulatl on of "'H-HA overflow in the 
cont.rol tissues but not those from tLe untreated diabetic group supports 
• 
this conclusion. 
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Uptake, is dependent on the &a+ gradient produced by Ha-K- Al~ase 
activity (lversen, 1974). Amino acid uptake by cells is also dependent 
on a lfa+ gradient maintained by Ha+K+ ATPase activity (Schultz et aI, 
1966). This process has been found to be depressed in diabetic 
peripheral nerve, an effect which is prevented by aldose reductase 
inhi bi tion or myo-inosi tol supplements .". (Greene & 
Lattiner, 1985) both of which have been ·found to prevent diabetes 
induced decreases in lla+K+ ATPase activity. 
Decreases in the latter could, therefore, underlie the apparent 
depression of Uptake, observed in this study. Impaired uptake, would 
also be present if sympathetic nerve numbers were reduced in neuropathy. 
however, this is not consistent with the similar basal uptake of HA in 
diabetic compared to control tissues; also it is not consistent with 
unChanged responses to HA in 6 weeks ponalrestat treated diabetic rats. 
The effect of an aldose reductase inhibitor could be due to its 
prevention of Jfa+K+ ATPase activity depression. 
The hypothyroidism hypothesis mayJ'b .. important since T", treatment also 
produced a significant increase in stimulated "'H-HA release When the 
experiment Was repeated with an extra T", treated group. Ve have 
demonstrated that T", treatment is effective in elevating Ha+K+ ATPase 
activity in skeletal nRlscle in 6 weeks diabetic rats. Therefore, the 
potentiatiou by hypothyroidism of noradrenaline turnover could be due to 
decreased Uptake, caused by reduced Ha+K+ ATPase activity. The 
effectiveness of T", in increasing stimulated "H-HAD release could be 
that it is normalizing Na+K+ ATPase activity and so restoring Uptake,. 
The gradients of the regression lines, see appendix, were similar for 
each of the three groups of tissues. This nay mean that basal "'!I-HA 
turnover rates were not altered by diabetes or by the administration of 
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an aldose reductase inhibitor. The gradient nay have been affected by 
the presence of deSipramine at 2br and by the presence of both 
desipramine and yohimbine at 2.5hr. However blockade of Uptake, or of 
presynaptic u'" receptors per se is unlikely to have affected basal 3H 
release to any great extent since most of the latter probably 
represented "'R-HA metaboli tes rather than intact "'H-lfAD. Marshall (1983) 
found only about '1'1. of basal "H release from nouse vas deferens to 
represent intact 3H-lfA. In contrast, during stimulation a figure of 35'1. 
was obtained. Langer (19'10) reported 50'1. of "'H released from stinulated 
rat vas deferens being in the form of "'H-IfA while Farnebo (19'{1) 
reported a figure of 80-907. using stimulated rat irises. Consequently 
any impairment of Uptake" although unlikely to affect basal "'If release 
from isolated tissues loaded with "'H-lfA, is likely to increase ]I·A 
turnover during stimulation e.g. by normal sylllpathetic activity in 
vivo. A polyol pathway dependent depression of Uptake, may, therefore, 
explain, at least in part, the increased in-vivo noradrenaline turnover 
in diabetic rats and its prevention by aldose reductase inhibition which 
were observed recently in our laboratory (Lucas & Qirbi, 1989). 
Alpha", adrenorecptor 1Jlediated contractions of isolated rat aorta have 
been reported to be enhanced by diabetes (Scarhorough & Carrier, 1984) 
while u'" receptor numbers all platelets from human diabetics have heen 
reported to be decreased (Abraham et aI, 1986). Noradrenaline, released 
by nerv~ stinulation is believed to inhibit further noradrenaline 
release yia CX';2 receptors located OD. thE~: sympathetic nerve terminals 
(Langer, 1981; Karshall, 19133). The present study found the potentiation 
by U2 blockade with yohimbine of 3H-NA release to be very similar in the 
three groups of tisues initially stUdied. In the repeat experiment, 
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whilst~he sol" effect of d"5ipramine W-dS . confirmed. the mean stimulated 
release of 3H-HA in presence of both desipramine and yohimbine was lower 
in the diabetic group and not so low in the ARI and T3 treated groups; 
however these differences were not significant. The concentration of 
yohimbine used (lO-GM), it has an ECso of less than 10- 7 , is likely 
to result in almost complete blockade of Cl" receptors. It seelll6 that Cl", 
mediated inhibition of 3H-HA release by the sympathetic neurones of this 
ti6Sue is unchanged by diabetes, and by ARI or Ta adninistration in the 
present study. 
The implication of Na··K- ATPase activity in both changes in sensitivity 
to HA and overflow and stillulated release of "H-HA strongly suggests 
that its activity should be measured in neurones. However, though highly 
desirable, this was not practical since neuronal Ha-[-ATPase acti vi ty 
would be swamped by activity in smooth muscle because of the relative 
anounts of each tissue type in he anococcygeus. Instead we chose to 
initially evaluate Ha-K- ATPase activity in other tissues, the 
diaphragm. and then in the superior cervical ganglion, the heart and the 
sciatic nerve. The results are discussed elsewhere. 
It would appear that any anococcygeus muscle changes occurring in the 6 
months diabetic rats are not Daintained, since thay are not evident in 
the 1 year diabetic aninals. The role of the polyol pathw-dy and T", is 
not significant in this tissue as treatment with MI, ponalrestat and T3 
failed to reverse the changes occurring in the 6 weeks study. 
There is no evidence of neuropathy occurring in this tissue after 6 
weeks, {) months and 1 year of experinelltal diabetes. Further work on 3H-
HA uptake and release in 6 months diabetic rats by a colleague failed to 
find any changes. Any in the rat anococcygeus 
appear to be transient; they do not indicate diabetic neuropathy. 
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IlI.Iscle 
The vas deferentia of stre1ptozotocin-diabetic rats were assessed for 
changes caused by diabetes. Changes in sensitivity to noradrenaline were 
evaluated after two periods of diabetes, 6 months and 1 year. 
In the 6 months diabetic group there was no change in sensitivity to 
noradrenaline, the mean ECso ranges were increased but not significantly 
so. This concurred with previous studies (Tomiinson & Yousuf, 1983) 
which found no chang .. s in responses to sensitivity to noradrenaline and 
noradrenergic nerve stimulation in vas deferentia from 7-8 months 
alloxan-induced diabetic rats. Similarly vas deferentia from 5-5¥.! months 
genetically diabetic mice showed no change in sensitivity to 
noradrenaline and nerve stinulation wh .. n compared to age-matched 
controls (W11son et aI, 1982). The Emax's for the 6 months diabetic 
group were increased (p<.05) and myo-inositol was effective in 
nor:malizing them. There appears to be no obvious mechaniGm to explain 
why this normalization occurred. Host likely the diabetic vas deferens 
was, like the anococcygeous muscle, closer to the optimum tension than 
the control animals, however further experiments were not carried to 
validate this contention. 
In the 1 year diabetic ani:mls there was no Change in s .. nsitivity to 
noradrenaline, and Enax's for all thr .. e groups were unchanged. 
It would appear there is no evidence to suggest any neuropathy is 
occurring in the rat vas def .. rens. Any cbang .. s, i.e. increased Emax for 
the 6 lIlonth diabetic group, are transient smooth muscle changes which 
are not present in the 1 y",ar animals. This suggests that adrenergic 
denervation is Ilot occurring in this -tissue, even after 1 y .. ar, and it 
would not appear, therefore, to be a valid experimental mod .. l of 
diabetic neuropathy. 
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4.5 PARASYl!PATHETIC SYB'fEK 
Dysfunction of the au"tonondc nervous system in human diabetes leads to 
changes in the gastrointestinal tract. These alterations manifest 
themselves by reduced peristalasis and dilation of the oesophagus, 
delayed gastric emptying, disordered small intestine movement, clonic 
atony and delayed small intestinal transit (Clarke et aI, 19'79;" 1Ielson 
et al. 1976; Schnidt et al. 1981; Scott & Ellis. 1980j Schnddt & Plurad, 
1986; Schmidt & Scharp, 1982; Schmidt et al. 1983). Specific studies 
have shown adrenergic and cholinergic denervation of the colon (Schmidt 
et aI, 1981>. degenerative changes in VIPergic nerVes in the ileum of 
the experimental diabetic rat (Loesch et aI, 1986), together with 
reduced responses to cholinergic nerve stimulation in rat terninal ileum 
longitudinal nuscle. 
We attempted to evaluate these cholinergic changes in two innervated 
snooth muscle preparations, the terminal ileum longitudinal muscle and 
the oesophageal musclaris mucosa. Since the sorbitol/polyol pathway has 
been implicated in diabetic neuropathy, as outlined above, we studied 
the effects of short (6 weeks) and medium term (6 D~nths) and long term 
(1 year) diabetes, in the case of the" oesophagus, with or without 
treatment with an aldose reductase inhibitor, ponalrestat. 
Previous stUdies of responses to transmural stimulation have supported 
the contention tha-t diabetes causes a depression of cholinergic nerve 
function (Schruidt et aI, 1981>, though this study did not, however, 
examine responses to exogenous acetylcholine. The pr,.sent study found 
responses to exogenous acetylcholine (ACh) in the terminal ileum 
longitudinal Duscle to be depressed, to at least the same extent as were 
responses to nerve stimulation, in 6 weeks diabetic rats. These results 
were corrobora-ted by the finding of a reduced sensitivity to ACH in 
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6 l!IOnths diabetic rat. These results suggest that stimulated ACH release 
fro:m nerves was not affected, but responses to released ACa may well 
have been reduced by diabetes. 
If degeneration of the cholinergic nervous function was occurring then 
one would expect responses to electrical stillAllation of cholinergic 
nerves to be depressed to a greater extent than those to exogenous ACh. 
Sensitivity to the latter is actually likely to be increased by 
compensatory n~chanisms, ego increase in receptor number in response to 
reduced ACh release by cholinergic neUrones. 
Sensitivity should have been increased, rather than decreased. The 
reduction in sensitivity suggests that the depression of responses were 
due to post-synaptic changes rather than to depression of cholinergic 
innervation. Therefore the reduced responses to stimulation of the 
ter:minal ileu:m longitudinal muscle 
model of human diabetic neuropathy. 
is unlikely to be an appropriate 
The post-synaptic changes, depression of smooth muscle responsiveness, 
may be significant; since if they are paralleled in human intestinal 
SlIOoth muscle they would "xplain the reduced tone reported by some 
studies (Clarke et aI, 1979). The mechanism of the reduction in 
responses of the ter:minal ileum longitudinal lIIJscle to ACh is not 
revealed 
agonists 
diabetic 
by the present stUdy. Reduced sensitivity to cholinergic 
has been previously observed in cardiac tissue similarly 
animals (Vadlamundi & McJfeill 1983; Kofo-Abeyomi & Lucas, 
1988). Binding tissues using ~Iuscarinic receptor ligand 3H-quinuclidinyl 
benzilate have revealed reductions in myocardial muscarinic receptor 
numbers in such animals (Kofo--Abeyomi & Lucas, 19B'{; Carrier & 
Aronstram, 198,(). The pattern of changes in atrial cholinergic function 
rmy not be the same as that observed here in the terminal ileum 
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longitudinal muscle, however, since untreated diabetes appeared to 
increase atrial responses to transmural cholinergic stimulation (Kofo-
Abeyoni & Lucas, 1988). 
The terminal ileum from the ponalrestat treated diabetic group produced 
maan responses to both transnllral nerve stimulation and exogenous ACh 
which were significantly greater than those of preparations from the 
untreated diabetic group (Lucas & Sardar, 199.1>. It would appear that 
ponalrestat enhanced responses via its inhibition of sorbitol synthesis. 
The possibility that ponalrestat restored terminal ileum function by a 
_chanism independent of diabetes was investigated by examining the 
effects of ponalrestat in non-diabetic age-matched rats (Lucas & Sardar, 
199:1). No elevation of responses was seen suggesting that ponalrestat 
enhanced responses via its inhibition of sorbitol syntheSis since the 
latter only occurs to excess in diabetic animals. The effect of 
ponalrestat in preventing a depression of responses of terminal ileum 
longi tudinal Dllscle preparations to ACh nay have been temporary 
since, in the six months study, such responses remained depressed and 
although Emax values were slightly higher than in the untreated diabetic 
group this difference was not significant. 
In contrast to the results obtained using the terminal ileum 
longitudinal muscle, responses of the oesophagus muscularis mucoSa 
preparations to transDlJral nerve stiIlulation and to exogenous ACI\ were 
not found to be changed by either diabetes or by an ARI. Variations in 
diabetes induced changes between different parts of the digestive tract 
have been observed preViously (Schm1dt et aI, 1983; Nowak et aI, 1986; 
Lincoln et aI, 1984; Belai et aI, 1991) although the reasons for such 
variations are not clear. 
The failure to denlOnstrate cholinergic neuropathy after the relatively 
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short 30 day period of diabetes is consistant with several previous 
neurochemical and histological studies. Lincoln et al (1984) found the 
activities of the cholinergic nerve marker choline acetyl transferase to 
be increased rather than decreased in the ileum after eight weeks of 
streptozotocin-induced diabetes. Sch:midt et al (1983) observed 
abnormalities in mesenteric axons after six or more lIlonths of 
streptozatocin-induced diabetes in the rat but not after three months. 
Similarly, J(altingly and Fisher (1985) observed axon dwindling in the 
common peroneal nerve after six or twelve months of such diabetes but 
not after four. The observation in this study of continued depression of 
responses to ACf:. after six months and 1 year of streptozotocin:-induced 
diabetes with no evidence of decreased EC-50 values (in fact mean EC-50 
values were in=eased) suggests that cholinergic denervation may not 
occur in these two tissues even after this longer period. They do not 
appear, therefore, to offer appropriate experimental models o:f diabetic 
neuropathy. 
• 
4,6 OUABAIN-SENSITIVE SODIUM-PQTASRIUK ATPase & Ta LEYELS 
The palyol/sorbitol pathway hypothesis proposes that increased :flux 
through the pa-thway leads to reduced motor nerve conduction velocity, 
reduced levels of myo--inositol and a decrease in lIa+K+ ATPase activity 
(Greene et aI, 1985; Greene & Lattimer, 1983). Reduced concentrations of 
ruyo-inos:i. tol lead to restricted metabolic synthesis and turnover of 
phosphoinositides (PI) and reduced catabolites of PI, diacylglycerol and 
inositol-1,4,5-triphosphate, which stiDulate lfa+K+ ATPase and protein 
kinase C activity (Sirumons et aI, 1982; Berridge, 1984; Greene & 
Lattiner, 1986). 
Administration of an aldose reductase inhibitor (ARD or myo-inositol 
prevents myo-inositol depletion, preserves normal lIa+K+ ATPase activity 
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and normalizes nerve conduction velocity in peripheral nerve (Greene & 
Lattiner, 1983; Tomlinson et aI, 1982; Finegold et aI, 1983; Gillon et 
aI, 1983; Tomlinson et ill, 1984; Greene et aI, 19'/5; Jilayer & Tomlinson, 
1983). Correlation between reduced membrane phosphol~pids and 
ATPase activity is however not verified by recent data. Researchers 
found reduced Na-K- ATPase activity concurrent with increased membrane 
phospholipid content and Ca2 - ATPase activity in humans suffering from 
diabetes mellitus (JilazztN:i et aI, 1990). In addition reduced motor nerve 
conduction velocity has been shown to coexist with increased lIa-K-
ATPase activity in galactose fed mice (Calcutt et aI, 1990), 
Phosphoinositide turnover in postsynaptic ganglion cells is activated by 
a range of stimulants, electrical, K- and muscarinic cholinergic or a-
adrenergic agonists, and confirms PI's role as a secondary messenger 
(Nagata et aI, 1973; Bone et aI, 1984; Bone & ltitchell, 1985; HeilbroM 
E., 1985; Nishizuka Y., 1984; Burt & Lartabee, 19'16; Hajerus et aI, 
1985). In diabetes reduced ganglionic XI levels nay hinder synaptic 
transnission by affecting PI-mediated postsynaptic muscarinic signal 
transduction. Reduced .lla-
maintaining the transmembrane 
K- ATPase activity, responsible for 
ion gradient, in diabetic ganglia may 
interfere with neuronal transmission by affecting neuronal 
Na+ K+ repolarization. Therefore, alterations in PI metabolism and 
ATPase activity in autonomic ganglia in diabetes may directly contribute 
to autonomic dysfunction. Also th" transmembrane ion gradient is 
intimately linked to transport eg. amino acids, any reduction in the 
gradient would adversly affect transport of essential conponents and may 
lead to the development of n"uropathy (Calcutt et at, 1988). 
Slowed motor nerve conduction velocity, reduced nerve XI content and 
reduced Na- K- ATPase activity are all normalised by treatment with an 
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ANI or Xl (Greene & Lattimer, 1983; Greene et aI, 1975; Xayer & 
Tomlinson, 1983), but restoration of Jla+ K+ ATPase activity by ANI's 
has not always been found (Lanbourne et aI, 1988). However sciatic 
nerves of genetically diabetic mice do not show a deficit in oubain-
sensitive Na+ K+ ATPase activity, or increased sorbitol and fructose 
content or reduced HI content, even though there is reduced motor nerve 
conduction velocity (\lhiteley & TOD.linson, 1985; Calcutt et aI, 1988; 
Bianchi et aI, 1987l. 
These findings have suggested that the polyol pathwdy is not the central 
mechanism by which diabetes reduces lla+K+ ATPase activity and nerve 
conduction velocity. 
An al ternati ve hypothesis suggests that hypothyroidisn is responsi bie 
for the neuropathy prevalent in diabetes. Diabetic rats are hypothyroid, 
a condition which has been shown to depress Na+ K+ ATPase activity 
(Ganguly et aI, 1987; Norgaard et aI, 198+0. We examined the roles of 
both hypothyroidism and the polyol pathway in skeletal (diaphragm) and 
cardiac muscle, superior cervical ganglion and sciatic nerve. 
We found significantly reduced T3 plasma levels in 6 weeks 
streptozotocin-induced diabetic rats <p<.01). These were corrected by 
T3 administration but not by treatment with ponalrestat. These reduced 
Ta plasma levels concurred with previous studies which showed reduced T3 
levels in 2, 4, and 8 weeks streptozotocin-induced diabetic rdts 
(Akiyama et aI, 1989), and neither 13 or ponalrestat treatment was found 
to affect blood glucose concentrations. 
Ha+K+ ATPase activity was significantly reduced in the diaphragm from 
the untreated diabetic aniD",ls (p<. 01). It was normalized by treatment 
with either T3 or ponalrestat. The same pattern was observed in the 
superior cervical ganglion where reduced Na+K+ ATPase activity in the 
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untreated diabetic animals was corrected by treatment with an ARI or 
1'",. This data agreed with the results of a previous study which found 
that reduced Na+ K<- ATPase activity and KI levels, in the superior 
cervical ganglion from 8 weeks streptozotocin-induced diabetic rats, 
were normalized by the administration of an ARI, sorbinil (Greene & 
XaCkway, 1986). These results suggest that the Na+K+ ATPase depression 
observed in the diaphragm and in the superior cervical ganglion was, at 
least in part, due to hypothyroidism. 
We found depressed Na+K"" ATPase activity in cardiac muscle from 
untreated diabetic rats (p<. 05) which was corrected but not 
normalized by treatment with either ponalrestat or 1'",. Since a-
adrenoreceptor density is reduced in the hypothyroid rat (Limas & Limas, 
1987), a feature of the diabetic state, this may affect PI turnover 
which would lead to a decrease in Na+K+ ATPase activity; as shown in 
our data. However neither ponalrestat or Ta administered singly 
adjusted this dysfunction. It could be that both are partially 
responsible rather than wholly for -the dysfunction occurring in the 
diabetic condition. Mean plasma T3levels of the diabetic treated with 1'3 
group were still lower that the control groups. However, plas:ma 1'3 
levels may not be an appropriate indicator of hypothyroidism in diabetes 
since sensi ti vi ty to 1'", has been reported to be depressed in diabetic 
patients (Bagchi, 1982; Cantanni et aI, 1988). This implies that 
hypothyroidism might, in effect, be more prevalent and more severe in 
the diabetic population than plas:ma 1'", measurements would suggest. 
The effectiveness of ARI treatment has been questioned by a recent study 
which examined Jla+K+ ATPase transport activity in lens from 2 weeks 
streptozotocin-induced diabetic rats and the effect of ARI (sorbinil) 
treatment. They suggested that restoration of lenticular Jla+K~ ATPase 
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activity is not secondary to a normalization of XI levels and may 
provide evidence that the tw~ parameters are not strictly associated in 
diabetic tissues <. Ye,,: et aI, 198'7). A recent study has found further 
evidence by examing XI levels, motor nerve conduction velaci ty and 
Ha+K+ ATPase activity in sciatic nerve from 4 weeks galactose-fed mice 
(Calcutt et aI, 1990). They suggested that exaggerated flux through the 
polyol pathway can cause a Entor nerve conduction velocity deficit that 
is unrelated to either XI levels or Ha+K+ ATPase activity (Calcutt et 
aI, 1990). Previously they had suggested that motor nerve conduction 
nerve velocity was not linked to Ha+K+ ATPase activity. Ganglioside 
treatuent was effective in normalizing reduced lfa+K+ ATPase activity 
whilst failing to restore reduced Dlotor nerve conduction velocity 
(Calcutt et aI, 1988). 
Our data of mean increased, but not significantly so, 
activity in diabetic rat sciatic nerve seemed to support this 
suggestion, but clashed with previous work which found reduced Ha+K+ 
ATPase activity in the diabetic rat sciatic nerve, however, it should be 
noted this was not a valid comparison since there were insufficient 
number of animals in our group for proper statistical analysis ( Greene 
et aI, 1985; Greene & Lattimer, 1983) . Treatment with 
ponalrestat and T", reduced this excess Ha+K+ ATPase activity. 
The existence of HI depletion in the nerves of humans with diabetes 
mellitus is contentious (Hale et aI, 198'/: Dyck et aI, 1988) and its 
significance in experimental animal diabetic neuropathy may not be 
reflected in human neuropathy. 
Ta treatment is effective in normalizing Na+K+ ATPase activity in 
skeletal muscle (diaphragm) and nervous tissue (superior cervical 
ganglion) and may be linked. Iodide ions are actively taken up to 
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synthesize Too and 1'''' it nay be that an initial diabetes-induced 
derangement of Ifa-K- ATPase activity reduces the Na- gradient and thus 
inhibits the uptake of iodide ions. This would lead to reduced T3 and T4 
levels and the resulting hypotbyroid state would reduce a-adrenoceptor 
density (Limas & Limas, 198?) , and may affect phosphatidylinositol 
turnover which would lead to a decrease in lla-K- ATPase activity. Thus a 
self-reinforcing cycle, of reduced lla-K+ ATPase activity leading to 
hypothyroidisn which further reduced lla··K- ATPase acti vi ty, would be 
estabUshed. In which case joint treatment with ponalres·tat and 1'3 would 
be worth investigating, especially ill tile heart which responded 
partially to each treatment. This, however, begs the question as to what 
initially caUSes lla+K+ ATPase activity depression in the diabetic state. 
Only when this is established will it be possible to develop effective 
treatnent. 
It may be deficiencies in the anterograde axonal transport, with a 
reduction in the transport of critical molecules to distal axons, which 
leads to axon shrinkage; this supports the above proposal since Na-K-
ATPase depression has been suggested to be linked to decreased axonal 
transport (Calcutt et aI, 1988; Tomlinson & Xayer, 1984; Hoffman et aI, 
198?). Studies have shown reduced substance P axonal transport in 3 
weeks streptozotocin-inuced diabetic rats (Tonlinson et aI, 1988). Kore 
selective ef.fects on conduction could arise from deficient 
delivery of voltage-sensitive lIa+ channels; because the latter are 
carried by fast anterograde axon transport C"lo/vl(,itSO!\' e E:- a (. (qK&l 
Anything that impairs Na·· channel deU very nay bave a significant effect 
on nerve conduction velocity. 
Inpaired axonal transport could contribute to eventual neuropathy by 
many mechanisms Le. if Doe or more of any nunlber of vital cellular 
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components were not supplied to the axon and nerve endings at a rate 
sufficient to prevent depletion then neuropathy could follow. This may 
be particularly important in neurones with longer axons and could 
explain why neuropathy is often detected in the feet (Xaclrury et aI, 
191)<1). A requirement for long axons for vulnerability to diabetic 
neuropathy could, of course, mean that small laboratory animals, such as 
the rat, may be relatively resistant to such damage. 
It is apparent from the data that the central :mechanism responsible for 
axon dysfunction remains to be elucidated and that XI levels may be less 
significant whilst conversely 
previously realised. 
1'3 levels maybe IIDre significant than 
4. '( CORCI.USIOli 
In all the tissues that we examined, in our attempt to delIDnstrate the 
streptozotocin-induced diabetic rat as a IIDdel for human diabetic 
neuropathy, we were unable to show sustained and conclusive evidence 
that neuropathy had occurred or was occurring. In tissues innervated by 
the cholinergic and tissues innervated by the adrenergic system 
neuropathy was not evident. The tissues used, the anococcygeus IlIUscle, 
the oesophagus, the terminal ileum longitudinal muscle, sciatic nerve, 
vas deferens, superior cervical ganglion, the heart and the diaphragm 
all failed to show distinct evidence of neuropathy. The different 
periods of diabetes used also failed to provoke the neuropathy we were 
searching for. 
The results from the 1 year diabetic rats were particularly 
disappointing, since this length of time represented a considerable 
proportion (about 40%) of the life-expectancy of the rat, and so could 
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be considered, in this respect, equivalent to long-term human diabetes. 
The mortality rate alOOng this group was high and it may be that there 
were rats in this group that were vulnerable to nervous/vascular damage 
by diabetes but that these were among those rats that died before 
testing. 
Several changes were observed in the diabetic rats, the reduction in the 
uptake of "'H-liAD and the changes in smooth muscle, though these were not 
proof of neuropathy. Indeed certain changes between the six week and 1 
year diabtic rats, as is discussed elsewhere, may have been due to 
ageing. Differences between age-matched control and diabetic groups were 
not due to ageing, but defects caused by diabetes which were not 
indicative of neuropathy. The relevance of these changes to human 
diabetic neuropathy may be marginal, and it could be that these changes 
are peculiar to the diabetic rat. 
Our failure to demonstrate neuropathy meant that the role of the polyol 
pathway in diabetes could not be properly evaluated. It nay be that 
the polyol p,,"thway is a required element in the development of human 
diabetic neuropathy, though whether it is THE element remains doubtful. 
The normalization of lia+K+ ATPase activity in diabetic rats treated with 
T3 is stro~~ evidence that hypothyroidism may contribute to it's 
depression by diabetes. Further work on this aspect of diabetes could 
prove fruitful. However, the link between reduced lia+K+ ATPase activity 
and neuropathy, itself, remains speculative. 
Testing of the hypothyroidism hypothesis is now essential and data 
generating from. this may provide a crucial insight into human diabetic 
neuropathy. Also, it may be, that no one mechanism is responSible for 
the varied dysfunctions found in hunen diabetes and it will only be 
through the correction of several that the cure will be found. 
(205) 
The development of an effective nodel of neuropathy still remains a high 
priority. It will be only through this that the biochemical and 
physiological basis for neuropathy will be understood. An appropriate 
IIDdel also allows the evaluation of the different treatments suggested 
for diabetic neuropathy. As described, it is very difficult to assess 
the netiology of neuropathy or the efficacy of treatments/preventative 
measures in human diabetes. It is ethically questionable to treat one 
set of diabetics whilst allowing another to develop the symptons of 
diabetic neuropathy, or , alternatively, to subject patients to side 
effects of treatments for conditions which many would not, in any case, 
develop. 
There still re_ins much further work to be carried out in this field 
before a proper understanding of diabetic neuropathy is achieved. It is 
possible that the period of diabetes which we used in the 
streptozotocin-induced rat was insufficient to properly mindc the 
defects occurring in human diabetes. A longer period of diabetes in the 
rat may show the development of the defects that we were searching for. 
However, as previously noted, it may be that the rats that do survive 
the ravages of diabetes are peculiarly resistant to neuropathy, as is· 
the case in some long-term human diabetics. 
In human diabetes various tissues are differently effected due to 
diabetes and it could be that the same situation is prevalent in the 
diabetic rat. It could be that the tissues we exandned for signs of 
neuropathy were not susceptible ·to diabetic dysfunction. Ve used tissues 
that we thought were reI event to human diabetes, such as the aorta, 
oesophagus, heart etc., and it may be that neuropathy is occurring in 
other tissues. Further research could be conducted into a new set of 
tissue to establish whether diabetic neuropathy is occurring. However, 
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if tiS6ueG are used from the diabetic rat which do not Guffer 
dysfunction in hunan diabetics then the problem of interpretation 
arises. It is questionable as to how relevent would it be to establish 
neuropathy in tissues from diabetic rats which have no direct 
correlation with the dysfunctions occurring in hu_n diabetes? It nay 
well be that the diabetic rat is only susceptible to early changes which 
it then corrects and that it is unusually resistant to diabetic 
neuropathy. In this light it would seem that this species offers little 
oppertunity to evaluate diabetic neuropathy. The rat is relatively 
resistant to atherosclerosis and if this underlies diabetic neuropathy, 
as has been suggested (Low et aI, 198), then this night explain the 
rats resistance to diabetic neuropathy. 
It _y be possible that the defects that are absent in the diabetic rat 
are present in other species. Since different patients vary considerably 
in their vulnerability to diabetic neuropathy it would not be suprising 
if species also differed in this respect. Whilst other species have been 
used, such as rabbit, mice and genetically-diabetic Chinese hamsters, 
the predominant work has been carried out on the rat. Following our 
efforts to show neuropathy in the rat, it could be that another species 
would provide IDOre fruitful data. Further work should be carried out on 
different species to evaluate their effectiveness as models of diabetic 
neuropathy. Some researchers have already IDOved on from the diabetic rat 
to diabetic mice to evaluate neuropathy and this trend should be 
developed; together with other species. A recent study in alloxan-
diabetic rabbits reportedsympatheUc denervation in the carotid artery 
(Tesfamarin et aI, 1990). This species is also lllOre vulnerable to 
. atherosclerosis, induced by a high cholesterol diet, than are rats 
(Xauriello et aI, 1991). This might therefore provide a lllOre appropriate 
( 207 ) 
model for future study despite pasing soma prfictic~l di5advfint~ges, such 
as greater size regarding housing and higher mortality rate after 
induction of diabetes. 
Diabetes, whilst causing no direct excessive discomfort to the patient, 
has an insidious effect·, on other components. The interplay of different 
factors is well known, however, researchers only examine diabetes in 
isolation. It could be that additional risk factors need to be 
considered so that diabetic neuropathy is effectively evaluated. It is 
Imo.in that hypertension together with diabetes leads to vasculopathy, 
and it may well be that vasculopathy is the pivotal step that leads to 
neuropathy, though a direct correlation between hypertension and 
neuropathy has not been reported. The interplay of different risk 
factors needs to be investigated thoroughly and it could be that this 
finally leads to an effective model of diabetic neuropathy and STeater 
understanding of its etiology and neans of prevention. 
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CHAPTE"R SIX 
APPENDIX 
6.1 STATISTICAL AllALYSlS 
The significance of difference between groups for the results analysis 
were assessed initially by one-way analysis of variance and, where p 
values less than 0.05 were obtained, individual groups were compared by 
Duncans multiple comparisons (Bruning & Klntz, 1968). 
6. la DuncaD§ Xult:fple Comparisgns Tests 
step 1: The mean score for each group is obtained 
Kean of group 1 = Sum of grOUp 1 
n 
when n is the number in the group 
step 2: The standard error of the means is derived by the following 
formula 
when DSw'~h'n is the Deans within a group. 
If however the numbers of cases in SODe groups are unequal then the 
harmonic mean, l'I, of the numbers is obtained, but only if the numbers 
between groups are not too disparate. If there are not more than twice 
as many in the largest group as in the snallest group then it is 
permissable to use the harmonic mean, fi, where 
l'I = numbers of sroups 
1. + 1. + 1.+ ... +1.. 
n, D::z D3 ni 
When n" n2, D3 etc. are the numbers per group in the different 
groups. 
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Step 3: The significant studentized ranges are obtained fron the 
literature. The literature tables have values for different degrees of 
freedom, df, for the mean square within groups; whilst the exact df may 
not be listed the next closest df suffices for our purpose. Once the 
appropriate df column has been assigned then the different ranges of 
means (k) to be compared are obtained. 
Step 4: Each significant range obtained from the literature table is 
then JIRlltiplied by the S.e. obtained in step 2. This results in the 
minimum mean differences (R) for the given ranges of comparisons. 
Step 5: The means obtained are intially ranked from the smallest to the 
largest so that the differences between the various means can be tested 
for significance. If the difference between the means, obtained in step 
1, is larger than the minimum mean difference, obtained in step 4, for 
that range tben this is considered to be significant. 
6,2 BASIS FOR TRIIODQTRYR06IDE ASSAY 
There are several commercially available test kits, eD~loying a variety 
of principles. The kit used in this study utilised the "competition" 
principle. 
Tubes were supplied which had a specific antibody coated on to the tube 
wall. Intially an immunological reaction was carried out by placing the 
serum in the tube together with enzyme labelled antigen. Both antigens, 
the enzyme labelled and the serum antigens, reacted with the antibody on 
the tube wall. After a short time the mixture was emptied out and the 
tube washed several times with buffer solutions (see figure below). 
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Specific Antibody 
on tube wall 
+ 
o 
o 
o + 
.. 
Serum Antigen Enzyme labelled Antigen 
o 
+ 
Immunological Reaction 
In the I1ext step an indicator reaction took place which produced the 
colour change which was measured in a spectrometer. To the tube, which 
had been previously eluted, substrate chrollDgen was added leading to a 
colour change. The greater the binding by the enzyme labelled antigen 
the lower the concentration of serum antigen. 
o SUBSTRATE 
+ -l DYE 
CHROJlOGEH 
Indicator ReactioD 
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6.3 BASAL OVERFLOli OF "H-IiA FRO! Al'lOCQCCYGEUS IllISC!.E 
Basal "H Overflow 
( _ pmol "H-BA Ig/min) 
2.5 
0.5 ~/ ______________________________ ~ __________________ ~ ___ 
I I 
1'5 
Duration of superfusion (h) 
I 
2'5 
Basal overflow of "H expressed as equivalent p mol "H-BA Ig from 6 weeks 
diabetic anocn=ygeus muscle. The results approximated to first order 
kinetics and are plotted logarithlllically. The regression coefficients 
were calculated for each ti5Sue (n = 6 for each group). Jl!ean values ± 
s. d. which were used for the above plots were: controls :.. -0.564 ± 
0.243 h- 1 • diabetic 1f • -0.46'7 ± 0.203 h- 1 and diabetic treated with 
ponalrestat~·. -0.454 ± 0.298 h-'. Difference between these means were 
not significant. 
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